From activated leukocyte cell adhesion molecule to melanoma metastasis : towards the unravelling of a paradox by Kilsdonk, J.W.J. van
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/83281
 
 
 
Please be advised that this information was generated on 2018-07-08 and may be subject to
change.
FR
O
M
 A
C
TIV
A
TED
 LEU
KO
C
Y
TE C
ELL A
D
H
ESIO
N
 M
O
LEC
U
LE TO
 M
ELA
N
O
M
A
 M
ETA
STA
SIS 
 
JER
O
EN
 V
A
N
 K
ILSD
O
N
K
 
2009
U����������
voor het bijwonen van de
verdediging van mijn proefschri� 
F��� A�������� L��������
C��� A������� M������� 
�� �������� ����������
op woensdag 24 juni 2009
om 12:00 precies
in de Aula Major van de 
Radboud Universiteit Nijmegen
Comeniuslaan 2 te Nijmegen
aansluitend is er een recep� e
P����� ���
T�� R�������
06-24777398
E��� ��� K�������
06-20300651
J����� ��� K�������
J������������ 4
5708 KK HELMOND
0492-840262
J.vankilsdonk@derma.umcn.nl
ISBN 978-90-9024292-7
Cover-uitnodiging Jeroen 250409.indd 26-4-2009, 17:311
From Ac�vated Leukocyte Cell Adhesion Molecule to 
melanoma metastasis
Towards the unravelling of a paradox
 
Een wetenschappelijke proeve op het gebied van de 
Natuurwetenschappen, Wiskunde en Informa�ca
Proefschri�
ter verkrijging van de graad van doctor 
aan de Radboud Universiteit Nijmegen, 
op gezag van de rector magnificus prof. mr. S.C.J.J. Kortmann, 
volgens besluit van het College van Decanen
in het openbaar te verdedigen op 
woensdag 24 juni 2009, 
om 12.00 uur precies
door
Jeroen Wilhelmus Johannes van Kilsdonk
geboren op 19 december 1979   
te Helmond
Promotores:
Prof. dr. G.J.M. Pruijn
Prof. dr. D.J. Ruiter
Copromotores:
Dr. G.W.M. Swart
Dr. L.L.C.T. van Kempen
Manuscriptcommissie:
Prof. dr. E.J.J. van Zoelen (voorzi�er)
Prof. dr. J.A. Schalken
Prof. dr. J.J. van den Oord (Katholieke universiteit Leuven)
ISBN 978-90-9024292-7
© 2009 by Jeroen van Kilsdonk 
Printed by PrintPartners Ipskamp, Enschede, The Netherlands
Cover illustra�on: Jeroen van Kilsdonk
In the beginning of the research presented in this thesis this picture was taken of living BLM melanoma 
cells. At that �me it was unknown what these ‘wires’ between the cells were. Later it turned out that they 
might be tunneling nanotubes. Tunneling nanotubes are involved in the transfer of informa�on between 
cells, yet another mechanism of cell contact dependent signaling. 
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General introduc�on   
 
 The term cancer is generally used for 
malignant neoplasms. A malignant neoplasm 
is a group of transformed cells that display 
growth and division beyond normal limits and 
form tumor �ssue. Due to this uncontrolled 
growth the tumor expands beyond its 
boundaries and invades adjacent �ssues. 
The final developmental stage of most solid 
cancers and main cause of pa�ent mortality 
is tumor metastasis. Metasta�c cells released 
from the primary tumor, enter the lympha�cs 
or blood circula�on, colonize and grow within 
distant organs (Hanahan and Weinberg, 
2000;Bidard et al., 2008).
Metastasizing tumor cells con�nuously alter 
the repertoire of adhesion molecules either 
to detach from the primary tumor or to pass 
and travel along with other cells encountered 
during migra�on. Many adhesion molecules 
are present on tumor cells, based on general 
characteris�cs they can be divided in broad 
categories. The most studied adhesion 
molecules in tumor progression include 
cadherins, integrins, CD44, selec�ns and 
members of the immunoglobulin superfamily 
(Cavallaro and Christofori, 2004). Adhesion 
molecules can be homophilic or heterophilic. 
Homophilic adhesion molecules only adhere 
to themselves, while heterophilic adhesion 
molecules interact with a ligand that is not 
iden�cal to the adhesion molecule itself. 
Interac�ons facilitated by adhesion molecules 
can be tumor cell to tumor cell, tumor cell 
to non-tumor cell or tumor cell to matrix. All 
these adhesion interac�ons can occur during 
tumor forma�on and metastasis. Presumably, 
clusters of adhesion interac�ons rather than 
individual interac�ons are necessary for 
neoplas�c progression. As single adhesion 
molecules make up the network of interac�ons 
it is important to know the contribu�on and 
func�on of each individual molecule. One 
molecule that gained interest because of its 
aberrant expression in many different human 
tumors is ac�vated leukocyte cell adhesion 
molecule (ALCAM) (Ofori-Acquah and King, 
2008). ALCAM, also named MEMD or CD166, 
is both a homophilic and heterophilic (ALCAM-
CD6) adhesion molecule belonging to the 
immunoglobulin (Ig) superfamily (Bowen et 
al., 1995;Degen et al., 1998).   
ALCAM expression in malignancies 
 The first studies on the expression of 
ALCAM in human malignancies were performed 
in melanoma tumors. A strong correla�on 
was found between ALCAM posi�vity and 
stage of melanoma tumor progression in an 
immunohistochemical analysis of 121 frozen 
melanocy�c lesions, ranging from common 
melanocy�c nevus to melanoma metastasis 
(van Kempen et al., 2000). ALCAM expression 
correlates with tumor stage according to two 
histopathological classifica�ons (Breslow 
thickness and Clark levels of invasion). Only a 
small number of thin primary tumors (Breslow 
thickness <1.5mm) were ALCAM posi�ve, 
whereas the majority of thick tumor samples 
(Breslow thickness >1.5mm) were ALCAM 
posi�ve. According to Clark classifica�on levels 
ALCAM was not detected in RGP melanomas 
(Radial growth phase, Clark levels I and II). As 
the level of tumor invasion gradually increases 
from Clark level III, via Clark IV to Clark level 
V (Ver�cal growth phase melanomas, VGP, 
Clark IV and V) ALCAM posi�vity drama�cally 
increased to 100% in Clark V lesions. Strikingly, 
ALCAM expression was predominantly 
observed in a subset of melanoma cells at 
the invasive front of the tumor. Another 
immunohistochemical study confirmed the 
ALCAM expression pa�ern in melanomas 
(Klein et al., 2007). 
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Similar to melanoma, ALCAM overexpression 
was observed in bladder cancer, colorectal 
carcinoma and esophageal squamous cell 
carcinoma. In these tumors ALCAM expression 
is associated with tumor grade, metastasis, 
late clinical stage and shortened pa�ent 
survival (Tomita et al., 2003;Weichert et 
al., 2004;Verma et al., 2005). In contrast to 
these studies ALCAM downregula�on was 
predominantly observed in aggressive high-
grade prostate cancer (Kris�ansen et al., 
2003). Addi�onally, decrease or loss of ALCAM 
membrane expression is a marker of poor 
outcome in epithelial ovarian cancer pa�ents 
and is an independent prognos�c factor of their 
survival (Mezzanzanica et al., 2008). Altogether 
these studies show conflic�ng data about the 
expression of ALCAM and the prognos�c value 
of ALCAM in human cancers. The incongruous 
data regarding ALCAM expression in breast 
cancer makes the prognos�c value of ALCAM 
in tumor progression even more confusing. 
ALCAM expression is observed in many human 
breast cancer cell lines and �ssues. However, 
the published results about the prognos�c 
value of ALCAM expression are contradictory. 
High levels of ALCAM mRNA and protein 
were associated with small tumor diameter, 
low tumor grade, poor clinical outcome 
and metastasis. In contrast, another study 
showed that high levels of ALCAM correlated 
with shortened disease-free survival of 
breast carcinoma pa�ents (Burkhardt et al., 
2006). Recently, Ihnen et al showed that 
no correla�on between ALCAM expression 
and breast cancer progression was obtained 
(Ihnen et al., 2008). The only correla�on 
observed was that pa�ents who received 
adjuvant chemotherapy and had high ALCAM 
mRNA levels showed a longer overall survival 
(Ihnen et al., 2008). 
Overall these data show that altered  expression 
Table 1. Overview of ALCAM expression among different tumors. Adapted from Ofori-Acquah et al., 2008 
Cancer type Expression References
increased 
expression
melanoma increased during melanoma progression (van Kempen et al., 2000)
bladder cancer increased with tumor stage (Tomita et al., 2003)
esophageal squamous 
cell carcinoma
overexpression was associated with late clinical stage , 
enhanced tumor invasiveness , and nodal metastasis 
(Verma et al., 2005)
colorectal cancer increased in early malignant transforma�on (Weichert et al., 2004)
heterogeneous expression
breast cancer Low  mRNA levels correlated with poor clinical outcome 
and metastasis
(King et al., 2004) (Davies et 
al., 2008)
high protein levels asscociated with suppresion of 
invasion
(Jezierska et al., 2006)
high protein levels correlated with shortened disease-
free survival 
(Burkhardt et al., 2006)
no correla�on, predic�ve factor for responsiveness to 
adjuvant chemotherapy.
(Ihnen et al., 2008)
decreased 
expression
ovarian carcinoma decreased/lost  membrane expression is a marker of 
poorer outcome
(Mezzanzanica et al., 2008)
prostate cancer decreased with tumor grade (Kris�ansen et al., 2003)
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Figure 1. Working model for ALCAM func�on. 
ALCAM is a 105-kDa transmembrane cell adhesion molecule 
belonging to the immunoglobulin superfamily. It consists 
of five extracellular IgG domains (D1–D5): D1 and D2 are 
variable (V-type) domains and D3 to D5 are constant (C2-
type) domains followed by a transmembrane domain (tm) 
and a short (32 amino acids) COOH-terminal cytoplasmic 
tail (ct). Domains D3 to D5 form a oligomeriza�on module 
(o), which is involved in lateral ALCAM oligomeriza�on 
thereby increasing the avidity of homophilic ligand binding 
mediated by the ligand binding module (lb) consis�ng of 
D1 and D2. 
is observed in many different human tumor 
types and that it can be used as a prognos�c 
marker (table 1). However,  is upregulated in 
some tumors while being downregulated in 
other tumors. This heterogeneity in expression 
among the different tumors raises ques�ons 
about the correla�on between  expression 
and tumor progression in general. Unraveling 
the func�on and regula�on mechanism of 
ALCAM is important to clarify these confusing 
observa�ons.  
ALCAM structure-func�on analysis  
 ALCAM is found in mul�ple species, and 
it has different names amongst species; the 
chicken homologue of ALCAM is the neural 
adhesion molecule BEN/SC1/DM-grasp 
(Tanaka et al., 1991;Burns et al., 1991;Pourquie 
et al., 1992), in rat KG-CAM (Peduzzi et al., 
1994) and in fish neurolin (Paschke et al., 
1992). Like MUC18/MelCAM/CD146 and B-
CAM/Lutheran/CD239, ALCAM belongs to 
the VVC2C2C2 subgroup of the Ig superfamily. 
ALCAM is composed of five extracellular 
Ig-domains (D1-D5), two membrane distal 
N-terminal variable (V) type domains (D1-D2) 
followed by three membrane proximal constant 
(C2) type domains (D3-D5), a transmembrane 
region and a short cytoplasmic tail of 32 
amino acids. The predicted molecular weight 
is 65kDa, but because of the nine puta�ve N-
glycosyla�on sites in the extracellular domain 
ALCAM has an observed molecular weight of 
approximately 105 kDa (Bowen et al., 1995). 
Both the heterophilic and homophilic ALCAM 
interac�ons are mediated by the N-terminal 
D1 domain. The affinity of heterophilic 
ALCAM-CD6 interac�ons (K
D
‘ = 0.4–1.0 µM) 
is about two orders of magnitude higher than 
homophilic ALCAM-ALCAM interac�ons (K
D
‘ 
= 29–48 µM) (Hassan et al., 2004). The low 
affinity of the homophilic interac�ons may 
be strengthened by lateral oligomeriza�on 
of ALCAM molecules on the cell surface (cis-
oligomeriza�on). Cis-oligomeriza�on may 
increase avidity and therefore reinforce and 
stabilize cell-cell interac�ons thereby forming 
a 3D network between opposing cells (Swart 
et al., 2005). 
Based on structure-func�on analyses a 
working model for the homophilic cell 
adhesion func�on was proposed (figure 1; 
(Bowen et al., 2000;van Kempen et al., 2001). 
In this model the two membrane distal V-type 
domains (D1-2) form a ligand binding module 
that mediates the trans-interac�ons between 
two opposing ALCAM molecules from two 
opposing cells. The three C-type domains 
(D3-5) form an oligomeriza�on module and 
mediate cis-clustering of ALCAM on the cell 
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surface. Together cis-oligomeriza�on on the 
cell surface and trans-intercellular interac�ons 
would synergis�cally promote ALCAM 
recruitment and network forma�on at sites of 
cell-cell contact. 
ALCAM func�on
 ALCAM shows a characteris�c, 
temporal and spa�al distribu�on during the 
development of a wide variety of �ssues and 
cells in health and disease. ALCAM is involved 
in embryogenesis, neurogenesis, angiogenesis, 
hematopoiesis and immune response, and is a 
marker of pluripotent mesenchymal stem cells 
(for reviews Swart, 2002;Swart et al., 2005). 
Although the func�onal contribu�on of ALCAM 
to these processes is poorly understood, it is 
important to note that ALCAM expression is 
mostly restricted to cells that are involved in 
dynamic growth and migra�on. 
Evidence is accumula�ng that ALCAM-
mediated adhesion contributes to migra�on. 
Recently, Masedunskas et al (Masedunskas 
et al., 2006) showed that the passage of 
monocytes through an endothelial monolayer 
correlated with ALCAM levels on the monocytes 
and with endothelial ALCAM localized to the 
lateral plasma membrane. Similar results were 
shown for the transloca�on of leukocytes 
into the brain. ALCAM expressed on blood-
brain Barrier (BBB) endothelium localized 
together with CD6 on leukocytes and with 
BBB endothelium transmigratory cups which 
results in extravasa�on (Cayrol et al., 2008). 
Besides these transendothelial migratory 
processes, ALCAM expression is observed in 
human blastocysts and endometrial epithelial 
cells (Fujiwara et al., 2003). The stage specific 
expression suggests that ALCAM may be 
involved in ini�al interac�ons of the embryo 
with maternal endometrium, which precede 
and accompany implanta�on of the fetus into 
the uteral wall. This invasive developmental 
process is an example of collec�ve cell 
migra�on and may resemble dis�nct steps of 
tumor metastasis (Swart et al., 2005). 
The ini�al studies using melanoma cell lines 
demonstrated ALCAM expression in metasta�c 
human melanoma cell lines but not in non-
metasta�c cells. Its expression correlated with 
tumor cell aggrega�on (Degen et al., 1998). 
The homophilic cell adhesion func�on of wild-
type ALCAM mediates homotypic clustering of 
melanoma cells and would, thus, antagonize 
cell release from the primary tumor, an 
early prerequisite for metastasis. To study 
the paradoxical role of ALCAM in melanoma 
progression a truncated ALCAM (∆N-ALCAM) 
molecules was engineered (van Kempen et 
al., 2004). This N-terminally truncated ALCAM 
molecule consists only of the oligomeriza�on 
domains (D3-D5) and therefore lacks the ligand 
binding module (D1-D2) (figure 2). Ectopically 
expression of ∆N-ALCAM in wild-type ALCAM 
expressing melanoma cell lines interferes with 
Figure 2. Working model for amino-terminally truncated 
ALCAM (∆N-ALCAM). 
Ectopic expression of �N-ALCAM comprising domains D3 to 
D5 interferes with intercellular ALCAM network forma�on 
(van Kempen et al., 2004). 
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�ght ALCAM network forma�on, thereby 
inhibi�ng up to 50 % of normal cell clustering. 
∆N-ALCAM induced loss of cellular aggrega�on, 
increased cell mobility and invasiveness in 
skin reconstructs. The increased invasiveness 
of ∆N-ALCAM expressing cells is reflected 
in mouse xenogra�s, an accelera�on of 
spontaneous lung metastasis forma�on was 
observed at expense of primary tumor growth 
(van Kempen et al., 2004). Together these 
data show that ALCAM plays an important 
role in melanoma tumor progression and that 
modula�on of ALCAM network forma�on 
might interfere with metastasis rate. The 
data by van Kempen and collaborators (van 
Kempen et al., 2004) indicate that the intact 
cell adhesion func�on of ALCAM may both 
favor primary tumor growth and represent 
a rate-limi�ng step for metastasis from VGP 
melanoma. 
Regula�on and forma�on of ALCAM mediated 
cell-cell contacts could involve the ac�n 
cytoskeleton. Studies in prostate carcinoma 
cell lines show a recruitment and (par�al) 
colocaliza�on of ALCAM with E-cadherin 
on sites of cell-cell contacts and provide 
indirect evidence of a�achment to the ac�n 
cytoskeleton via α-catenin (Tomita et al., 
2000). Other evidence of ALCAM linkage to the 
ac�n cytoskeleton comes from experiments in 
Figure 3. Stepwise ALCAM working hypothesis. 
See text for details. 
ALCAM overexpressing K562 cells. Inhibi�on 
of ac�on polymeriza�on by cytochalasin D 
(CytD) alters ALCAM distribu�on on the cell 
surface and increases the lateral mobility 
of ALCAM (Nelissen et al., 2000). Enhanced 
ALCAM mediated adhesion was observed as a 
consequence of ALCAM clustering on the cell 
surface a�er CytD treatment. Recently, using 
immunoprecipita�on ALCAM was shown to 
interact with β-ac�n (Te Riet et al., 2007) but it 
remains elusive how ALCAM interacts with the 
cytoskeleton.  
Hypothesis: ALCAM, a rate-limi�ng 
step for melanoma invasion and 
metastasis
 Tumor metastasis is the ul�mate 
developmental stage of malignant solid tumors 
and requires release of invasive cells from a 
primary tumor. Loss of homotypic tumor cell 
adhesion usually accompanies metasta�c 
spread (Hanahan et al., 2000). Gain of ALCAM 
expression in melanoma intui�vely represents 
a counterproduc�ve event in this regard. 
Based on the available data ALCAM func�on 
in melanoma progression can be summarized 
in a stepwise hypothesis, which takes into 
account that ALCAM mediated homotypic cell 
clustering is rate limi�ng for metastasis (figure 
3) (adapted from Swart et al., 2005). 
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Outline of this thesis 
 ALCAM (CD166) was ini�ally iden�fied 
as a ligand for CD6 and later it was found 
that this heterophylic interac�on is mainly 
involved in immunological processes. The 
iden�fica�on of ALCAM in melanoma �ssue 
raised new ques�ons about the func�on of 
ALCAM. Since CD6 expression is almost absent 
in melanomas the importance for homophylic 
ALCAM-ALCAM interac�ons became 
evident. At the start of the study described 
in this thesis, the importance of ALCAM in 
melanoma progression was recognized, but 
its role in tumor progression in general and 
melanoma specifically remained elusive. 
The hypothe�cal model of ALCAM func�on 
(described above) predicts that sustained 
tumor growth and ALCAM clustering induces 
a pro-invasive signalling cascade that allows 
ALCAM to func�on as a rate-limi�ng step 
in melanoma invasion. The main goal of the 
research described in this thesis is to unravel 
the poten�al signalling role ALCAM has in 
melanoma tumor progression. 
 Chapter 2 addresses the ques�on if 
ALCAM clustering ac�vates proteoly�c 
ac�va�on of matrix metalloproteinase 
(MMP)-2. By siRNA-mediated knock-down 
experiments and the use of truncated ALCAM 
(∆N-ALCAM) it is shown that, besides integrin-
matrix interac�ons and sufficient cell-cell 
interac�ons, ALCAM regulates the ac�va�on of 
MMP-2 by interfering with the expression and 
ac�va�on of membrane-type 1 MMP (MT1-
MMP, MMP14). In chapter 3 we make use of a 
recently discovered small secreted N-terminal 
ALCAM fragment (sALCAM). Overexpression of 
sALCAM diminishes ALCAM re-localiza�on to 
regions of cell-cell contact, reduced migra�on 
and invasion in vitro. Addi�onally, interference 
of sALCAM with endogenous ALCAM impaired 
the metasta�c spread in nude mice. Similar 
The tumor model starts with RGP melanoma 
growth (stage 0) and is followed by stage 
1 which represents VGP melanoma. The 
progressive development of VGP melanomas 
is characterized by the de novo expression of 
ALCAM. Due to increased ALCAM clustering 
and sustained oncogenic growth (stage 2) 
a cri�cal primary tumor mass is reached. 
When this threshold is passed adhesion 
should be a�enuated so that invasive and 
metasta�c competent cells can be released 
in stage 3. Once beyond this point of no-
return metasta�c cells can invade and grow 
at secondary sites (step 4). As a primary 
phenotypic consequence, ALCAM apparently 
reinforces homotypic interac�ons and favors 
primary tumor growth (passage from stage 1 
to 2). 
The most cri�cal point of the model is the 
a�enua�on of cell adhesion (stage 3). The 
model illustrates that primary tumor growth 
is required to reach a certain signaling 
threshold that ini�ates tumor cell release 
and migra�on. If the increasing tumor mass 
ac�vates intracellular signaling cascades, it 
is temp�ng to suggest that ALCAM clustering 
itself should generate s�muli to overcome 
stage 3. Several pro-invasive signaling events 
like PKC ac�va�on, cytoskeletal remodeling 
and proteolysis may be downstream of ALCAM 
clustering. The ques�on remains whether and 
how ALCAM regulates extra- and intracellular-
signaling. 
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to the use of truncated ALCAM (∆N-ALCAM), 
sALCAM expression reduced MMP-2 
ac�va�on. Besides signalling to the MMP-2 
ac�va�on cascade ALCAM modula�on with 
sALCAM and ∆N-ALCAM expression alters 
the expression of adhesion molecule L1CAM. 
To further elucidate the poten�al signalling 
role of ALCAM and its role in the adapta�on 
to changes in cell density extensive micro-
array studies were performed (chapter 4). 
The micro-array results show that ALCAM acts 
both as a cell adhesion and as a cell surface 
signalling sensor for cell density. To inves�gate 
the invasion, migra�on and basement 
membrane penetra�on of melanoma cells in 
more detail an in vitro model was developed 
using de-epidermized skin models (chapter 
5). During our search for ALCAM regula�ng 
transcrip�on factors we came along the 
interes�ng tumor marker nuclear pore 
complex protein 88 (Nup-88). Nup-88 appears 
to be involved in the transloca�on of the 
ac�ve form of transcrip�on factor NF-κB from 
the cytoplasm to the nucleus (chapter 6). A 
literature review of tumor progression related 
adhesion molecules and their soluble forms is 
presented in chapter 7. In Chapter 8 we discuss 
the role NF-κB might play in the transcrip�on 
regula�on of ALCAM. Addi�onally, chapter 8 is 
a general discussion of the results presented in 
this thesis in. 
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Ac�vated leukocyte cell adhesion molecule (ALCAM/CD166/MEMD) could func�on as a cell surface sensor for cell density, controlling the transi�on between local cell prolifera�on and �ssue invasion in melanoma progression. We have tested the hypothesis that 
progressive cell clustering controls the proteoly�c cascade for ac�va�on of gela�nase A/matrix 
metalloproteinase-2 (MMP-2), which involves forma�on of an intermediate ternary complex 
of membrane type 1 MMP (MT1-MMP/MMP-14), �ssue inhibitor of metalloproteinase-2 
(TIMP-2), and pro–MMP-2 at the cell surface. Surprisingly, trunca�on of ALCAM severely 
impaired MMP-2 ac�va�on in a nude mouse xenogra� model, in which we previously observed 
diminished primary tumor growth and enhanced melanoma metastasis. Compara�ve studies of 
twodimensional monolayer and three-dimensional collagen-gel cultures revealed that extensive 
cell-to-cell contacts, wildtype ALCAM, and cell-to-matrix interac�ons were all indispensable for 
efficient conversion of pro–MMP-2 to its ac�ve form in metasta�c melanoma cells. Truncated, 
dominantnega�ve ALCAM diminished MMP-2 ac�va�on via reduced transcript levels and 
decreased processing of MT1-MMP. Failure of the proteoly�c cascade a�er selec�ve ALCAM 
deple�on by RNA interference was mainly due to incomplete MT1-MMP processing, which was 
otherwise promoted by extensive cell-to-cell contacts. These data a�ribute a novel signaling role 
to ALCAM in regula�on of proteolysis and support its previously postulated sensor func�on in 
invasive growth. 
Introduc�on
 Matrix metalloproteinases (MMP) are Zn2+-
dependent proteinases whose expression is 
implicated in physiologic processes involving 
�ssue remodeling and cell migra�on. MMP 
ac�vity is also implicated in �ssue invasion, 
metastasis, and angiogenesis (for reviews, 
see refs. 1–3). MMP-2/gela�nase A is the 
most abundant MMP and a marker of poor 
prognosis in various cancer types (4–6). 
MMPs are synthesized as preproenzymes and 
ac�vated by proteoly�c processing. According 
to current models, a complex of membrane 
type 1 MMP (MT1-MMP/MMP-14) and �ssue 
inhibitor of metalloproteinases-2 (TIMP-2) 
recruits pro–MMP-2 from the extracellular 
milieu to the cell surface. Subsequent 
ac�va�on requires an addi�onal molecule of 
ac�ve MT1-MMP and autocataly�c cleavage 
steps (7–11).
Interac�ons between extracellular matrix 
components and their cognate membrane 
receptors play an important role in the 
ac�va�on of the MT1-MMP/MMP-2 cascade 
in tumor cells. Clustering of integrin β1 chains 
or fibronec�n binding promotes ac�va�on 
of MMP-2 (12, 13). Culturing metasta�c 
melanoma cell lines in three-dimensional 
collagen la�ces ac�vates MT1-MMP and 
subsequently MMP-2 (14). Integrin αvβ3 binds 
MMP-2 and promotes its ac�va�on (15–18). 
The extracellular matrix may also determine 
the subcellular localiza�on of MT1-MMP (19). 
Pro–MT1-MMP is  ac�vated intracellularly 
by the furin convertase (20) or on the cell 
surface by plasmin (21). Whereas the role of 
cell-to-matrix signaling in MMP-2 ac�va�on is 
rela�vely well documented, the contribu�ons 
of other �ssue architectural factors, such as 
homotypic cell-to-cell adhesion, are scarcely 
explored.
In human melanoma cell lines, expression of 
ac�vated leukocyte cell adhesion molecule 
(ALCAM/CD166/MEMD) and MMP-2 
ac�va�on correlate strongly with metasta�c 
poten�al (22, 23). Furthermore, ALCAM 
expression was observed at the invasive front 
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of ver�cal growth phase melanoma, indica�ng 
that ALCAM expression correlates with 
advanced melanoma tumor progression (24). 
Likewise,  expression of MT1-MMP, TIMP-2, 
and ac�va�on of MMP-2 were also correlated 
to melanoma progression in xenogra�s and 
fresh human lesions (25). 
ALCAM is a member of the immunoglobulin 
superfamily and has a characteris�c VVC
2
C
2
C
2
 
domain structure. The NH
2
-terminal V-type 
immunoglobulin folds cons�tute a homophilic 
ligandbinding module, whereas the membrane 
proximal C-type folds mediate oligomeriza�on 
in cis. Together, these modules apparently 
contribute to the forma�on of a high- affinity, 
high-avidity molecular network that promotes 
cell-to-cell binding (26). 
Interfering with endogenous ALCAM by 
expression of aminoterminally truncated 
ALCAM (∆N-ALCAM) in metasta�c melanoma 
cells increased cell migra�on in vitro and 
invasive growth in skin reconstruc�ons, but 
reduced xenogra� growth in nude mice while 
accelera�ng lung  metastasis (27). These 
results suggested that  proteoly�c processing 
of ALCAM, as mimicked in these experiments 
by recombinant expression of ∆N-ALCAM, 
should induce a shi� from primary tumor 
growth to invasive growth and metastasis. 
As these results also suggested that cell 
growth and invasion are separate phenotypic 
characteris�cs of tumor cells, we hypothesized 
that ALCAM expression coordinated these 
events in an oncogenic program that couples 
primary tumor growth and metastasis (for 
reviews, see refs. 28, 29).
In view of the observed role of ALCAM as 
a rate-limi�ng factor in the transi�on from 
primary tumor growth to metastasis and as 
a poten�al substrate of metastasis-related 
proteinases (27), we addressed whether 
ALCAM-mediated cell adhesion would 
regulate MMP-2 ac�va�on. We show here that 
ac�va�on of MMP-2 depends on cell-to-cell 
adhesion and an intact ALCAM network. These 
results thus support a role for ALCAM in cell 
density–dependent ac�va�on of metastasis-
promo�ng proteinase  cascades.
Figure 1. Integrin β1 clustering s�mulates MMP-2 
ac�va�on in confluent monolayers only in the presence 
of an intact ALCAM network. 
A, confluent (2.5x104/cm2) and nonconfluent (5x103/cm2) 
BLM or BLM/ΔN-ALCAM cells were cultured in monolayers 
and treated with beads coated with an�-integrin �1 
an�body 4B4, BSA as control, or were le� untreated. The 
samples of the nonconfluent cultures were loaded in 5-fold 
volume for normaliza�on of cell numbers. B, cell extracts 
of mock-transfected and an�-ALCAM siRNA-treated BLM 
cells were probed with an�-ALCAM an�body AZN-L50. 
C, 5x104/cm2 mock-transfected or ALCAM-depleted BLM 
cells were cultured as in (A). Cells were treated with 5 
μL (lanes 2 and 6), 10 μL (lanes 3 and 7), or 20 μL (lanes 
4 and 8) of bead suspension coated with an�body 4B4. 
Untreated mock-transfected (lane 1) and ALCAM-depleted 
BLM cells (lane 5) served as controls. Condi�oned media 
samples were analyzed by gela�n zymography. Posi�ons 
of pro–, intermediate, and ac�ve MMP-2 with sizes in kDa 
are indicated. 
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Results 
Influence of cell-to-cell interac�ons on MMP-
2 ac�va�on induced by integrin clustering in 
monolayer culture. 
To evaluate the rela�ve contribu�ons of cell-
to-cell and cell-to-matrix interac�ons to MMP-
2 ac�va�on in metasta�c melanoma BLM 
cells, we used a well-defined, two-dimensional 
monolayer culture system in which cell-
to-matrix interac�ons were mimicked by 
overlaying cells with an�-integrin β1 an�body-
coated beads. In DOV13 ovarian carcinoma 
cells, this approach induced integrin clustering 
and ac�va�on of MMP-2 (13). Nonconfluent 
(5x103 /cm2) and 100% confluent (2.5x104/cm2) 
cell monolayers were overlaid with latex beads 
coated with the an�-integrin β1 an�body 4B4 
or with BSA as a control. Condi�oned media 
from these cultures were analyzed by gela�n 
zymography. Nontreated BLM cultures and 
those treated with BSA-coated beads did not 
show conversion of pro–MMP-2 (72 kDa) to 
ac�ve MMP-2 (59 kDa; Fig. 1A, top). Confluent 
BLM cultures treated with 4B4-coated beads 
showed slight but reproducible conversion 
to intermediate (62 kDa) and ac�ve (59 kDa) 
MMP-2, whereas in nonconfluent cultures no 
significant ac�va�on was observed. similar 
results were obtained with the an�-integrin β1 
an�body Lia1/2 (data not shown). Therefore, 
MMP-2 ac�va�on in response to clustering 
of integrin β1 clearly depended on cell 
confluence. 
To assess the role of cell-to-cell interac�ons 
more specifically, we tested how disrup�on 
of the ALCAM network in BLM cells affected 
MMP-2 ac�va�on. The BLM/∆N-ALCAM cell 
line expresses an ALCAM dele�on mutant as 
well as wild-type ALCAM at a similar level as 
the parental BLM cells (26). 
Figure 2. Cleavage of pro–MMP-2 to ac�ve MMP-2 in 
metasta�c cells is promoted in collagen gels, requires 
high cell numbers, and depends on forma�onof an intact 
ALCAM network at cell-to-cell junc�ons. 
A, 530, 530/ALCAM, BLM, and BLM/ΔN-ALCAM melanoma 
cell lines were cultured in collagen gels or as monolayers 
in 24-well plates. Condi�oned media were analyzed 
by gela�n zymography. B, HT1080 cells were cultured 
in collagen la�ces and monolayers (six-well plates). 
Condi�oned media were analyzed by gela�n zymography. 
A�er overnight incuba�on, contrac�on of collagen gels 
was evident in high-density BLM and HT1080 cultures, 
reduced in BLM/ΔN-ALCAM cells, and absent in 530 and 
530/ALCAM cells. C, BLM and BLM/ΔN-ALCAM cells were 
s.c. injected into nude mice and extracts of dissected 
tumors were analyzed by gela�n zymography. Results of 
three independent tumors per cell line are shown. Posi�ons 
of pro–MMP-9, pro-, intermediate, and ac�ve MMP-2 with 
sizes in kDa are indicated. 
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Interes�ngly, 4B4-coated beads failed to 
induce MMP-2 ac�va�on in BLM/∆N-ALCAM 
cells, regardless of culture confluence (Fig. 
1A, bo�om). Alterna�vely, we used synthe�c 
siRNAs and selec�vely knocked down ALCAM 
protein to levels virtually undetectable by 
Western  blo�ng (Fig. 1B). In overconfluent 
(5x104/cm2) siRNA-transfected cultures, 
addi�on of an�-integrin β1-coated beads 
induced only slight pro–MMP-2 cleavage, 
whereas a stronger, dose-dependent increase 
in the cleavage of pro–MMP-2 was observed 
in mocktransfected control cultures (Fig. 1C). 
These results showed that in monolayer BLM 
cultures, MMP-2 ac�va�on promoted by 
an�body-induced clustering of integrin β1 
depended on the degree of confluence (Fig. 
1A), ALCAM protein levels (Fig. 1B and C), and 
Figure 3. Ac�va�on of MMP-2 coincides with cell-to-cell contact forma�on in BLM cells but not in BLM/ΔN-ALCAM cells 
and is inhibited by ALCAM deple�on. 
A and B, BLM and BLM/ΔN-ALCAM cells were cultured in varying cell numbers in collagen gels (six-well plates). A, gela�n 
zymogram of the condi�oned media from cultures shown in (B). Posi�ons of pro–, intermediate, and ac�ve MMP-2 with 
sizes in kDa are indicated. B, H&E-stained sec�ons of formalin-fixed, paraffin-embedded collagen cultures of BLM cells 
(le� column) and BLM/ΔN-ALCAM cells (right column) at increasing cell densi�es from 104 (top row), to 105 (middle 
row), to 106 (bo�om row) cells per gel. Bar, 100 µm. C and D, 106 mock-transfected and ALCAM-depleted BLM cells were 
cultured in collagen gels in 24-well plates and processed as in (A). C, gela�n zymogram of the condi�oned media from 
cultures shown in (D). Posi�ons of pro–MMP-9, pro-, intermediate, and ac�ve MMP-2 with sizes in kDa are indicated. 
D, immunohistochemical stainings using an�-ALCAM an�body (top row) and H&E stainings (HE, bo�om row) of mock-
transfected control BLM cells (le� column) and ALCAM-depleted BLM cells (right column). Bar, 100 μm. 
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an intact ALCAM network (Fig. 1A). Hence, 
cell-to-cell interac�ons involving ALCAM were 
required for MMP-2 ac�va�on as well as cell-
to-matrix nterac�ons mediated by integrin 
β1. 
Influence of increasing cell density and an 
intact ac�vated leukocyte cell adhesion 
molecule cell-to-cell adhesion network on 
ac�va�on of MMP-2 in three-dimensional 
collagen gel cultures. 
We next studied the requirements for 
MMP-2 ac�va�on in a more complex, 
three-dimensional culture model. Culturing 
metasta�c melanoma cells in type I collagen 
gels provided improved condi�ons for MMP-
2  ac�va�on (14). Embedding cells in these 
gels exposed integrin β1 to a common ligand 
in a structured la�ce resembling stroma, but 
influences of cell-to-cell adhesion were not 
studied in this model. If integrin clustering 
were the major inducer, one could expect 
significant ac�va�on of MMP-2 to occur 
regardless of cell density in collagen gel.  
Increasing numbers of BLM cells, BLM/∆N-
ALCAM cells, nonmetasta�c melanoma 530 
cells (ALCAM-nega�ve), and 530 cells stably 
expressing ALCAM (530/ALCAM) were grown 
in collagen gels and as monolayers in 24-
well plates.  Condi�oned  media from 530 
and 530/ALCAM cells grown in collagen gels 
showed a 72 kDa band corresponding to 
pro–MMP-2 in zymograms, whereas media 
from monolayer cultures of the same cell lines 
did not (Fig. 2A, two top panels). Neither of 
the two cell lines showed MMP-2 ac�va�on 
in collagen regardless of cell density and 
ALCAM expression. A fainter 92 kDa band, 
corresponding to pro–MMP-9/gela�nase B, 
was also visible in both cell lines when grown 
in collagen gels, but not in monolayers. 
BLM cells showed stronger expression of 
pro–MMP-2 in either collagen or monolayer 
culture than 530 or 530/ALCAM and also 
expressed pro–MMP-9 in collagen culture 
(Fig. 2A, third panel). In monolayers in general 
and in low-density BLM collagen cultures (103 
cells per gel), ac�ve MMP-2 (59 kDa band) 
was not or barely detectable, while MMP-2 
ac�va�on was very efficient in collagen gels 
at high cell density (105 cells per gel). For a 
normalized comparison, 10- and 100-fold 
dilu�ons, respec�vely, of condi�oned media 
from the intermediate (104) and high (105) cell 
density collagen gel cultures showed stronger 
MMP-2 ac�va�on than the undiluted 103 
culture, underscoring that MMP-2 ac�va�on 
was enhanced with increasing cell density (not 
shown). 
BLM/∆N-ALCAM cells cultured in collagen gel 
Figure 4. Quan�ta�ve real-�me PCR analysis of MT1-
MMP, MMP-2, and TIMP-2 gene expression. A, analysis 
of BLM cells at a density of 5x105/cm2 (white columns) and 
BLM/ΔN-ALCAM cells at a density of 4.5x105/cm2 (black 
columns). B, analysis of mock-transfected (white columns) 
and an�-ALCAM siRNA-treated BLM cells (black columns) 
at a density of 2x105 cm2. The expression level of each 
gene was set at 100% for BLM cells in (A), and for mock-
transfected BLM cells in (B). Columns, means (n = 3); bars, 
SD. *Significant difference (P ≤ 0.05, Student’s t test). 
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showed no ac�va�on of MMP-2 at all at the 
low and intermediate cell densi�es. Only at 
the highest density, faint intermediate and 
ac�vated MMP-2 forms were visible (Fig. 2A, 
bo�om panel). Hence, the apparent disrup�on 
of an intact ALCAM network inhibited MMP-2 
ac�va�on in BLM cells in collagen gel.  
To inves�gate whether the dependence of 
MMP-2 ac�va�on on cell density was a more 
general phenomenon, human fibrosarcoma 
HT1080 cells were seeded in collagen gels 
and monolayers in varying densi�es in six-well 
plates (note that cell numbers were 10-fold 
higher to compensate for the larger surface 
area and volume). This cell line expresses 
ALCAM on the mRNA and the protein level 
(ref. 22 and data not shown). As observed in 
BLM melanoma cells, significant pro–MMP-
2 conversion in collagen culture occurred 
only at the highest cell density (Fig. 2B). In 
HT1080 monolayers, very li�le conversion 
of pro–MMP-2 occurred and only a faint 
intermediate band was visible at the highest 
cell density. Similar results were obtained in 
MV3 metasta�c melanoma cells (data not 
shown). This indicated that cell density–
dependent ac�va�on of MMP-2 in collagen 
la�ces also occurred in other tumor cell 
lines with endogenous ALCAM expression 
and was not restricted to melanoma. 
Strikingly, whereas cell-to-matrix interac�ons 
and clustering of integrin β1 were limi�ng 
condi�ons in confluent monolayer cell culture 
(Fig. 1), cell-to-cell interac�ons seemed to 
be limi�ng factors for MMP-2 ac�va�on in a 
threedimensional collagen gel (Fig. 2). 
Effects of ac�vated leukocyte cell  adhesion 
molecule trunca�on on MMP-2 ac�va�on in 
nude mouse xenogra�s. 
To confirm that disrup�on of the ALCAM 
network also inhibited MMP-2 ac�va�on in 
vivo, BLM and BLM/∆N-ALCAM cells were 
s.c. injected into nude mice. A�er 4 weeks of 
incuba�on, tumors were collected. Extracts 
from healthy, nonnecro�c �ssue were 
analyzed by gela�n zymography (Fig. 2C). 
BLM tumors showed extensive ac�va�on of 
MMP-2, whereas BLM/∆N-ALCAM tumors did 
not, indica�ng that interference with ALCAM 
network forma�on also inhibits MMP-2 
ac�va�on in mouse xenogra� tumors.
Figure 5. Genera�on of ac�ve MT1-MMP is promoted in 
collagen gels, depends on an intact ALCAM network, and 
supports conversion of pro–MMP-2 to ac�ve MMP-2. 
One million BLM and BLM/∆N-ALCAM cells were grown 
incollagen gels or as monolayers in six-well plates for 48 
hours. Cell lysates were analyzed by Western blo�ng using 
polyclonal an�serum against MT1-MMP (A), monoclonal 
an�bodies against MMP-2 (B), and monoclonal an�bodies 
against TIMP-2 (C). Sizes (in kDa) of molecular weight 
markers (le� ) and posi�ons of protein bands (right ) are 
indicated.
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Correla�on between pro–MMP-2 ac�va�on 
and cell-to-cell contact forma�on and the need 
of ac�vated leukocyte cell adhesion molecule. 
The observa�on that collagen gel–induced 
MMP-2 ac�va�on occurred only at higher 
cell densi�es and was dependent on ALCAM 
func�on suggested that cell-to-cell contacts 
were necessary for MMP-2 ac�va�on in 
addi�on to clustering of integrin β1. To 
determine if MMP-2 ac�va�on actually 
coincided with cell-to-cell contact forma�on, 
BLM and BLM/∆N-ALCAM cells were seeded 
in varying cell densi�es in collagen gels. Six-
well plates were used to facilitate histologic 
processing. A�er incuba�on and collec�on 
of condi�oned media, the collagen cultures 
were processed for paraffin embedding and 
histochemistry. As in previous experiments, 
gela�n zymograms of the condi�oned media 
showed an increase in MMP-2 ac�va�on as 
BLM cell density increased from 104 to 106 
cells per gel, and virtually no ac�va�on was 
observed in BLM/∆N-ALCAM cells seeded 
at the same densi�es (Fig. 3A). H&E-stained 
collagen gel sec�ons of both BLM and BLM/
∆N-ALCAM cells seeded at low cell density 
showed few cell-to-cell contacts, whereas at 
the highest cell density extensive cell-to-cell 
contacts were visible (Fig. 3B). Despite the 
progressive forma�on of cell-to-cell contacts 
(Fig. 3B, right column), BLM/∆N-ALCAM cells 
were unable to ac�vate MMP-2 (Fig. 3A). Thus, 
MMP-2 ac�va�on and cell-to-cell contact 
forma�on did coincide in BLM cells, but not in 
BLM/∆N-ALCAM cells. 
An�-ALCAM siRNA-treated and mock-
transfected BLM cells were cultured in 
collagen gels at high cell density (106 cells 
in 24- well plates). Zymograms showed that 
mock-transfected control BLM cells cleaved 
pro–MMP-2 efficiently, whereas MMP-2 
ac�va�on in siRNA-treated BLM cells was 
much less efficient, indica�ng that ALCAM 
Figure 6. MT1-MMP ac�va�on depends on ALCAM 
expression. One million mock-transfected and an�-ALCAM 
siRNA-treated BLM cells were grown in collagen gels in 
six-well plates for 48 hours. Cell extracts were analyzed by 
Western blo�ng using polyclonal an�serum against MT1-
MMP (A), monoclonal an�bodies against MMP-2 (B), and 
monoclonal an�bodies against TIMP-2 (C). Sizes (in kDa) of 
molecular weight markers (le� ) and posi�ons of protein 
bands (right ) are indicated. 
was necessary for collagen-induced MMP-
2 ac�va�on in BLM cells (Fig. 3C). The gels 
were processed for histochemistry as before. 
Immunohistochemical staining of specimens 
with an�-ALCAM an�body showed clear 
ALCAM signals in mock-transfected cells, 
whereas siRNA-treated BLM cells only showed 
background signals (Fig. 3D, top row). Mock-
transfected BLM cells showed extensive cell 
clustering in contrast to siRNAtreated cells 
(Fig. 3D, bo�om row). Taken together, these 
results show that ALCAM-mediated cell-to-cell 
adhesion favors cell clustering and efficient 
MMP-2 ac�va�on in collagen gel.
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Effects of ac�vated leukocyte cell adhesion 
molecule status on MT1-MMP, TIMP-2, and 
MMP-2 messenger RNA expression. 
Current models state that assembly of a 
ternary complex of MT1-MMP, TIMP-2, 
and pro–MMP-2 is involved in the MMP-2 
ac�va�on cascade. We, therefore, inves�gated 
whether any changes occurred in expression 
of these components upon disrup�on of 
the ALCAM network or deple�on of ALCAM. 
Messenger RNA levels of MT1-MMP, TIMP-2, 
and MMP-2 were determined by quan�ta�ve 
real�me PCR in BLM, BLM/∆N-ALCAM, and in 
BLM cells transfected with an�-ALCAM siRNA 
in monolayer culture. The only significant 
change observed concerned the reduced 
MT1-MMP xpression levels in BLM/∆N-ALCAM 
cells, whereas MMP-2 and TIMP-2 levels 
were not significantly affected (Fig. 4A). An�-
ALCAM siRNA treatment did not affect MT1-
MMP and MMP-2 expression, whereas TIMP-2 
expression was slightly lowered upon siRNA 
treatment (Fig. 4B). The reduced expression of 
MT1-MMP may explain the decreased MMP-
2 ac�va�on in BLM/∆N-ALCAM cells. On the 
other hand, the reduc�on in MMP-2 ac�va�on 
in ALCAM depleted cells is likely due to other 
causes as no changes in mRNA expression 
levels were observed in siRNA-treated cells. 
Regula�on of MT1-MMP expression and 
ac�va�on by ac�vated leukocyte cell adhesion 
molecule network forma�on. 
Whereas the previous zymograms (Figs. 
1–3) showed MMP-2 isoforms secreted from 
cells into the growth medium, we wanted to 
study expression of cell-associated proteins 
involved in MMP-2 ac�va�on in the next 
series of experiments. With this purpose, we 
prepared soluble cell lysates of BLM and BLM/
∆N-ALCAM cells grown at high cell densi�es 
in collagen gels or monolayers and analyzed 
them by Western blo�ng. MT1-MMP in BLM 
cells grown in collagen gels was visible as a 65 
kDa precursor band and as an ac�ve 60 kDa 
band (Fig. 5A; ref. 30). The same bands were 
present in BLM cells grown in monolayer, but 
the prominent appearance of an addi�onal 64 
kDa band and the rela�vely lower intensity 
of the 60 kDa band indicated that processing 
of MT1-MMP was incomplete in monolayers. 
Consistent with the reduced mRNA levels 
(Fig. 4A), expression of MT1-MMP protein in 
BLM/∆N-ALCAM cells was lower in general, 
and the major band in collagen was the 65 kDa 
band. In the monolayers, the most prominent 
MT1-MMP species was the par�ally processed 
64 kDa band. Overexpression of DN-ALCAM 
apparently reduced both expression levels of 
MT1-MMP and its processing. 
The MMP-2 an�body recognized 72, 62, and 
59 kDa bands in BLM cells in collagen, and 
only the upper two bands were observed 
in monolayers (Fig. 5B). In BLM/∆N-ALCAM 
cells in collagen, the most prominent band 
was the 72 kDa band, indica�ng a lack of 
pro–MMP-2 processing. A faint 59 kDa band 
was also visible, but the intensity of this band 
was clearly reduced compared with BLM cells. 
The prominent presence of the 62 kDa band 
in monolayers (BLM/∆N-ALCAM and BLM) 
pointed to incomplete processing. These 
results were in agreement with the previous 
zymograms (Figs. 2 and 3), showing a general 
lack of ac�ve MMP-2 in the condi�oned media 
of BLM/∆N-ALCAM cultures. The expression 
levels of TIMP-2 in BLM and BLM/∆N-ALCAM 
cultures were similar (Fig. 5C). In summary, 
these results indicate that the protein levels 
of MT1-MMP are generally decreased in 
BLM/∆NALCAM cells. Furthermore, MT1-
MMP processing to the ac�ve 60 kDa form is 
less efficient in monolayer culture and upon 
overexpression of ∆N-ALCAM also in collagen 
gel. The reduced conversion of pro–MMP-2 
to its ac�ve form may thus  be a�ributed to 
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diminished levels of the 60 kDa isoform of 
MT1-MMP. 
Because an�-ALCAM siRNA treatment offered 
an alterna�ve strategy to impair the MT1-
MMP/MMP-2 ac�va�on cascade, soluble 
cell lysates of the transfected cells grown 
in collagen gels were analyzed by Western 
blo�ng. Whereas mock-transfected BLM 
cells showed 65 and 60 kDa bands in an MT1-
MMP Western blot, only 65 and 64 kDa bands 
were visible in ALCAM-depleted cells (Fig. 
6A). This showed that, although an�-ALCAM 
siRNA treatment does not affect MT1-MMP 
expression (compare with Fig. 4B), ALCAM 
is necessary for the processing of MT1-MMP 
to its ac�ve 60 kDa form. The incomplete 
processing of MT1-MMP in ALCAM-depleted 
cells was accompanied by poor ac�va�on of 
MMP-2 (Fig. 6B; compare with zymography 
results in Fig. 3C). TIMP-2 levels were 
unaltered (Fig. 6C). Together, these results 
show that ALCAM is involved in expression 
and processing of MT1-MMP and, thus, affects 
the subsequent conversion of pro–MMP-2 to 
ac�ve MMP-2. 
as cell-to-matrix interac�ons in this process. 
This is remarkable because it implies that cell 
prolifera�on in a developing �ssue may, by 
itself, generate signals to ac�vate proteoly�c 
cascades. 
When cultured in collagen gels, BLM cells up-
regulate expression of the collagen receptor, 
integrin α2β1 (33), and readily ac�vate MMP-2 
(14). The contribu�on of cell-to-cell adhesion 
to MMP-2 ac�va�on in this model has not been 
studied thus far. The dependence of the MT1-
MMP/MMP-2 cascade on cell-to-cell adhesion 
was clearly shown by the observa�ons that 
MMP-2 ac�va�on induced by treatment with 
an�-integrin β1-coated beads (Fig. 1) or by 
culture in collagen gels (Figs. 2 and 3) occurred 
only in dense BLM cell cultures, but not in 
sparse cultures. 
The func�onal status of the cell adhesion 
molecule ALCAM/CD166 was a primary 
determinant for the regula�on of MMP-2 
ac�va�on in the melanoma cells analyzed 
because inhibi�on of the MMP-2 cascade 
was achieved both by overexpression of a 
truncated ALCAM mutant, which a�enuated 
cell-to-cell adhesion, or by an�-ALCAM siRNA 
treatment. Surprisingly, the present analysis 
also revealed that impaired MMP-2 ac�va�on 
in nude mice xenogra�s accompanied 
the enhanced invasiveness of metasta�c 
melanoma cells a�er overexpression of NH
2
-
terminally truncated ALCAM (Fig. 2C; ref. 27).
 
As ALCAM func�ons as a homophilic cell 
adhesion molecule in BLMmelanoma cells, 
our data suggest that ALCAM-mediated 
cell-to-cell adhesion contributes to MMP-2 
ac�va�on. Indeed, we have found a strong 
correla�on between pro–MMP-2 cleavage 
and the incidence of cell-to-cell contacts in 
BLM cells, but not in BLM/∆N-ALCAM cells 
(Fig. 3A and B). Together, these experiments 
clearly indicate that ac�va�on ofMMP-2 in 
Discussion
 Tissue homeostasis and extracellular 
matrix remodeling rely heavily on control of 
proteoly�c events. Invasive tumor growth is 
commonly accompanied by MMP ac�va�on 
and proteolysis of matrix proteins. In 
par�cular, ac�va�on of the MT1-MMP/MMP-
2 cascade is linked to melanoma progression 
(25, 31). Although the (patho)physiologic 
condi�ons for ac�va�on of these proteinases 
are ot completely understood, it is known 
that integrin receptor clustering contributes 
to up-regula�on of pericellular MMP-2 
ac�vity (13, 32). In this study, we show that 
cell-to-cell contacts are at least as important 
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the metasta�c process in clinical trials (42). 
Also, it was shown that invasive tumor cells 
could compensate for blocked proteolysis by 
changing their migratory strategies (43). BLM/
∆N-ALCAM cells showed increased invasive 
growth in skin reconstruc�ons and increased 
metastasis with reduced primary xenogra� 
growth in nude mouse models (27). Despite 
the apparent inhibi�on of MMP-2 ac�va�on 
(this report), BLM/∆N-ALCAM cells display 
increased invasive behavior, sugges�ng that 
these proper�es should be less dependent on 
MMP-2 ac�vity. 
Our data indicate a novel role for ALCAM 
in the cell density–dependent regula�on 
of MT1-MMP expression and processing 
and subsequent ac�va�on of MMP-2. 
Thus, in metasta�c melanoma BLM cells, 
MMP-2 ac�va�on is regulated by cell-to-
cell interac�ons, mediated by ALCAM, 
in addi�on to cell-to-matrix interac�ons 
involving integrin β1. The importance of 
ALCAM in this mechanism suggests that 
ALCAM acts as a cell density sensor and 
ini�ates a signal toward MMP-2 ac�va�on. 
We hypothesize that the MMP-2 ac�va�ng 
s�mulus in three-dimensional collagen gels 
originates from extensive ALCAM-ALCAM 
clustering interac�ons in cell-to-cell junc�ons. 
Thus, an effec�ve s�mulus should exceed a 
minimum threshold as a func�on of increasing 
cell number and density. It is noteworthy 
that in invasive lesions, tumor cells display 
polariza�on with regard to cell-to-cell and 
cell-to-matrix binding. At the invasive front 
in par�cular, tumor cells engage in both 
cell-to-matrix and cell-to-cell binding. It 
has been shown that ALCAM expression 
and MMP-2 ac�va�on occur at this site in 
melanocy�c tumors (24, 25). Together with 
our observa�ons that ALCAM regulates cell 
density–dependent expression of tumor 
progression–related genes, these results 
metasta�c melanoma cells requires (a) cell-
to-cell adhesion, (b) wild-type ALCAM, and (c) 
integrin clustering. 
The effects of func�onal interference with 
ALCAM could be a�ributed to diminished 
mRNA expression and/or incomplete 
processing of MT1-MMP (Figs. 4-6). BLM cells 
efficiently promoted MT1-MMP processing 
upon culture in collagen gels, whereas only 
poor processing occurred in monolayers (in 
agreement with ref. 14). ∆N-ALCAM expression 
lowered MT1-MMP expression and processing. 
The observed lack of MMP-2 ac�va�on a�er 
ALCAM deple�on by siRNA could not be 
a�ributed to any changes in mRNA or protein 
levels of MT1-MMP and merely affected MT1-
MMP processing. These observa�ons indicate 
that coordinate and progressive cis and 
trans clustering of ALCAM should generate 
a signal and s�mulate produc�ve MT1-MMP 
processing and subsequent MMP-2 ac�va�on. 
Cell adhesion and matrix metalloproteinase 
ac�vity. 
The observa�on that density-dependent MMP-
2 ac�va�on occurs in ALCAM-posi�ve human 
fibrosarcoma HT1080 cells suggests that this 
phenomenon is not restricted to melanoma. 
Besides, other cell adhesion molecules 
may perform similar roles as ALCAM. The 
extracellular MMP inducer EMMPRIN/CD147 
is highly expressed in tumor cells and induces 
adjacent fibroblasts to express MMPs (34–37). 
Furthermore, E-cadherin may control MT1-
MMP expression levels through the Wnt 
signaling pathway, but it is likely that these 
effects are cell type dependent (38–41). 
MMPs were tradi�onally thought to promote 
metastasis by breakdown of extracellular 
matrix proteins, thus allowing tumor cells 
to pass through �ssue barriers. This view 
was challenged because various MMP 
inhibitors proved unsuccessful at inhibi�ng 
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Materials and Methods
Cell lines and reagents.
 The human melanoma cell lines BLM 
(metasta�c; ALCAM-posi�ve), BLM/∆N-
ALCAM (metasta�c; ALCAM posi�ve; 
truncated, dominant-nega�ve ALCAM 
transfectant), 530 (nonmetasta�c; ALCAM-
nega�ve), and 530/ALCAM (nonmetasta�c; 
wild-type ALCAM transfectant; ref. 26), and 
the human fibrosarcoma cell line HT1080 
(metasta�c; ALCAM posi�ve) were maintained 
in DMEM containing 10% FCS. 
An�bodies. 
 Mouse an�-ALCAM monoclonal an�body 
AZN-L50 (26) was used at 3 µg/mL for Western 
blo�ng. Rabbit an�–MT1-MMP polyclonal 
an�body AB815 (Chemicon, Hampshire, 
United Kingdom) was used at 0.5 µg/mL. 
Mouse an�-MMP2 monoclonal an�body Ab-
3 (Merck Biosciences, No�ngham, United 
Kingdom) was used at 0.5 µg/mL for Western 
blo�ng. Mouse an�-TIMP2 monoclonal 
an�body Ab-1 (Merck) was used at 5 µg/mL for 
Western blo�ng. For immunohistochemical 
detec�on of ALCAM, monoclonal an�-ALCAM 
an�body NCL-CD166 (Novocastra, Newcastle, 
United Kingdom) was used at a dilu�on of 
1:40. Goat an�-mouse immunoglobulin-
coupled horseradish peroxidase (HRP) and 
swine an�rabbit immunoglobulin-coupled 
HRP (DAKO, Glostrup, Denmark) were used as 
secondary an�bodies in Western blo�ng at 1 
µg/mL. Monoclonal an�bodies 4B4 and Lia1/2 
(Beckman Coulter, Fullerton, CA), both against 
the extracellular domain of human integrin 
β1, were used for coa�ng of latex beads (see 
below).
Short interfering RNA–mediated ac�vated 
leukocyte cell adhesion molecule 
knockdown.
imply that ALCAM contributes posi�vely to 
melanoma metastasis, and, therefore, explain 
why expression of a cell adhesion molecule that 
mediates homotypic cell adhesion correlates 
with metasta�c poten�al. Furthermore, 
the regula�on of proteoly�c ac�vity by 
progressive cell clustering suggests a novel 
aspect of growth control in transformed cells. 
Thus, invasive growth and metastasis may 
be elements of an intrinsic response to local 
cell satura�on in cells unable to obey growth 
arrest signals, offering an alterna�ve mode 
to react to crowding condi�ons in the tumor 
microenvironment.
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and 2 mL serum-free DMEM were added. 
Condi�oned medium was collected a�er 48 
hours. For histochemical analyses, collagen 
gel cultures were supported by cell-free gels 
of half the volume of the gel that contained 
the cells to keep the specimens intact during 
processing. 
Gela�n zymography. 
 Condi�oned media were mixed with 2 
nonreducing sample buffer [150 mmol/L 
Tris-HCl (pH 7.0), 4% SDS, 22% glycerol] 
and incubated for 10 minutes at 65°C. Five 
microliters of media/ sample buffer mixture, 
or tumor extract (prepared as described 
previously ref. 25), were separated on a 10% 
polyacrylamide gel containing 1 mg/mL gela�n 
(Merck). A�er electrophoresis, the gel was 
washed and incubated for 1 hour in 50 mmol/L 
Tris-HCl (pH 7.4) containing 2% Triton X-100 to 
renature the gela�nases. A�er washing twice 
in 50 mmol/L Tris-HCl (pH 7.4), the gel was 
incubated for 18 hours in 50 mmol/L Tris-HCl 
(pH 7.4), 5 mmol/L CaCl
2
, 1% Triton X-100, 
0.02% NaN
3
, and subsequently stained by 
Coomassie brilliant blue R-250. 
In vivo tumor growth. 
 Animal studies were approved by the 
Ins�tu�onal Review Board for animal 
experiments. Male BALB/c athymic nude mice 
(nu/nu) were bred under specified pathogen-
free condi�ons and used when 8 weeks old. 
Tumor cells were harvested using trypsin/
EDTA, washed, and suspended in PBS. One 
hundred microliters of suspension containing 
2x106 cells were inoculated s.c. Mice were 
inspected twice a week for general condi�on 
and local tumor growth was monitored. A�er 
4 weeks, the animals  were euthanized, tumors 
were dissected, frozen in liquid nitrogen, and 
stored at -70°C. Extracts from nonnecro�c 
tumor �ssue were analyzed by gela�n 
 BLM cell cultures were transiently 
transfected using Oligofectamine reagent 
(Invitrogen,  Carlsbad, CA) and a blunt-
ended duplex of the RNA oligonucleo�des 
5‘-AAGCCCGAUGGCUCCCCAGUAUU-3‘ and 
5‘-AAUACUGGGGAGCCAUCGGGCUU-3‘ (RNA-
TEC, Leuven, Belgium). Seventy-two hours 
pos�ranfec�on, the transfec�on procedure 
was repeated. Short interfering RNA (siRNA)–
treated cells were detached from the culture 
vessel by a trypsin/EDTA treatment and used 
in subsequent experiments. 
Coa�ng of latex beads. 
A 10% (w/v) mixture of 3.0 µm latex beads 
(Sigma- Aldrich, Zwijndrecht, the Netherlands) 
was incubated with 100 µg/mL an�body 
solu�on in the presence of 50mmol/L MES (pH 
6.1). A�er overnight incuba�on on a rotator at 
4°C, the beads were washed twice with PBS 
and blocked by 90 minutes incuba�on with 
10 mg/mL bovine serum albumin (BSA) in PBS 
while rota�ng. The beads were washed twice 
in serum-free medium. Twentymicroliters of 
bead suspension were added to cell cultures 
in 24-well plates. Condi�oned media were 
isolated a�er 48 hours of incuba�on. 
Three-dimensional collagen culture. 
 Cells were cultured in either 5 mL (six-well 
plate, surface area 10 cm2) or 1 mL (24-well 
plate, surface area 2 cm2) cultures. Five-
milliliter cultures were prepared by mixing 
420 µL of 3.6 mg/mL rat tail collagen type I (BD 
Biosciences, Alphen a/d Rijn, the Netherlands) 
with 4 mL DMEM containing 10% serum and 
neutralized by 14 µL of 0.1 mol/L NaOH. Two 
hundred microliters of cells suspended in 
DMEM-containing serum were added a�er 
mixing and were incubated at 37°C. Gels 
formed a�er 10 to 15 minutes of incuba�on. 
A�er overnight incuba�on, the medium was 
removed, the gels were washed with PBS, 
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levels were evaluated as the number of cycle 
difference from GAPDH. Significant changes 
from control samples were determined using 
the standard Student’s t test (n = 3). P ≥ 0.05 
was considered significant. 
Western blo�ng.
 Collagen gels were centrifuged and washed 
with PBS. Cell extracts were prepared by using 
lysis buffer [50 mmol/L Tris-HCl (pH 7.4), 1% 
NP40, 140 mmol/L NaCl, 1 mmol/L MgCl
2
, 
and 1 mmol/L CaCl
2
] containing 1 mmol/L 
phenylmethylsulfonyl fluoride and proteinase 
inhibitor cocktail. Protein concentra�ons 
were determined using the BCA kit (Pierce, 
Rockford, IL). Twenty micrograms of cell lysate 
were separated by SDS-PAGE on 10% PAA gels 
for MT1-MMP and MMP-2 detec�on or 15% 
PAA gels for TIMP-2 detec�on, and transferred 
to polyvinylidene difluoride membrane. 
Bound primary an�bodies were visualized by 
appropriate HRPcoupled secondary an�bodies 
and enhanced chemiluminescence using the 
ECL Plus Western blo�ng Detec�on System 
(Amersham Biosciences, Roosendaal, the 
Netherlands). 
zymography as described.
Histochemical staining of collagen gels. 
 Collagen gels were fixed 4 hours in 
formaldehyde containing 0.2% Tween 20, 
dehydrated, and embedded in paraffin. 
Microtome specimens (6 µm) were stained 
by H&E staining procedure. For ALCAM 
visualiza�on on paraffin-embedded material, 
an an�gen retrieval procedure was used 
in which specimens were heated in a rice 
steamer in citrate buffer for 10 minutes. 
Specimens were incubated in normal horse 
serum, followed by an�-ALCAM monoclonal 
an�body, and subsequently by bio�nylated 
secondary horse an�-mouse IgG (Vector 
Labs, Burlingame, CA). Bound an�body was 
visualized by incuba�on with avidin/bio�n 
complex (Vector Labs), bio�nylated HRP, and 
aminoethylcarbazole as the substrate.
Quan�ta�ve real-�me PCR.
 mRNA was isolated using the RNeasy mini 
kit (Qiagen, Venlo, the Netherlands) and used 
as cDNA synthesis template using Superscript 
III reverse transcriptase (Invitrogen). For 
amplifica�on of glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) cDNA, the forward 
primer 5‘- ATCTTCTTTTGCGTCGCCAG-3‘ and 
reverse primer 5‘-TTCCCCATGGTGTCTGAGC-
3‘ were used. For MT1-MMP cDNA, forward 
primer 5‘-ATCATGGCACCCTTTTACCA-3‘ and 
reverse primer 5‘CCTGACTCACCCCCATAAAG- 
3‘ were used. For MMP-2 cDNA, forward 
primer 5‘-GGCATTCAGGAGCTCTATGG-3‘ and 
reverse primer 5‘-GAGCGATGCCATCAAATACA- 
3‘ were used. For TIMP-2 cDNA, forward 
primer 5‘-GTAGTGATCAGGGCCAAAGC-3‘ and 
reverse primer 5‘-CAGGCCCTTTGAACATCTTT-
3‘ were used. cDNA levels were determined 
using SYBR green fluorescence with the Abi-
Prism 7000 (Applied Biosystems, Nieuwerkerk 
a/d IJssel, the Netherlands). Expression 
34 Chapter 2 35ALCAM and Matrix Metalloproteinase Activity
References
1.  McCawley LJ, Matrisian LM. Matrix metalloproteinases: mul�func�onal contributors to tumor progression. 
Mol Med Today 2000;6:149–56.
2.  Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001;17:
463–516.
3.  Brinckerhoff CE, Matrisian LM. Matrix metalloproteinases: a tail of a frog that became a prince. Nat Rev Mol Cell 
Biol 2002;3:207–14.
4.  Koshiba T, Hosotani R, Wada M, et al. Involvement of matrix metalloproteinase-2 ac�vity in invasion and 
metastasis of pancrea�c carcinoma. Cancer 1998;82:642–50.
5.  Baker EA, Bergin FG, Leaper DJ. Matrix metalloproteinases, their �ssue inhibitors and colorectal cancer staging. 
Br J Surg 2000;87:1215–21.
6.  Edwards JG, McLaren J, Jones JL, Waller DA, O’Byrne KJ. Matrix metalloproteinases 2 and 9 (gela�nases A and 
B) expression in malignant mesothelioma and benign pleura. Br J Cancer 2003;88:1553–9.
7.  Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI. Mechanism of cell surface ac�va�on 
of 72-kDa type IV collagenase. Isola�on of the ac�vated form of the membrane metalloprotease. J Biol Chem 
1995;270:5331–8.
8.  Butler GS, Butler MJ, Atkinson SJ, et al. The TIMP2 membrane type 1 metalloproteinase ‘‘receptor’’ regulates 
the concentra�on and efficient ac�va�on of progela�nase A. A kine�c study. J Biol Chem 1998;273: 871–80.
9.  Kinoshita T, Sato H, Okada A, et al. TIMP-2 promotes ac�va�on of progela�nase A by membrane-type 1 matrix 
metalloproteinase immobilized on agarose beads. J Biol Chem 1998;273:16098–103. 
10.  Itoh Y, Takamura A, Ito N, et al. Homophilic complex forma�on of MT1-MMP facilitates proMMP-2 ac�va�on on 
the cell surface and promotes tumor cell invasion. EMBO J 2001;20:4782–93.
11.  Sounni NE, Baramova EN, Munaut C, et al. Expression of membrane type 1 matrix metalloproteinase (MT1-
MMP) in A2058 melanoma cells is associated with MMP-2 ac�va�on and increased tumor growth and 
vasculariza�on. Int J Cancer 2002;98:23–8.
12.  Stanton H, Gavrilovic J, Atkinson SJ, et al. The ac�va�on of ProMMP-2 (gela�nase A) by HT1080 fibrosarcoma 
cells is promoted by culture on a fibronec�n substrate and is concomitant with an increase in processing of 
MT1-MMP (MMP-14) to a 45 kDa form. J Cell Sci 1998;111:2789–98.
13.  Ellerbroek SM, Fishman DA, Kearns AS, Bafe� LM, Stack MS. Ovarian carcinoma regula�on of matrix 
metalloproteinase-2 and membrane type 1 matrix metalloproteinase through h1 integrin. Cancer Res 1999;59: 
1635–41.
14.  Kurschat P, Wickenhauser C, Groth W, Krieg T, Mauch C. Iden�fica�on of ac�vated matrix metalloproteinase-2 
(MMP-2) as the main gela�noly�c enzyme in malignant melanoma by in situ zymography. J Pathol 2002;197:
179–87.
15.  Brooks PC, Stromblad S, Sanders LC, et al. Localiza�on of matrix metalloproteinase MMP-2 to the surface of 
invasive cells by interac�on with integrin avh3. Cell 1996;85:683–93.
16.  Hofmann UB, Westphal JR, van Kraats AA, Ruiter DJ, van Muijen GN. Expression of integrin a(v)h(3) correlates 
with ac�va�on of membrane-type matrix metalloproteinase-1 (MT1-MMP) and matrix metalloproteinase-2 
(MMP-2) in human melanoma cells in vitro and in vivo . Int J Cancer 2000;87:12–9.
17.  Hofmann UB, Westphal JR, Waas ET, Becker JC, Ruiter DJ, van Muijen GN. Coexpression of integrin a(v)h3 and 
matrix metalloproteinase-2 (MMP-2) coincides with MMP-2 ac�va�on: correla�on with melanoma progression. 
J Invest Dermatol 2000;115:625–32.
18.  Deryugina EI, Ratnikov B, Monosov E, et al. MT1-MMP ini�ates ac�va�on of pro-MMP-2 and integrin avh3 
promotes matura�on of MMP-2 in breast carcinoma cells. Exp Cell Res 2001;263:209–23. 19. Galvez BG, 
Ma�as-Roman S, Yanez-Mo M, Sanchez-Madrid F, Arroyo AG. ECM regulates MT1-MMP localiza�on with h1 or 
avh3 integrins at dis�nct cell compartments modula�ng its internaliza�on and ac�vity on human endothelial 
cells. J Cell Biol 2002;159:509–21.
20.  Yana I, Weiss SJ. Regula�on of membrane type-1 matrix metalloproteinase ac�va�on by proprotein 
convertases. Mol Biol Cell 2000;11:2387–401.
21.  Okumura Y, Sato H, Seiki M, Kido H. Proteoly�c ac�va�on of the precursor of membrane type 1 matrix 
metalloproteinase by human plasmin. A possible cell surface ac�vator. FEBS Le� 1997;402:181–4.
22.  Degen WG, van Kempen LC, Gijzen EG, et al. MEMD, a new cell adhesion molecule in metastasizing human 
melanoma cell lines, is iden�cal to ALCAM (ac�vated leukocyte cell adhesion molecule). Am J Pathol 1998;152:
805–13.
23.  Hofmann UB, Westphal JR, Waas ET, et al. Matrix metalloproteinases in human melanoma cell lines and 
xenogra�s: increased expression of ac�vated matrix metalloproteinase-2 (MMP-2) correlates with melanoma 
progression. Br J Cancer 1999;81:774–82.
24.  van Kempen LC, van den Oord JJ, van Muijen GN, Weidle UH, Bloemers HP, Swart GW. Ac�vated leukocyte cell 
adhesion molecule/CD166, a marker of tumor progression in primary malignant melanoma of the skin. Am J 
34 Chapter 2 35ALCAM and Matrix Metalloproteinase Activity
Pathol 2000;156:769–74.
25.  Hofmann UB, Westphal JR, Zendman AJ, Becker JC, Ruiter DJ, van Muijen GN. Expression and ac�va�on of 
matrix metalloproteinase-2 (MMP-2) and its co-localiza�on with membrane-type 1 matrix metalloproteinase 
(MT1-MMP) correlate with melanoma progression. J Pathol 2000;191:245–56.
26.  van Kempen LC, Nelissen JM, Degen WG, et al. Molecular basis for the homophilic ac�vated leukocyte cell 
adhesion molecule (ALCAM)-ALCAM interac�on. J Biol Chem 2001;276:25783–90.
27.  van Kempen LC, Meier F, Egeblad M, et al. Trunca�on of ac�vated leukocyte cell adhesion molecule: a gateway 
to melanoma metastasis. J Invest Dermatol 2004;122:1293–301.
28.  Swart GW. Ac�vated leukocyte cell adhesion molecule (CD166/ALCAM): developmental and mechanis�c 
aspects of cell clustering and cell migra�on. Eur J Cell Biol 2002;81:313–21.
29.  Swart GW, Lunter PC, van Kilsdonk JW, van Kempen LC. Ac�vated Leukocyte cell adhesion molecule (ALCAM/
CD166): signaling at the divide of melanoma cell clustering and cell migra�on? Cancer Metastasis Rev 2005;24:
223–36.
30.  Leh� K, Lohi J, Valtanen H, Keski-Oja J. Proteoly�c processing of membrane-type-1 matrix metalloproteinase is 
associated with gela�nase A ac�va�on at the cell surface. Biochem J 1998;334:345–53.
31.  Kurschat P, Zigrino P, Nischt R, et al. Tissue inhibitor of matrix metalloproteinase-2 regulates matrix 
metalloproteinase-2 ac�va�on by modula�on of membranetype 1 matrix metalloproteinase ac�vity in high 
and low invasive melanoma cell lines. J Biol Chem 1999;274:21056–62.
32.  Ellerbroek SM, Stack MS. Membrane associated matrix metalloproteinases in metastasis. Bioessays 1999;21:
940–9.
33.  Klein CE, Dressel D, Steinmayer T, et al. Integrin a2h1 is upregulated in fibroblasts and highly aggressive 
melanoma cells in three-dimensional collagen la�ces and mediates the reorganiza�on of collagen I fibrils. J 
Cell Biol 1991;115:1427–36.
34.  Guo H, Zucker S, Gordon MK, Toole BP, Biswas C. S�mula�on of matrix metalloproteinase produc�on by 
recombinant extracellular matrix metalloproteinase inducer from transfected Chinese hamster ovary cells. J 
Biol Chem 1997;272:24–7.
35.  Sameshima T, Nabeshima K, Toole BP, et al. Glioma cell extracellular matrix metalloproteinase inducer 
(EMMPRIN) (CD147) s�mulates produc�on of membrane-type matrix metalloproteinases and ac�vated 
gela�nase A in co-cultures with brain-derived fibroblasts.Cancer Le� 2000;157:177–84.
36.  Li R, Huang L, Guo H, Toole BP. Basigin (murine EMMPRIN) s�mulates matrix metalloproteinase produc�on by 
fibroblasts. J Cell Physiol 2001;186:371–9. 
37.  Suzuk S, Sato M, Senoo H, Ishikawa K. Direct cell-cell interac�on enhances pro-MMP-2 produc�on and 
ac�va�on in co-culture of laryngeal cancer cells and fibroblasts: involvement of EMMPRIN and MT1-MMP. Exp 
Cell Res 2004;293:259–66. 
38.  Takahashi M, Tsunoda T, Seiki M, Nakamura Y, Furukawa Y. Iden�fica�on of membrane-type matrix 
metalloproteinase-1 as a target of the h-catenin/Tcf4 complex in human colorectal cancers. Oncogene 
2002;21:5861–7.
39.  Hlubek F, Spaderna S, Jung A, Kirchner T, Brabletz T. h-catenin ac�vates a coordinated expression of the 
proinvasive factors laminin-5 g2 chain and MT1- MMP in colorectal carcinomas. Int J Cancer 2004;108: 321–6.
40.  Nawrocki-Raby B, Gilles C, Pole�e M, et al. E-cadherin mediates MMP down-regula�on in highly invasive 
bronchial tumor cells. Am J Pathol 2003;163: 653–61.
41.  Kohya N, Kitajima Y, Jiao W, Miyazaki K. Effects of E-cadherin transfec�on on gene expression of a gallbladder 
carcinoma cell line: repression of MTS1/ S100A4 gene expression. Int J Cancer 2003;104:44–53. 
42.  Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribula�ons. 
Science 2002;295:2387–92. 
43.  Wolf K, Mazo I, Leung H, et al. Compensa�on mechanism in tumor cell migra�on: mesenchymalamoeboid 
transi�on a�er blocking of pericellular proteolysis. J Cell Biol 2003;160:267–77.

chapter 3
A� enua� on of melanoma invasion 
by a secreted variant of Ac� vated 
Leukocyte Cell Adhesion Molecule
Cancer Research 2008; 68: (10)
Jeroen W.J. van Kilsdonk 1 
Roel H. Wil� ng 1
Mieke Bergers 2
Goos N.P. van Muijen 3
Joost Schalkwijk 2
Léon C.L.T. van Kempen 3
Guido W.M. Swart 1
1 Department of Biochemistry, Nijmegen Center of Molecular Life   
   Sciences, Radboud University Nijmegen 
2 Department of Dermatology, University Medical Center st Radboud,         
   Nijmegen, the Netherlands 
3 Department of Pathology, University Medical Center st Radboud,         
   Nijmegen, the Netherlands
38 Chapter 3 39soluble ALCAM and melanoma metastasis
38 Chapter 3 39soluble ALCAM and melanoma metastasis
Ac�vated leukocyte cell adhesion molecule (ALCAM/CD166/MEMD), a marker of various cancers and mesenchymal stem cells, is involved in melanoma metastasis. We have exploited a secreted NH
2
-terminal fragment, sALCAM, to test the hypothesis that 
ALCAM coordinates �ssue growth and cell migra�on. Overexpression of sALCAM in metasta�c 
melanoma cells disturbed clustering of endogenous ALCAM and inhibited ac�va�on of matrix 
metalloproteinase-2 (MMP-2). Exposure of HT1080 fibrosarcoma cells to sALCAM similarly 
inhibited MMP-2, sugges�ng a broader effect on ALCAMposi�ve tumor cells. In contrast to the 
previously reported, promo�ve effects of an NH
2
-terminally truncated, transmembrane variant 
(∆N-ALCAM), sALCAM impaired the migratory capacity of transfected cells in vitro, reduced 
basement membrane penetra�on in recons�tuted human skin equivalents, and diminished 
metasta�c capacity in nude mice. Remarkably, L1 neuronal cell adhesion molecule (L1CAM/
CD171), another progression marker of several cancers including melanoma, was suppressed 
upon sALCAM overexpression but was up-regulated by ∆N-ALCAM. The par�ally overlapping and 
opposite effects induced by alterna�vestrategies targe�ng ALCAM func�ons collec�vely a�ribute 
an integra�ve role to ALCAM in orchestra�ng cell adhesion, growth, invasion, and proteolysis in 
the tumor �ssue microenvironment and disclose a therapeu�c poten�al for sALCAM. 
Introduc�on
 Cancer is frequently accompanied by 
aberrant distribu�ons and/or func�ons of cell 
adhesion molecules, e.g., involving members 
of the cadherin and/or immunoglobulin 
families (1–3). Aberrant expression profiles 
of ac�vated leukocyte cell adhesion molecule 
(ALCAM/MEMD/CD166) were reported 
in a series of different cancer �ssues and 
cells (e.g., melanoma, prostate carcinoma, 
breast cancer, esophageal squamous cell 
carcinoma, colorectal carcinoma, and bladder 
cancer; refs. 4–9). Addi�onally, random 
phage display searches iden�fied ALCAM as 
a readily accessible, therapeu�c target on 
different cancer cells (10, 11). ALCAM is a 
member of the small VVC2C2C2 subgroup 
of the immunoglobulin superfamily, which 
also includes MUC18/MelCAM/CD146 and 
B-CAM/Lutheran/CD239. ALCAM shows 
a characteris�c, temporal, and spa�al 
distribu�on in development of a wide variety of 
�ssues and cells in health and disease. Besides 
cancer, ALCAM is involved in embryogenesis, 
neurogenesis, angiogenesis, hematopoiesis, 
immune response, and it is applied as a marker 
of pluripotent mesenchymal stem cells (for 
reviews, see refs. 12, 13). 
In general, dynamic modula�on of cell adhesion 
is crucial for �ssue architecture, growth, and 
migra�on. It tunes cellular responses and 
microenvironmental signals and maintains 
the proper embedding of cells in a �ssue. 
To address the pleiotropic roles of ALCAM 
in cancer dynamics, we have proposed a 
working model for its homophilic cell adhesion 
func�on based on structurefunc�on analyses 
(Fig. 1A; refs. 14, 15). Briefly, oligomeriza�on 
on the cell surface and intercellular receptor–
ligand binding would synergis�cally promote 
ALCAM recruitment and network forma�on in 
regions of cell-cell contact. The dual func�ons 
are provided by an oligomeriza�on module, 
which consists of the membrane-proximal, 
C2-type immunoglobulin domains (D3–D5), 
and a ligand-binding module, which consists of 
the membrane-distal, V-type immunoglobulin 
domains (D1–D2). ALCAM clustering may be 
controlled by unconven�onal anchoring of 
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its short cytoplasmic tail (32 amino acids) 
to the ac�n cytoskeleton (16, 17). Cognate 
ALCAM proper�es are disturbed by a dele�on 
mutant, ΔN-ALCAM, which conserves the 
oligomeriza�on proper�es (domains D3–D5) 
but lacks the ligand-receptor binding func�on 
(D1–D2). Ectopic expression of ∆N-ALCAM 
interferes with intercellular ALCAM network 
forma�on (Fig. 1B). Overexpression of ΔN-
ALCAM in metasta�c melanoma cells not 
only interfered with endogenous ALCAM but 
also aggravated the invasive cell behavior 
(18). Unexpectedly, increase and accelera�on 
of spontaneous metastasis in nude mice 
were accompanied by the near-complete 
inhibi�on of the ac�va�on cascade for matrix 
metalloproteinase-2 (MMP-2; ref. 19). The 
overall phenotype induced by ΔN-ALCAM was 
remarkable because it apparently uncoupled 
proteolysis from invasiveness. The associa�on 
of these proper�es is commonly believed 
to favor tumor growth and metastasis. 
Therefore, the results suggested that the 
proper integra�on of oligomeriza�on and 
ligand receptor–binding proper�es of ALCAM 
could be pivotal to coordinate tumor �ssue 
development and invasion. 
Our previous experiments with ΔN-ALCAM 
primarily targeted the oligomeriza�on module. 
The present study aimed at supplemen�ng this 
strategy by targe�ng the ligand binding module 
via overexpression of a secreted (s)ALCAM 
variant (Fig. 1C). The sALCAM variant, which 
apparently impaired cell-cell interac�ons, was 
recently isolated as an alterna�ve, shortened 
ALCAM transcript in endothelial cells (20). 
This transcript comprised the first three exons 
and only encoded the NH
2
-terminal signal 
sequence plus immunoglobulin domain D1. 
Immunoglobulin domain D1 was required for 
ligand binding (14). Exposure of endothelial 
cells to recombinant sALCAM increased 
cell migra�on and decreased capillary tube 
Figure 1. Working model for ALCAM func�on. 
A, ALCAM is a 105-kDa transmembrane cell adhesion 
molecule belonging to the immunoglobulin superfamily. 
It consists of five extracellular IgG domains (D1–D5): D1 
and D2 are variable (V-type) domains and D3 to D5 are 
constant (C2-type) domains followed by a transmembrane 
domain (tm) and a short (32 amino acids) COOH-
terminal cytoplasmic tail (ct). Domains D3 to D5 form a 
oligomeriza�on module (o), which is involved in lateral 
ALCAM oligomeriza�on thereby increasing the avidity 
of homophilic ligand binding mediated by the ligand 
binding module (lb ) consis�ng of D1 and D2. B, model for 
amino-terminally truncated ALCAM (ΔN-ALCAM). Ectopic 
expression of ΔN-ALCAM comprising domains D3 to D5 
interferes with intercellular ALCAM network forma�on. 
C, model for soluble ALCAM (sALCAM). sALCAM refers to 
secreted domain D1, which is involved in ligand binding. 
sALCAM presumably blocks homophilic receptor ligand 
binding. 
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Results
 Expression of sALCAM. 
The recent isola�on of an alterna�ve transcript 
encoding a secreted sALCAM variant in 
endothelial cells hinted at a novel regulatory 
mechanism of ALCAM (20). Therefore, we 
determined if sALCAM transcripts were 
present in the human melanoma cell line BLM. 
Semiquan�ta�ve PCR assays revealed posi�ve 
signals for GAPDH and ALCAM, whereas no 
sALCAM signal could be observed (not shown). 
In agreement with previous Northern blot 
analyses (28), we again concluded that BLM 
cells expressed neither alterna�ve ALCAM 
forma�on (20). We thus an�cipated that 
transfec�on of sALCAM into metasta�c 
melanoma cells would influence cell clustering 
by challenging ligand-receptor binding and 
intercellular network forma�on of endogenous 
ALCAM (cf. Fig. 1C) and, as a consequence, 
affect the coordina�on of proteolysis, tumor 
growth, and metastasis (cf. ref. 19). 
Whereas the ectopic ΔN-ALCAM mainly 
aggravated the invasive behavior of the 
previously metasta�c melanoma cells, the 
present series of experiments revealed 
that overexpression of sALCAM primarily 
a�enuated the invasive proper�es of the 
targeted cells. Furthermore, we found 
that disturbance of ALCAM func�on had a 
major effect on neuronal L1 cell adhesion 
molecule (L1CAM/CD171), which is involved 
in tumorigenesis (21–27). Interpre�ng the 
par�ally overlapping and opposite effects 
of overexpressing sALCAM or ΔN-ALCAM 
in melanoma cells, our results disclose that 
ALCAM involvement in cell clustering is 
important for coordina�on of local growth 
and �ssue invasion. 
transcripts nor any related secreted ALCAM 
isoforms.
Then, we transfected sALCAM expression 
constructs into BLM cells to check the effects 
on cognate ALCAM. A series of stable cell 
clones was generated expressing and secre�ng 
sALCAM, ranging from low (BLM/sAlow), 
medium (BLM/sAmed), to high secre�on (BLM/
sAhigh). Using the COOH-terminally a�ached 
FLAG-epitope tag, sALCAM was detected 
in cell lysates (Fig. 2A, le�) and condi�oned 
culture medium of BLM/sALCAM cells (Fig. 
2A, right), confirming protein expression and 
secre�on. The double bands on the Western 
blot were due to two N-linked glycosyla�on 
sites in sALCAM (20). It was no�ced in the 
course of the experiments that BLM/sAhigh 
clones tended to completely lose sALCAM 
expression. The reverted phenotype was 
always comparable with parental BLM (results 
not shown). sALCAM expression in BLM/sAmed 
remains constant and BLM/sALCAM generally 
refers to BLM/sAmed cells in the following 
sec�ons. 
sALCAM effects on ALCAM clustering and cell 
migra�on.
Previous confocal  experiments showed strong 
fluorescent bands reflec�ng recruitment of 
ALCAM and apparent network forma�on
in regions of cell-cell contact (Fig. 2B, BLM, 
arrows; cf. ref. 28). Upon overexpression of 
sALCAM, the banding pa�ern was lost and the 
transfected cells maintained an even ALCAM 
distribu�on all along the plasma membrane 
despite direct cell-cell contacts (Fig. 2B, BLM/
sALCAM, arrowheads). This suggested that 
sALCAM impaired focal recruitment of ALCAM 
clusters along the plasma membrane and, as 
a consequence, prevented extended ALCAM 
network forma�on. Cell morphology was not 
significantly affected by sALCAM.  
The disrup�on of the ALCAM network by 
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Figure 2. sALCAM expression influences membrane distribu�on of ALCAM and cell migra�on. 
A, Western blot analysis was used to determine the expression levels of sALCAM in cell lysates of stable transfectants (15 
Ag; le� ) and in condi�oned medium (right ). Three representa�ve independently isolated transfectants with increasing 
amounts of sALCAM expression and secre�on were selected—BLM/sALCAM with high expression (sAhigh ), BLM/sALCAM 
with medium expression (sAmed), and BLM/sALCAM with low expression (sAlow ). BLM/sALCAM control (Cont.) is resistant to 
neomycin but lacks sALCAM expression. B, ALCAM membrane distribu�on by confocal analysis. BLM and BLM/sALCAM cells 
were grown on coverslips and stained with monoclonal an�body AZN L-50 recognizing the membrane proximal domains 
D4 and D5. Le�, arrows, cell-cell junc�ons with increased ALCAM staining as a result of ALCAM clustering in BLM cells. 
Right, a random membrane distribu�on of ALCAM is observed in BLM/sALCAM cells; arrowheads, cell-cell junc�ons where, 
in contrast to BLM, no increase in ALCAM staining is observed. Both images were taken using the same instrument se�ngs. 
C, pictures taken of in vitro wound closure in �me. Monolayer cultured confluent BLM, BLM/ΔN-ALCAM, and BLM sALCAM 
cells at 2, 4, 6, and 8.5 h a�er scraping of the monolayer 
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Figure 3. sALCAM expression prevents MMP-2 ac�va�on. A, zymography of medium condi�oned by BLM, HT1080, 
and/or BLM/sALCAM. 
Cells were grown as superconfluent monolayers (>2.5x105/cm2) and in three-dimensional type 1 collagen cultures (7.5x105 
per gel). A�er 24 h of incuba�on, all samples taken from monolayer cultures are nega�ve for the 59 kDa ac�ve form of 
MMP-2 (act MMP). BLM cells, and to a lower extent sAlow, are capable of ac�va�ng MMP-2 when grown in collagen. The 
effect of sALCAM on HT1080 was assessed by preparing separate collagen gels embedded with either BLM/sALCAM or 
HT1080 (5.0x105 cells each); a�er 24 h, the two gels were transferred to one well and incuba�on was con�nued with fresh 
serum-free medium for another 24h before condi�oned medium was collected from the combined culture (right). Note that 
physical contact between HT1080 and BLM/sALCAM was avoided in this setup. B, quan�ta�ve PCR analysis of MT1-MMP, 
TIMP-2, and MMP-2 mRNA levels in BLM and BLM/sALCAM cells. Cells were cultured as monolayers at high cell density 
(>2.5x105/cm2). mRNA levels of BLM cells (white columns) were compared with messenger levels of BLM/sALCAM cells 
(black columns). Expression levels of BLM cells were set to 100% for each gene. sALCAM expression significantly reduces the 
expression of MT1-MMP and MMP-2; TIMP-2 levels are unaffected by sALCAM. Experiments were performed in triplicates. 
*, P ≤ 0.05 significant difference (Student’s t test). C, BLM, BLM/∆N-ALCAM, and BLM/sALCAM cells were cultured as 
monolayers in a 24-well plate at low density (1.0x105). A�er overnight incuba�on, cells were treated without or with ConA 
for 24 h. Condi�oned media were harvested and subjected to gela�n zymography. Only BLM ac�vates MMP-2 when ConA 
is added. D, mock and siRNA (against ALCAM) transfected cells were treated with or without ConA. Knockdown of ALCAM 
cannot block the ConA mediated ac�va�on of MMP-2.
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ΔN-ALCAM resulted in increased cell mobility 
compared with BLM in a wound-healing assay 
in vitro (Fig. 2C; cf. ref. 18). BLM/ΔN-ALCAM 
cells rapidly migrated into the gap as sca�ered 
cells. By contrast, BLM/sALCAM cells were 
retarded in gap closure rela�ve to control cells 
(Fig. 2C; 16% gap closure for BLM/sALCAM 
in 8.5 h compared with 32% for BLM). Thus, 
interfering with ALCAM-ALCAM interac�ons 
by sALCAM decreased cell mobility in vitro. 
sALCAM and the ac�va�on cascade of MMP-
2.
The ac�va�on cascade of MMP-2 involves 
the assembly of a ternary complex of MT1-
MMP, �ssue inhibitor of metalloproteinase-
2 (TIMP-2), and pro–MMP-2 (32, 33). We 
previously reported that efficient triggering of 
this ac�va�on cascade equally depended on 
sufficient cell-matrix and cell-cell interac�ons 
and required func�onal ALCAM (19). To 
inves�gate puta�ve sALCAM effects on MMP-
2 ac�va�on, a representa�ve series of BLM/
sALCAM cells were grown to high cell densi�es 
as two-dimensional monolayer and three-
dimensional collagen cultures. Zymography 
revealed one single band of 72 kDa in the 
condi�oned medium from all twodimensional 
monolayer cultures, represen�ng pro–MMP-
2 (Fig. 3A, monolayer; cf. refs. 19, 34). 
Furthermore, the amounts of secreted 
pro–MMP-2 diminished with increasing levels 
of sALCAM. BLM cells grown in collagen gels 
processed pro–MMP-2 via an intermediate 
(62 kDa) to ac�ve MMP-2 (59 kDa; Fig. 3A, 
collagen matrix). BLM clones secre�ng 
sALCAM at intermediate and high levels 
showed no ac�va�on of MMP-2 at all, whereas 
secre�on of sALCAM at low levels reduced the 
conversion of pro–MMP-2 to ac�ve MMP-2 
compared with control cells (Fig. 3A, collagen 
matrix). Therefore, the apparent disrup�on of 
the ALCAM network by sALCAM prevented 
MMP-2 ac�va�on. This result was similar to 
the effects induced by ΔN-ALCAM and ALCAM 
deple�on (19). 
To inves�gate whether the induced effects 
would be more generally applicable, collagen 
gels of human fibrosarcoma HT1080 and BLM/
sALCAM cells were separately prepared and 
transferred to one culture well a�er 24 hours 
with the aim to evaluate the effects of sALCAM 
on HT1080. Physical contacts between 
HT1080 and BLM/sALCAM were avoided 
in this experimental setup. Zymography 
analysis of the biculture condi�oned medium 
revealed that sALCAM also decreased the 
levels and ac�va�on of MMP-2 in HT1080 (Fig. 
3A, HT1080). The presence of sALCAM also 
correlated with a reduced amount of MMP-
9 (this effect was not further analyzed). The 
analysis of condi�oned medium from control 
cocultures of HT1080 and BLM showed that 
MMP levels essen�ally reflected the addi�on 
of separate contribu�ons (not shown). The 
influences of sALCAM on na�ve HT1080 
reassured that the effects observed in BLM/
sALCAM were indeed due to the secreted 
protein and not to poten�al side effects of 
overexpression. 
To check for upstream changes in the cascade, 
we applied quan�ta�ve PCR and found 
significant decreases in mRNA levels of both 
MT1-MMP and MMP-2 upon overexpression 
of sALCAM, whereas TIMP-2 levels did not 
significantly change (Fig. 3B). The reduced 
mRNA levels of MMP-2 corresponded with the 
zymography results (Fig. 3A). Further assessing 
the deficient conversion of pro–MMP-2 to 
the ac�ve enzyme, we used ConA to test the 
involvement of MT1-MMP. ConA potently 
promoted ac�va�on of MMP-2 in a MT1-
MMP–dependent manner and bypassed the 
need of cell-matrix interac�ons (35–38). The 
addi�on of ConA to BLM cells in monolayer 
indeed triggered MMP-2 ac�va�on (Fig. 3C) 
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Figure 4. sALCAM affects the invasive poten�al of BLM cells in reconstructed skin. 
The invasive poten�al of BLM cells expressing sALCAM was tested in human reconstructed skin. H&E, heparan sulfate, and 
calcyclin staining were performed on the skin constructs. A, sAhigh cells showed no invasion into the dermis. sAmed cells invade 
the dermis through the basement membrane as single cells; however, many cells remain in the reconstructed epidermis. 
BLM/sALCAM cells with low expression of sALCAM (sAlow) are aggressively invading the dermis, compared with sAmed in 
which few cells remain in the reconstructed epidermis; B, the presence of basement membranes is shown by heparan 
sulfate staining. C, tumor cells are iden�fied with calcyclin staining. D, melanoma cells accumulate on top of basement 
membrane and dermal structures in the absence of kera�nocytes and epidermis. 
and, furthermore, this induc�on also bypassed 
the need for cell-cell contacts (results not 
shown). BLM cells depleted for ALCAM by 
small interfering RNA (siRNA) treatment did 
not ac�vate  MMP-2 when grown in collagen 
(19). Addi�on of ConA to monolayer cultures of 
ALCAM-depleted BLM cells, however, induced 
MMP-2 ac�va�on (Fig. 3D). In contrast, the 
triggering by ConA was abolished in BLM/
sALCAM and in BLM/ΔN-ALCAM cultures 
(Fig. 3C). Therefore, physiologic ac�va�on 
of the MMP-2 cascade depended on ALCAM. 
The pharmacologic bypass provided by ConA 
relieved this dependence but was impaired by 
the presence of defec�ve ALCAM. 
sALCAM and melanoma growth in recons�tuted 
human skin equivalents. 
A�er the encouraging observa�ons of 
reduced cell mobility and inhibi�on of MMP-2 
processing, we were interested to inves�gate 
the invasive capacity of BLM/sALCAM cells 
in recons�tuted skin equivalents assembled 
on human DED. The histologic analysis of 
the recons�tuted skin equivalents revealed 
an inverse rela�on between sALCAM 
overexpression levels and invasive poten�al 
of different BLM/sALCAM cells (i.e., sAlow 
cells were most invasive; sAhigh cells were 
least invasive; Fig. 4A). The presence of the 
basement membrane was confirmed by 
heparan sulfate (Fig. 4B), laminin, and collagen 
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IV (data not shown) staining. Melanoma cells 
were iden�fied by calcyclin staining (Fig. 4C, 
arrowheads). In the absence of kera�nocytes, 
all melanoma cells, with or without sALCAM 
expression, accumulated on top of DED and 
did not penetrate the basement membrane 
structures (Fig. 4D). BLM/sAlow cells 
abundantly invaded the dermal structures 
as single cells; the number of  invasive BLM/
sAmed cells was reduced rela�ve to BLM/sAlow; 
BLM/sAhigh cells did not detectably invade into 
DED (Fig. 4A). These findings indicated that 
the overexpression of sALCAM inhibited the 
invasive poten�al of BLM.
sALCAM and spontaneous lung metastasis in a 
xenogra� mouse model. 
To extrapolate the apparent, invasion-
suppressing role of sALCAM to an in vivo 
metastasis model, series of nude mice were 
s.c. inoculated with BLM/sALCAM cells. Tumor 
take was detected in all animals a�er 14 days 
and the xenogra� growth was recorded twice a 
week. Mice were sacrificed a�er 24 or 34 days 
to vary primary xenogra� sizes. In �me, average 
tumor volumes of  BLM/sALCAM did not differ 
from those of BLM/control, minimizing any 
prolifera�on bias (Supplementary Fig. 1, at the 
Table 1. Metasta�c poten�al of BLM/sALCAM cells in nude mice
NOTE: The metasta�c poten�al of BLM cells expressing sALCAM was tested in male nude BalB/c mice. [The average number 
of metastasized cells in the lungs of BLM/sALCAM mice at day 34 is significantly lower compared with control animals (P ≤ 
0.05, Mann-Whitney test)]. BLM/control cells (cf. Fig. 2) and BLM/sALCAM cells were s.c. inoculated. All mice showed tumor 
take and local tumor growth was measured every 3 days. The mice were kept for 24 or 34 days to vary primary tumor sizes. 
The average weight of all 25 tumors was 4 g; all tumors taken at day 24 were smaller than 4 g, and all tumors taken at 
day 34 were bigger than 4 g. The table shows the numbers and percentages of animals with lung metastasis. Furthermore, 
lung metastasis is measured as total numbers and as average number per injected animal. *A difference of borderline 
significance (P = 0.028, t test) was found between the number of metastases per mouse at day 34 a�er inocula�on. 
end of this chapter). A�er sacrificing the mice, 
primary tumors were weighed and lungs were 
collected for microscopic analysis. The average 
weight of all primary tumors was  about 4g; all 
tumors harvested at day 24 were less than 
4g; and all tumors collected at day 34 exceeded 
4g (Table 1). Although primary tumor weights 
were comparable, BLM/control cells displayed 
more frequent lung metastasis than BLM/
sALCAM cells; this is true for both groups 
with small and large tumor sizes (Table 1: <4 
g, 60% versus 29%, respec�vely; and >4 g, 
100% versus 63%, respec�vely). BLM/sALCAM 
cells were not only a�enuated in metastasis 
frequency but also the number of metasta�c 
lesions was smaller. In the group of large 
tumors (>4 g), BLM/control induced almost 
thrice as many metasta�c lesions on average 
compared with BLM/sALCAM (8 versus 2.75 
lesions per injected animal,  respec�vely; Table 
1). In line with the previous in vitro results, the 
overexpression of sALCAM thus a�enuated 
the in vivo metasta�c phenotype of BLM. 
ALCAM and expression of L1CAM/CD171. 
In recent years, the neuronal cell adhesion 
molecule L1CAM was repeatedly reported as 
a marker of carcinoma and melanoma (22, 24, 
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Figure 5. ALCAM func�on regulates the expression of L1CAM. 
A, BLM, BLM/sALCAM, and BLM/∆N-ALCAM cells were cultured as monolayers; cell lysates were subjected to Western 
blot analysis using a monoclonal an�body against L1CAM (L1-11A). BLM and BLM/∆N-ALCAM cells are posi�ve for 
L1CAM in contrast to BLM/sALCAM cells. Both full-length and plasmin-cleaved L1 are detected. B, a�er s.c. injec�on into 
nude mice with different cell lines (BLM, BLM/∆N-ALCAM, and BLM/sALCAM), frozen nonnecro�c tumor �ssues were 
analyzed by Western blo�ng and stained for L1CAM and sALCAM with an an�-FLAG an�body. Samples were extracted 
from independent tumors (three samples for control and sALCAM tumors; two samples for BLM/∆N-ALCAM tumors). As 
confirmed by an�-FLAG staining, the sALCAM-posi�ve tumors have the lowest amount of L1CAM. Tumor samples did not 
contain the (proteoly�c) L1 fragment generated by plasmin cleavage (loading control is given in Supplementary Fig. 2). 
25, 39). Addi�onally, affinity chromatography 
experiments with avian cells detected an 
interac�on between the chicken variants 
of ALCAM and L1CAM (40). Therefore, it 
was worthwhile to determine the levels of 
L1CAM expression in our series of BLM cells 
overexpressing mutant ALCAM variants 
and to see if L1CAM could contribute to the 
significantly changed, invasive proper�es. 
Western blot analysis indeed revealed 
considerable L1CAM protein levels in BLM 
cell extracts (Fig. 5A). Remarkably, sALCAM 
overexpression almost completely suppressed 
L1CAM, whereas ΔN-ALCAM overexpression 
increased the levels of L1CAM (Fig. 5A). 
Subsequently, we also analyzed tumor 
extracts from nude mice experiments for 
the presence of L1CAM. Western blo�ng 
again detected rela�ve decreases of L1CAM 
in extracted BLM/sALCAM xenogra�s and 
increases in BLM/ΔN-ALCAM (Fig. 5B). We 
Discussion
 Tissue development is a highly complex 
process in which dynamic growth of cells 
and stroma generates and maintains �ssue 
architecture. Although oncogenesis may 
hijack developmental pathways, tumor 
growth is counterproduc�ve and frequently 
results in metastasis and host killing. ALCAM 
is involved in development and oncology, but 
its mechanism of ac�on is s�ll elusive. Using 
a melanoma model, this study addresses 
also checked the xenogra� levels of sALCAM 
by Western blo�ng and confirmed its stable 
overexpression (Fig. 5B, bo�om).
In conclusion, alterna�ve targe�ng of ALCAM 
had a major effect on L1CAM expression both 
in vitro and in vivo, sugges�ng orchestrated 
roles of ALCAM and L1CAM in tumor 
development.
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the hypothesis that the modular structure 
of ALCAM (cf. Fig. 1) integrates diverse 
func�ons involved in coordina�on of local 
growth and metastasis. The secreted variant 
sALCAM, which is an�cipated to target the 
ligandbinding module, prevents the apparent 
focal recruitment of ALCAM clusters and 
interrupts extended, intercellular ALCAM 
network forma�on. Furthermore, sALCAM 
impairs more complex cellular responses 
(e.g., MMP-2 ac�va�on, L1-CAM expression, 
cell migra�on, invasion, and metastasis). The 
similar inhibi�on of the MMP-2 ac�va�on 
cascade in HT1080 fibrosarcoma cells 
indicates that the sALCAM effects may be 
more generally applicable to the spectrum of 
ALCAM-posi�ve tumor cells.  
The present set of experiments supplements 
previous characteriza�ons of cellular 
proper�es induced by overexpression of ΔN-
ALCAM (cf. Fig. 1B). In the la�er case, ALCAM 
malfunc�on also inhibits MMP-2 ac�va�on but 
nevertheless provides a gateway to melanoma 
metastasis, thereby uncoupling proteolysis 
from invasiveness (18, 19). The phenotypes 
induced by either sALCAM or ΔN-ALCAM thus 
display both overlapping and opposite cellular 
proper�es and cannot be accommodated by a 
plain role of ALCAM in cell-cell interac�ons. 
Closer inspec�on discloses that the pleiotropic 
effects are well compa�ble with a networking 
role of ALCAM that integrates complex, 
microenvironmental signaling and invasive 
growth dynamics. 
ALCAM and control of MMP-2 ac�va�on. 
An effec�ve networking role in response to 
increasing cell clustering seems dependent on 
ALCAM integrity. In agreement with this, the 
defects caused by sALCAM inhibit the MMP-2 
ac�va�on cascade similar to ΔN-ALCAM (Fig. 
3; ref. 19). Both strategies diminish expression 
of the genes encoding the proteases (MMP2, 
MMP14) without significant changes in TIMP2 
levels and thus affect the balance and assembly 
of MT1-MMP, TIMP2, and pro–MMP-2 to form 
a ternary complex, which is an intermediate 
in MMP-2 ac�va�on. Furthermore, ALCAM 
defects prevent the s�mulatory ac�ons 
of ConA, which usually serves as an 
efficient trigger of the cascade (35–38). 
ALCAM malfunc�on therefore introduces 
a permanent hurdle for ConA effects. By 
contrast, ConA relieves the inhibi�on of MMP-
2 in the absence of ALCAM a�er its deple�on 
by siRNA treatment (Fig. 3). Notably, ALCAM 
deple�on is not accompanied by any changes 
in the levels of MMP2 or MMP14 (19). These 
observa�ons support the interpreta�on that 
ALCAM inserts a condi�onal control switch 
in the signaling pathways regula�ng MMP-2 
ac�va�on. Overexpression of sALCAM or ΔN-
ALCAM aborts the prevailing ConA ac�va�on 
and indicates that the switch is blocked in 
a disconnected state due to a defec�ve 
networking role of ALCAM. 
ALCAM and control of cell migra�on and 
metastasis. 
In contrast to MMP-2 ac�va�on, which 
apparently requires forma�on of an 
integral ALCAM network, the migratory and 
metasta�c proper�es of BLM are differen�ally 
dependent on the dissected oligomerizing or 
ligand-receptor binding modules of ALCAM. 
Overexpression of sALCAM inhibits ALCAM 
clustering in line with a deficiency to sustain 
oligomer recruitment into an extended 
network (Figs. 1C and 2B). As a consequence, 
the genera�on of downstream signals that 
depend on ALCAM integrity is not sufficient 
to promote proteolysis, cell migra�on, and 
metastasis. Overexpression of ΔN-ALCAM 
interrupts the integra�ve func�on too (Fig. 1B) 
and impairs proteolysis (19). Nevertheless, the 
merely increased number of transmembrane 
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oligomer clusters could overall mimic network 
forma�on to some extent and thus provide 
bypasses, which suffice for par�al genera�on 
of downstream signals and sustain cell 
migra�on and metastasis (18). It is noteworthy 
in this regard that the apparent networking 
capacity of ALCAM could confer proper�es 
supplementary or even dominant to a plain 
cell adhesion func�on. 
ALCAM and cell adhesion. 
The profile of L1CAM in our series of BLM cells 
directly correlates with the invasive poten�al 
and adds a striking feature to the par�ally 
dissected and integrated func�ons of ALCAM. 
Several reports have iden�fied L1CAM as 
a melanoma progression marker (21–27). 
Respec�ve overexpression or suppression of 
L1CAM alterna�vely enhanced or diminished 
invasiveness (21). Moreover, L1CAM can 
be released into the microenvironment via 
ectodomain cleavage from cells, catalyzed 
by a disintegrin and metalloprotease (ADAM) 
10 and ADAM-17 (41), or via shedding of 
microvesicles (42). Interes�ngly, ALCAM 
may also be shed by ADAM-17, resul�ng 
in a soluble form comprising most of the 
extracellular structures (43). Although the 
poten�al of L1CAM to serve as a therapeu�c 
target is already explored (44), random 
phage display strategies have independently 
iden�fied ALCAM as a novel cell surface target 
of different cancers with a readily applicable 
poten�al for intracellular delivery of a toxic 
payload (10, 11). Aberrant expression of 
ALCAM and L1CAM may thus synergize and 
favor tumor progression and metastasis. 
Furthermore, cell surface metabolism of 
ALCAM and L1CAM may significantly affect 
dynamic signaling processes, proteolysis, and 
vesicle turnover at the plasma membrane. 
Func�ons and nature of ALCAM network 
forma�on. 
The remarkable cellular responses disclosed in 
the present and previous sets of experiments 
raise urgent ques�ons on how ALCAM func�ons 
would favor invasive growth processes. The 
observa�on of ALCAM expression in human 
blastocysts and endometrial epithelium (45) 
suggested that ALCAM could be involved 
in fetal implanta�on into the uterine wall. 
Masedunskas et al. (46) showed that the 
passage of monocytes through an endothelial 
monolayer correlated with ALCAM levels in 
the monocytes and with endothelial ALCAM 
localized to the lateral plasma membrane. 
Soluble ALCAM variants and an�-ALCAM 
an�bodies inhibited the trans-endothelial 
migra�on of monocytes but did not affect their 
migra�on or adhesion to endothelium. Ectopic 
ALCAM overexpression generally promoted 
cell-cell interac�ons (14, 20), whereas soluble, 
recombinant ALCAM variants a�enuated cell-
cell interac�ons (refs. 20, 46; this report). 
The affinity of ALCAMALCAM interac�ons 
seemed rela�vely low in  solu�on (K
D
' = 29-48 
µmol/L; ref. 47). The weakness of homophilic 
interac�ons was consistent with the apparent 
lack of an�–FLAG-tag an�bodies to detect 
the binding of monovalent recombinant 
sALCAM to cells by flow cytometry and 
immunofluorescence (results not shown). 
Forma�on of a transcellular ALCAM network 
would thus be characterized by a mul�tude of 
weak interac�ons with fast on and off kine�cs. 
Progressive ALCAM clustering could promote 
the sequestra�on or tethering of addi�onal 
components (e.g., MT1- MMP, L1CAM) into this 
network. Besides, the dependence of robust 
cell-cell binding on focal ALCAM avidity could 
be compa�ble with the inherent plas�city and 
dynamics required for transmigra�on of cells 
(15). 
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sALCAM, an inhibitory device for metastasis. 
The experimental evidence presented and 
discussed above shows divergent biological 
signals and responses associated with par�ally 
dissected and integrated ALCAM func�ons 
in BLM and HT1080 cells. Notably, mimicry 
of limited or enhanced ALCAM recruitment, 
as induced by respec�ve overexpression of 
sALCAM or ΔN-ALCAM, directly correlates 
with a�enuated or enhanced metasta�c 
capaci�es. Whereas many cells commonly 
express high-affinity, cadherin-type cell 
adhesion molecules, BLM cells are apparently 
devoid of cadherins (48). This peculiarity may c 
ons�tute BLM as a prototype for characterizing 
rela�ve low-affinity cell adhesion interac�ons, 
as mediated by ALCAM. Effec�ve robustness 
and plas�city of malignant tumor cells 
presumably require coordinate processing of 
all microenvironmental signals to transform 
the input of complex informa�on into uniform 
cellular interpreta�ons that spa�ally and 
temporally control melanoma growth dynamics 
and metastasis (cf. ref. 49). The available 
experimental evidence is consistent with the 
hypothesis that ALCAM ac�vity contributes 
to a novel processor and integrator func�on 
that serially collects and connects mul�ple 
upstream, microenvironmental signals, and 
simultaneously inserts a switch that controls 
downstream responses. Interes�ngly, the 
inhibitory proper�es of sALCAM intefere with 
these func�ons and suggest that sALCAM-
like devices with improved binding affini�es 
and blocking effects may have a therapeu�c 
poten�al. 
Materials and Methods
Cell culture. 
 Adherent melanoma cells (BLM) and 
HT1080 fibrosarcoma cells were maintained 
as monolayers in DMEM (Invitrogen) 
supplemented with 10% FCS, 4 mmol/L L-
glutamine, and 2 mmol/L pyruvate. BLM cells 
with amino-terminally truncated ALCAM 
(BLM/ΔN-ALCAM) were cultured as described 
previously (14, 28). If indicated, concanavalin 
A (ConA; Sigma- Aldrich) was added to 
serum-free medium (20 µg/mL). All cells were 
grown to desired densi�es or split before 
confluence was reached. Threedimensional 
collagen cultures were prepared as described 
previously (19). Frequent tes�ng cer�fied that 
cells were free of Mycoplasma contamina�on.
Genera�on of BLM/sALCAM cells. 
 For the genera�on of BLM/ sALCAM cells, 
the vector sALCAM-p3XFLAG was transfected 
into BLM cells using Saint-mix (Synvolux 
Therapeu�cs). A mixture of 20 µL Saint-mix and 
80 µL HBS was made. Circular DNA (1.7 µg) was 
added to 100 µL HBS in a separate tube. A�er 
5 min of incuba�on at room temperature, both 
mixes were combined and supplemented with 
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800 µL medium. This DNA/Saint mixture was 
added directly to a 40% confluent monolayer. 
Cells were incubated at 37°C and 2 mL medium 
was added a�er 3h. For stable transfectants, 
the medium was supplemented with 0.5 mg/
mL G418 (Life Technologies/Invitrogen) 48h 
a�er transfec�on. Single, neomycin-resistant 
cells were sorted by flow cytometry and 
expanded in medium containing 0.5 mg/mL 
G418. 
In vitro wound-healing assay. 
 Wound-healing assays were done on 
confluent monolayers inflicted with a 
‘‘wound’’ made by a pipe�e �p. Detached 
cells were removed by washing with medium 
(37°C). Cell migra�on into the scratch was 
monitored at various �me points star�ng 
from 2h a�er wounding to avoid effects of 
cell spreading. Images were analyzed using 
CorelDraw 10 (Corel Corpora�on). Gap width 
was measured at six posi�ons per inflicted 
wound in six independent confluent cultures. 
To prevent interference of cell doubling, the 
experiment did not exceed the doubling �me 
of the cells tested (18h). 
Reverse transcrip�on-PCR and quan�ta�ve 
real-�me PCR. 
 RNA was isolated using the RNeasy kit 
(Qiagen) and a�er removal of genomic DNA 
(DNase I, Invitrogen) was used as cDNA 
synthesis template using Superscript III reverse 
transcriptase (Invitrogen). cDNA was diluted 
1/50 and stored at -20°C. Primer sequences 
are given in supplementary Table 1 at the end 
of this chapter. All primers were synthesized 
by Isogen Lifesciences. cDNA levels were 
determined using SYBR green fluorescence 
with the ABI-Prism 7000 (Applied Biosystems). 
Expression levels of three individual 
experiments were evaluated as the number 
of cycle difference from glyceraldehyde-
3-phosphate dehydrogenase (GAPDH). 
Significant changes from control samples were 
determined using Student’s t test. P ≤ 0.05 was 
considered significant. 
Western blo�ng and gela�n zymography. 
 Cell extracts were prepared and Western 
blo�ed as described previously (19). Serum-free 
media were precipitated using 2-propanone at 
-70°C for 20 min followed by 90 min at -20°C; 
precipitates were taken up in reducing sample 
buffer. A�er 5-min boiling, samples of medium 
precipitates or cell lysates (20 µg protein) 
were separated by SDS-PAGE and transferred 
to polyvinylidene difluoride membrane 
(Millipore). An�–FLAG M2 an�body (1:1,000; 
Stratagene) was used to detect FLAG-tagged 
proteins. The monoclonal an�bodies AZN-
L50 and L1-11A were used to detect ALCAM 
and L1CAM, respec�vely. Bound primary 
an�bodies were visualized by appropriate 
horseradish peroxidase–coupled secondary 
an�bodies and enhanced chemiluminescence 
(ECL plus, Amersham Biosciences). Analysis 
of nude mouse xenogra�s was performed on 
four nonnecro�c 10-µm frozen �ssue sec�ons 
solubilized in 15 µL of reducing sample buffer, 
of which 5 µL samples were loaded on gel. 
Gela�n zymography was described previously 
(19). 
Confocal laser scanning microscopy. 
 Cells were grown on glass coverslips 
and, a�er PBS washing, fixed in 4% 
paraformaldehyde in PBS (15 min room 
temperature). A�er thorough washing with 
PBS (3), cells were rendered permeable in 
PBS containing 0.1% Triton X-100 for 1 min. To 
block unspecific binding of the an�body, cells 
were incubated in 1% bovine serum albumin 
(BSA) in PBS for 30 min. Cells were stained 
overnight using 3 µg/µL AZN-L50 (in 1% BSA/
PBS) at 4°C and subsequently incubated with 
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Immunohistochemistry. 
 Sec�ons (6 µm) were deparaffinized 
in ethanol and rehydrated for 
immunohistochemical analysis of heparan 
sulfate proteoglycan an�body JM-403 (1:
1,000; ref. 30) and calcyclin (1:500; ref. 31). 
A�er incuba�on with primary an�bodies, 
sec�ons were stained with avidinbio�n-
peroxidase complex system (Vectastain elite 
ABC kit; Vector Laboratories, Inc.). To visualize 
an�body binding, AEC staining (Calbiochem) 
was performed. Counterstaining was 
performed with Mayer’s hematoxylin (Sigma). 
Finally, sec�ons were washed in tap water, 
dried, and mounted in glycerol gela�n (Sigma). 
In addi�on, we performed H&E staining on 
serial sec�ons.
In vivo tumor growth and metastasis. 
 Male BALB/c athymic nude mice (nu/nu) 
were bred and kept under specific pathogen-
free condi�ons. Tumor cells were harvested 
using trypsin/EDTA, washed, and suspended 
in PBS (2x107/mL). Mice, 7 wk old, were s.c. 
inoculated with 100 µL cell suspension. Every 
3 d, mice were inspected and local tumor size 
was measured. At the indicated �mes, mice 
were sacrificed and tumors were dissected, 
snap frozen in liquid nitrogen, and stored 
at 70°C. Nonnecro�c tumor samples were 
analyzed by Western blo�ng. Lungs were 
prepared with Tissue-tek OCT compound 
(Sakura), fixed in formalin, and embedded 
in paraffin for microscopic examina�on of 
H&E-stained sec�ons. Lung metastases were 
counted at mul�ple sec�ons (three to five) 
within the lungs to compare equal surface 
areas. Sizes of the metasta�c lesions were 
measured as cells per single lesion.
FITC-conjugated rabbit–an�-mouse (1:1,000 
in PBS; Dako) for 1h at room temperature. 
Unbound an�bodies were washed off using 
PBS. Finally, the coverslips were mounted in 
Mowiol and sealed with nail polish.
De-epidermized dermis. 
 Skin samples were obtained from donors 
who underwent abdominal skin correc�ons 
by plas�c surgery. Separa�on of epidermis 
and dermis was catalyzed by a 5- to 10-min 
incuba�on in PBS at 56°C. The dermis was 
incubated for 4 wk in PBS containing an�bio�cs 
at 37°C. Standardized de-epidermized dermis 
(DED) pieces were obtained as 8-mm punch 
biopsies. 
Genera�on of human skin equivalents.
 DEDs (basement membrane side up) 
were placed in transwells and seeded on top 
with 105 kera�nocytes and 104 melanoma 
cells in DED medium (adapted from ref. 29) 
supplemented with 5% defined bovine calf 
serum (Hyclone). DED medium consisted of 
DMEM/Ham’s F12 (2:1) medium, L-glutamine 
(4 mmol/L), penicillin/streptomycin (50 IU/
mL), adenine (24.3 µg/mL), ascorbic acid (50 
Ag/mL), insulin (0.2 µg/mL), hydrocor�sone 
(1 µmol/L), triiodothyronine (1.36 ng/mL), 
and cholera toxin (0.1 nmol/L). The cells were 
kept in submerged culture for 3 d. Then, the 
reconstructs were li�ed to the air-liquid 
interface and kept for 10 d in DED medium 
supplemented with L-serine (1 mg/mL), L-
carni�ne (2 µg/mL), BSA lipid mix palmi�c 
acid (25 µmol/L), arachidonic acid (7 µmol/L), 
linoleic acid (15 µmol/L), vitamin E (0.4 µg/mL 
in 20 mmol/L BSA in PBS), and epidermal 
growth factor (5 ng/mL). A�er harves�ng, 
the skin equivalents were formalin fixed and 
embedded in paraffin.
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Supplementary data.
supplementary figure 1.
Tumor volumes (mm3) of control animals (n=10) and 
sALCAM (n=15) animals were measured every three to four 
days star�ng from day 14. At day 24 five control and seven 
sALCAM animals were sacrificed, at day 34 the remaining 
animals were sacrificed. There is no effect of sALCAM 
expression on  tumor development.
supplementary figure 2.
Addi�on to figure 5. Coomassie-BLue staining, a�er semi-
dry blo�ng, indicated that proteins were extracted from 
sliced tumor xenogra�s with comparable efficiencies. 
supplementary table 1.
Primer sequences 
54 Chapter 3 55soluble ALCAM and melanoma metastasis
References
1.  Haass NK, Smalley KS, Li L, Herlyn M. Adhesion, migra�on and communica�on in melanocytes and melanoma. 
Pigment Cell Res 2005;18:150–9.
2.  McGary EC, Lev DC, Bar-Eli M. Cellular adhesion pathways and metasta�c poten�al of human melanoma. 
Cancer Biol Ther 2002;1:459–65.
3.  Bogenrieder T, Herlyn M. Axis of evil: molecular mechanisms of cancer metastasis. Oncogene 2003;22:6524–
36. 
4.  van Kempen LC, van den Oord JJ, van Muijen GN, Weidle UH, Bloemers HP, Swart GW. Ac�vated leukocyte cell 
adhesion molecule/CD166, a marker of tumor progression in primary malignant melanoma of the skin. Am J 
Pathol 2000;156:769–74. 
5.  Kris�ansen G, Pilarsky C, Wissmann C, et al. Expression profiling of microdissected matched prostate cancer 
samples reveals CD166/MEMD and CD24 as new prognos�c markers for pa�ent survival. J Pathol 2005;205:
359–76.
6.  King JA, Ofori-Acquah SF, Stevens T, Al Mehdi AB, Fodstad O, Jiang WG. Ac�vated leukocyte cell adhesion 
molecule in breast cancer: prognos�c indicator. Breast Cancer Res 2004;6:R478–87.
7.  Verma A, Shukla NK, Deo SV, Gupta SD, Ralhan R. MEMD/ALCAM: a poten�al marker for tumor invasion and 
nodal metastasis in esophageal squamous cell carcinoma. Oncology 2005;68:462–70.
8.  Weichert W, Knosel T, Bellach J, Dietel M, Kris�ansen G. ALCAM/CD166 is overexpressed in colorectal 
carcinomaand correlates with shortened pa�ent survival. J Clin Pathol 2004;57:1160–4.
9.  Tomita K, van Bokhoven A, Jansen CFJ, et al. Ac�vated leukocyte cell adhesion molecule (ALCAM) expression is 
associated with a poor prognosis for bladder cancer pa�ents. Urol Oncol 2003;3:121–9.
10.  Piazza T, Cha E, Bongarzone I, et al. Internaliza�on and recycling of ALCAM/CD166 detected by a fully human 
single-chain recombinant an�body. J Cell Sci 2005;118:1515–25.
11.  Liu B, Conrad F, Roth A, Drummond DC, Simko JP, Marks JD. Recombinant full-length human IgG1s targe�ng 
hormone-refractory prostate cancer. J Mol Med 2007;85:1113–23.
12.  Swart GW. Ac�vated leukocyte cell adhesion molecule (CD166/ALCAM): developmental and mechanis�c 
aspects of cell clustering and cell migra�on. Eur J Cell Biol 2002;81:313–21.
13.  Swart GW, Lunter PC, Kilsdonk JW, Kempen LC. Ac�vated leukocyte cell adhesion molecule (ALCAM/ CD166): 
signaling at the divide of melanoma cell clustering and cell migra�on? Cancer Metastasis Rev 2005;24:223–36.
14.  van Kempen LC, Nelissen JM, Degen WG, et al. Molecular basis for the homophilic ac�vated leukocyte cell 
adhesion molecule (ALCAM)-ALCAM interac�on. J Biol Chem 2001;276:25783–90.
15.  Bowen MA, Aruffo AA, Bajorath J. Cell surface receptors and their ligands: in vitro analysis of CD6–166 
interac�ons. Proteins 2000;40:420–8.
16.  Zimmerman AW, Nelissen JM, van Emst-de Vries SE, et al. Cytoskeletal restraints regulate homotypic ALCAM-
mediated adhesion through PKCa independently of Rho-like GTPases. J Cell Sci 2004;117:2841–52.
17.  Te Riet J, Zimmerman AW, Cambi A, et al. Dis�nct kine�c and mechanical proper�es govern ALCAMmediated 
interac�ons as shown by single-molecule force spectroscopy. J Cell Sci 2007;120:3965–76.
18.  van Kempen LC, Meier F, Egeblad M, et al. Trunca�on of ac�vated leukocyte cell adhesion molecule: a gateway 
to melanoma metastasis. J Invest Dermatol 2004;122:1293–301.
19.  Lunter PC, van Kilsdonk JW, van Beek H, et al. Ac�vated leukocyte cell adhesion molecule (ALCAM/CD166/
MEMD), a novel actor in invasive growth, controls matrix metalloproteinase ac�vity. Cancer Res 2005;65:
8801–8.
20.  Ikeda K, Quertermous T. Molecular isola�on and characteriza�on of a soluble isoform of ac�vated leukocyte 
cell adhesion molecule that modulates endothelial cell func�on. J Biol Chem 2004;279:55315–23.
21.  Meier F, Busch S, Gast D, et al. The adhesion molecule L1 (CD171) promotes melanoma progression. Int J Cancer 
2006;119:549–55.
22.  Thies A, Schachner M, Moll I, et al. Overexpression of the cell adhesion molecule L1 is associated with 
metastasis in cutaneous malignant melanoma. Eur J Cancer 2002;38:1708–16.
23.  Alonso SR, Tracey L, Or�z P, et al. A high-throughput study in melanoma iden�fies epithelial-mesenchymal 
transi�on as a major determinant of metastasis. Cancer Res 2007;67:3450–60.
24.  Huszar M, Moldenhauer G, Gschwend V, Ben Arie A, Altevogt P, Fogel M. Expression profile analysis in mul�ple 
human tumors iden�fies L1 (CD171) as a molecular marker for differen�al diagnosis and targetedtherapy. Hum 
Pathol 2006;37:1000–8.
25.  Talantov D, Mazumder A, Yu JX, et al. Novel genes associated with malignant melanoma but not benign 
melanocy�c lesions. Clin Cancer Res 2005;11:7234–42.
26.  Primiano T, Baig M, Maliyekkel A, et al. Iden�fica�on of poten�al an�cancer drug targets through the selec�on 
of growth-inhibitory gene�c suppressor elements. Cancer Cell 2003;4:41–53.
27.  Gelman MS, Ye XK, Stull R, et al. Iden�fica�on of cell surface and secreted proteins essen�al for tumor cell 
survival using a gene�c suppressor element screen. Oncogene 2004;23:8158–70.
54 Chapter 3 55soluble ALCAM and melanoma metastasis
28.  Degen WG, van Kempen LC, Gijzen EG, et al. MEMD, a new cell adhesion molecule in metastasizing human 
melanoma cell lines, is iden�cal to ALCAM (ac�vated leukocyte cell adhesion molecule). Am J Pathol 1998;152: 
805–13.
29.  Ponec M, Weerheim A, Kempenaar J, et al. The forma�on of competent barrier lipids in reconstructed human 
epidermis requires the presence of vitamin C. J Invest Dermatol 1997;109:348–55.
30.  van den Born J, Gunnarsson K, Bakker MA, et al. Presence of N-unsubs�tuted glucosamine units in na�ve 
heparan sulfate revealed by a monoclonal an�body. J Biol Chem 1995;270:31303–9.
31.  Weterman MA, van Muijen GN, Bloemers HP, Ruiter DJ. Expression of calcyclin in human melanocy�c lesions. 
Cancer Res 1993;53:6061–6.
32.  Ellerbroek SM, Stack MS. Membrane associated matrix metalloproteinases in metastasis. Bioessays 1999;21:
940–9.
33.  Itoh Y, Seiki M. MT1-MMP: a potent modifier of pericellular microenvironment. J Cell Physiol 2006;206: 1–8.
34.  Kurschat P, Wickenhauser C, Groth W, Krieg T, Mauch C. Iden�fica�on of ac�vated matrix metalloproteinase-2 
(MMP-2) as the main gela�noly�c enzyme in malignant melanoma by in situ zymography. J Pathol 2002;197:
179–87.
35.  Overall CM, Sodek J. Concanavalin A produces a matrix-degrada�ve phenotype in human fibroblasts. Induc�on 
and endogenous ac�va�on of collagenase, 72-kDa gela�nase, and Pump-1 is accompanied by the suppression 
of the �ssue inhibitor of matrix metalloproteinases. J Biol Chem 1990;265:21141–51.
36.  Sato T, Kondo T, Fujisawa T, Seiki M, Ito A. Furinindependent pathway of membrane type 1-matrix 
metalloproteinase ac�va�on in rabbit dermal fibroblasts. J Biol Chem 1999;274:37280–4.
37.  Gingras D, Page M, Annabi B, Beliveau R. Rapid ac�va�on of matrix metalloproteinase-2 by glioma cells occurs 
through a pos�ransla�onal MT1-MMPdependent mechanism. Biochim Biophys Acta 2000; 1497:341–50.
38.  Toth M, Hernandez-Barrantes S, Osenkowski P, et al. Complex pa�ern of membrane type 1 matrix 
metalloproteinase shedding. Regula�on by autocataly�c cells surface inac�va�on of ac�ve enzyme. J Biol 
Chem 2002; 277:26340–50.
39.  Fogel M, Mechtersheimer S, Huszar M, et al. L1 adhesion molecule (CD 171) in development and progression of 
human malignant melanoma. Cancer Le� 2003;189:237–47.
40.  DeBernardo AP, Chang S. Heterophilic interac�ons of DM-GRASP: GRASP-NgCAM interac�ons involved in 
neurite extension. J Cell Biol 1996;133:657–66. 
41.  Maretzky T, Schulte M, Ludwig A, et al. L1 is sequen�ally processed by two differently ac�vated metalloproteases 
and presenilin/g-secretase and regulates neural cell adhesion, cell migra�on, and neurite outgrowth. Mol Cell 
Biol 2005;25:9040–53.
42.  Stoeck A, Keller S, Riedle S, et al. A role for exosomes in the cons�tu�ve and s�mulus-induced ectodomain 
cleavage of L1 and CD44. Biochem J 2006;393:609–18. 
43.  Bech-Serra JJ, San�ago-Josefat B, Esselens C, et al. Proteomic iden�fica�on of desmoglein 2 and ac�vated 
leukocyte cell adhesion molecule as substrates of ADAM17 and ADAM10 by difference gel electrophoresis. Mol 
Cell Biol 2006;26:5086–95.
44.  Arlt MJ, Novak-Hofer I, Gast D, et al. Efficient inhibi�on of intra-peritoneal tumor growth and dissemina�on of 
human ovarian carcinoma cells in nude mice by an�-L1-cell adhesion molecule monoclonal an�body treatment. 
Cancer Res 2006;66:936–43.
45.  Fujiwara H, Tatsumi K, Kosaka K, et al. Human blastocysts and endometrial epithelial cells express ac�vated 
leukocyte cell adhesion molecule (ALCAM/CD166). J Clin Endocrinol Metab 2003;88:3437–43.
46.  Masedunskas A, King JA, Tan F, et al. Ac�vated leukocyte cell adhesion molecule is a component of the 
endothelial junc�on involved in transendothelial monocyte migra�on. FEBS Le� 2006;580:2637–45.
47.  Hassan NJ, Barclay AN, Brown MH. Frontline: Op�mal T cell ac�va�on requires the engagement of CD6 and 
CD166. Eur J Immunol 2004;34:930–40.
48.  Van Marck V, Stove C, Van Den BK, et al. P-cadherin promotes cell-cell adhesion and counteracts invasion in 
human melanoma. Cancer Res 2005;65:8774–83.
49.  Swart GW. Cell ‘‘guidling’’. EMBO Rep 2006;7:348–51.

chapter 4
ALCAM-mediated cell adhesion 
aff ects gene expression in 
melanoma cells and contributes to 
invasion and metastasis.
Jeroen W.J. van Kilsdonk 1 
Nozomi Takahashi 2
Mohamed R. Daha 3
Léon C.L.T. van Kempen 4
Guido W.M. Swart 1
1 Department of Biochemistry, Nijmegen Center of Molecular Life   
   Sciences, Radboud University Nijmegen 
2 Department of Rheumatology, University Medical Center st Radboud,         
   Nijmegen, the Netherlands 
3 Department of Nephrology, Leiden University Medical Center,         
   Leiden, the Netherlands
4 Department of Pathology,  University Medical Center st Radboud,         
   Nijmegen, the Netherlands
58 Chapter 4 59ALCAM-mediated Cell Adhesion
58 Chapter 4 59ALCAM-mediated Cell Adhesion
Ac�vated leukocyte cell adhesion molecule (ALCAM/MEMD/CD166) is a marker of progression of a variety of cancers, including cutaneous melanoma. ALCAM expression triggers matrix metalloproteinase ac�vity and correlates with the transi�on between 
superficial melanoma growth and deep dermal invasion. In order to reveal how ALCAM can 
contribute to melanoma progression, we have manipulated ALCAM func�on in metasta�c 
melanoma cells by overexpressing different ALCAM dele�on mutants. This either accelerated or 
suppressed spontaneous metastasis in nude mice. Comparing the transcriptomes of these variant 
series of melanoma cells under sub- and super-confluent culture condi�ons and in 3-dimensional 
collagen gels, we have iden�fied a gene cluster responsive to increasing cell densi�es and ALCAM 
func�onality. Furthermore, this gene cluster is linked to differen�al growth phenotypes with 
respect to invasive and metasta�c proper�es. Major varia�ons in gene expression profiles of 
complement proteinases C1r and C1s and of the cell adhesion molecule L1CAM/CD171 were 
confirmed in protein assays. Our results support the assump�on that ALCAM could func�on 
as a cell signaling molecule which can promote invasion that depends on cell density-induced 
ALCAM-ALCAM interac�ons. 
Introduc�on 
 Cell adhesion molecules play an important 
role during most stages of tumor progression. 
Tumors use adhesion molecules to form a 
solid mass, while metastasizing tumor cells 
con�nuously alter the repertoire of adhesion 
molecules to detach from the primary 
tumor, migrate into the surrounding �ssue 
either as single or small clusters of cells, and 
interact with with other cells encountered 
during migra�on, intravasa�on, circula�on 
and extravasa�on. One adhesion molecule 
that gained interest is ac�vated leukocyte 
cell adhesion molecule (ALCAM/MEMD/
CD166) because of its aberrant expression 
in many different human tumors, including 
melanoma (Ofori-Acquah and King, 2008). 
A strong correla�on was found between 
ALCAM posi�vity and cutaneous melanoma 
progression (van Kempen et al., 2000). ALCAM 
expression was predominantly observed in 
a subset of cells at the invasive front of the 
tumor and correlates with the transi�on 
from local cell prolifera�on to invasive tumor 
growth (van Kempen et al, 2000). ALCAM 
is a homophilic and heterophilic (ALCAM-
CD6) adhesion molecule belonging to the 
immunoglobulin (Ig) superfamily (Bowen et 
al., 1995;Degen et al., 1998). The homophilic 
cell adhesion func�on of wild-type ALCAM 
mediates homotypic clustering of melanoma 
cells and would, thus, antagonize cell release 
from the primary tumor, an early prerequisite 
for metastasis. To study the paradoxical 
role of ALCAM in melanoma progression a 
truncated ALCAM (ΔN-ALCAM) molecules 
was engineered (van Kempen et al., 2004). 
ΔN-ALCAM in wild-type ALCAM expressing 
melanoma cell lines interferes with �ght 
ALCAM network forma�on, thereby inhibi�ng 
normal cell clustering (van Kempen et al., 2004). 
Ectopic expression of ΔN-ALCAM in melanoma 
cells induces loss of cellular aggrega�on, 
increased cell mobility and invasiveness in 
skin reconstructs. In addi�on an accelera�on 
of spontaneous lung metastasis forma�on 
was observed at expense of primary tumor 
growth in mouse xenogra�s (van Kempen et 
al., 2004). A small secreted form of ALCAM 
(sALCAM), which is an�cipated to target ligand 
binding, prevents focal recruitment of ALCAM 
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clusters and interrupts extended, intercellular 
ALCAM network forma�on (van Kilsdonk et al., 
2008). Whereas the ectopic ΔN-ALCAM mainly 
aggravated the invasive behavior, sALCAM 
expression inhibits melanoma migra�on in 
vitro and lung metastasis forma�on in nude 
mice (van Kilsdonk et al., 2008). Besides 
these contradic�ve effects of sALCAM and 
ΔN-ALCAM on melanoma invasion and 
metastasis, both approaches modula�ng 
ALCAM func�onality impaired ac�va�on of 
the pro-invasive matrix metalloproteinase-2 
(MMP-2) (Lunter et al., 2005;van Kilsdonk 
et al., 2008). Remarkably, L1 neuronal cell 
adhesion molecule (L1CAM/CD171), another 
progression marker of several cancers 
including melanoma, was suppressed upon 
sALCAM overexpression but was up-regulated 
by N-ALCAM (van Kilsdonk et al., 2008). The 
par�ally overlapping and opposite effects 
induced by alterna�ve strategies targe�ng 
ALCAM func�ons collec�vely suggest that 
ALCAM fulfills a role in melanoma progression 
beyond its adhesive func�on. Further 
inves�ga�ons into the regulatory proper�es 
of ALCAM are necessary to clarify the role of 
ALCAM in melanoma tumor progression. 
 In the present study we used micro-array 
analysis to examine the gene expression 
profiles of melanoma cells expressing ΔN-
ALCAM and sALCAM with the inten�on to 
iden�fy genes that contribute to the opposing 
invasive melanoma phenotypes induced by 
these ALCAM variants. Iden�fica�on of genes 
responsive to ALCAM could contribute to the 
unraveling of the role ALCAM has in melanoma 
tumor progression. Here, gene expression 
profiling has resulted in the iden�fica�on of 
several genes that are regulated by ALCAM 
func�onality. To test the validity of this 
ALCAM response gene cluster we compared 
the transcript levels of cells grown at low cell 
density having limited homotypic cell and 
homophilic ALCAM interac�ons with cells 
grown at super confluence having numerous of 
cell-cell and thus ALCAM-ALCAM interac�ons. 
Coupling these gene responses to the invasive 
behavior of the cells narrowed the gene 
cluster to genes involved in the progression 
and metasta�c poten�al of melanoma cells. 
A similar gene response was iden�fied when 
the ALCAM mutant cell lines were cultured 
in, more in vivo like, 3-dimensional collagen 
matrices. Unexpectedly, most of the genes 
in this density and ALCAM depending gene 
cluster are involved in innate immunity. We 
confirmed on protein level that ALCAM is 
involved in the density dependent upregula�on 
of classical complement proteases C1r and 
C1s, furthermore we showed that expression 
of C1r is found in invasive melanomas. In 
addi�on we show that the expression of cell 
adhesion molecule L1CAM is responsive to 
ALCAM status. Overall, our findings indicate 
that increased tumor cell clustering induces 
a pro-invasive gene response, which can be 
modulated by ALCAM func�onality. 
Mean fold change in the expression of a selec�on of genes 
determined by affymetrix cDNA array comparing BLM 
cells with BLM/ΔN-ALCAM cells. Genes are grouped by 
increasing fold change in BLM cells. 
Table 1: cDNA array overview 
Gene Accesion # Fold change
DNA pol a  NM002689 + 5.9
hASNA-i BC002651 + 5.9
Htr A1 NM002775 - 2.1
SCCA NM002974 - 2.2
Wnt-5a NM003392 - 2.4
C1r NM001733 - 2.5
TFPi-2 BC005330 - 2.5
C1s NM001734 - 2.7
Ena-78 NM002994 - 3.0
FAP U09278 - 4.4
KIAA 0316 AB002314 - 4.9
GAS-1 NM002048 - 9.8
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Overview of the fold change in mRNA expression of 
candidate genes comparing BLM cells at low and high cell 
density measured by quan�ta�ve real �me PCR. The first 
column represents the expression in BLM cells cultured at 
low cell confluence. The expression levels of BLM cells at 
high cell density are compared with the expression levels 
in BLM cells at low cell confluence (second column). Fold 
changes indicated in gray are not significantly increased. 
Fold changes are given with standard devia�on, significant 
is p<0.05 in student T-test. 
RESULTS 
Candidate genes responsive to ALCAM status 
iden�fied by cDNA micro-array analysis 
 Affymetrix HuGeneFL GeneChip (5600 
cDNAs) analyses were applied to iden�fy 
genes that were differen�ally expressed 
between BLM and BLM/ΔN-ALCAM cells. 
Differen�al expression of the ALCAM func�on 
dependent genes could be involved in the 
previously reported phenotypic transi�on 
between localized primary tumor growth 
and �ssue invasion (van Kempen et al., 2004). 
Five independent, sub-confluent clonal BLM/
ΔN-ALCAM lines were compared with two 
independent BLM clones transfected with the 
empty expression vector. While selec�ng for 
more than two-fold expression changes, the 
analyses revealed 17 reproducibly suppressed 
genes and 32 reproducibly up-regulated genes 
in all five clonal cell lines expressing varying 
amounts of ectopic ΔN-ALCAM. Table 1 shows 
a selec�on of differen�al genes of which 
expression was verified by quan�ta�ve real-
�me PCR (qPCR). This collec�on of genes was 
included in subsequent analyses to test the 
effects of increasing cell confluence and thus 
increased ALCAM-ALCAM interac�ons on the 
expression levels. 
Iden�fica�on of genes responsive to cell 
density 
 The next series of experiments was 
designed to test the effect of increasing 
cell clustering on the selected genes from 
table 1. We compared the transcript levels 
of these genes in BLM cells harvested under 
sub-confluent (0.5-1x105 cells/cm2) and 
super-confluent (> 2.5 x 105 cells/cm2) culture 
condi�ons. Under sub-confluent condi�ons 
the degree of cell-cell contact forma�on was 
limited, while mul�ple cell-cell contacts were 
present when melanoma cells piled up in 
super-confluent cultures. In order to illustrate 
the effect of increasing cell confluence on gene 
expression, normalized transcript levels of BLM 
cultures under sub-confluent condi�ons were 
compared to that of super-confluent culture 
condi�ons (table 2). Transcript levels of genes 
involved in MMP-2 ac�va�on were included 
as well as we have previously demonstrated 
that ALCAM is involved in MMP-2 ac�va�on 
(Lunter et al., 2005;van Kilsdonk et al., 2008). 
As illustrated in Table 2, except for DNA-
polymerase and MT-1MMP, all genes tested 
were up-regulated with increasing confluence 
of BLM cell cultures. In conclusion, the qPCR 
Table 2: qPCR analysis reveals density effects on gene 
expression 
    low cell density  high cell density
gene BLM normalized BLM
DNA pol a  1 N.S.
MT1-MMP 1 N.S.
TIMP-2 1 1,3 ± 0,3
hASNA-i 1 1,9 ± 0,5
GAS-1 1 2,0 ± 0,4
KIAA 0316 1 2,5 ± 0,5
Ena-78 1 2,7 ± 0,3
FAP 1 3,7 ± 1,1
TFPi-2 1 3,9 ± 0,2
Wnt-5a 1 4,1 ± 1,0
Htr A1 1 6,1 ± 2,4
C1r 1 10,8 ± 1,5
MMP-2 1 11,8 ± 4,8
SCCA 1 38,1 ± 18,1
C1s 1 65,3 ± 8,5
62 Chapter 4 63ALCAM-mediated Cell Adhesion
analyses validated of a set of genes whose 
expression increased with increasing cell 
density.
Genes responsive to ALCAM status and cell 
density 
 The micro-array and qPCR analysis revealed 
a small set of genes both responsive to ALCAM 
status and changes in cell clustering. A large 
micro-array experiment was performed to 
expand these data and to demonstrate a 
rela�onship between cell density, ALCAM 
func�onality, differen�al gene expression 
profiles and invasive proper�es of melanoma 
cells. To this end, we compared the transcript 
levels of highly metasta�c BLM/ΔN-ALCAM 
(van Kempen et al. 2004), poorly metasta�c 
BLM/sALCAM (van Kilsdonk et al., 2008) and 
metasta�c parental BLM cells cultured at low 
and high density. 
At low density a limited number of genes 
was differen�ally expressed between BLM 
and BLM/sALCAM cells (n=112) and between 
BLM and BLM/ΔNALCAM (n=131) (Table 
1. supplemental data at the end of this 
chapter). A set of 371 genes was iden�fied 
that were upregulated more than 3 �mes in 
high density cultures of parental BLM cells 
(figure 1) whereas only 35 genes were down 
regulated (supplemental data figure 1 at the 
end of this chapter) compared to a low density 
BLM culture. Differen�al gene expression in 
response to cell density was also observed 
in BLM/ΔN-ALCAM and BLM/sALCAM cells. 
Whereas increasing cell density of BLM/ΔN-
ALCAM cells resulted in the upregula�on of 
245 genes and down regula�on of 31 genes, 
expression of only 67 genes was found 
upregulated and 17 genes downregulated in 
the non-metasta�c BLM/sALCAM cells. From 
this it appears that the cell density response 
is tempered in the BLM/sALCAM cells and that 
increased cell density mainly induces gene 
expression. 
Genes that are upregulated in BLM and BLM/
ΔN-ALCAM cells but not in the BLM/sALCAM 
might explain the different invasive behaviors. 
Therefore, coupling the invasive phenotypes 
of the three different BLM cell lines to their 
transcriptome might reveal genes important 
Figure 1: Venn diagram 
overview of the microarray 
results, effects of ALCAM status 
and cell density. 
Monolayer cultures of BLM, 
BLM/sALCAM and BLM/ΔN-
ALCAM cells grown at low and 
high cell density are compared 
using micro-array analysis. For 
each cell line all genes with an 
increased expression (> 3x) upon 
cell clustering are depicted. The 
responses to ALCAM and cell 
clustering can be divided into 
three major groups (arrows). 
The cluster of 146 genes both 
increased upon cell density and 
ALCAM status are coupled to a 
more invasive phenotype. 
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for invasive growth. A set of 187 (146+41) 
genes was increasingly expressed by the 
invasive cell lines BLM and BLM/ΔN-ALCAM 
upon increasing cell density (figure 1). Of 
these, 41 genes were also expressed by non-
invasive BLM/sALCAM cells and indicates that 
the increased expression of these genes in 
response to cell density was not affected by 
ALCAM integrity. Conversely, the cluster of 
146 genes could contribute to the invasive 
phenotype of BLM and BLM/ΔN-ALCAM cells 
(figure 1). 
To test if the ALCAM and cell density gene 
response could also be observed in a more 
in vivo-like situa�on, the three cell lines were 
cultured in 3D collagen la�ces. The gene 
response for 57 out of the 146 genes was 
maintained when these cells were cultured 
at high cell density in collagen type 1 gels 
(table 3). This set of genes contains several 
know tumor markers and genes with no 
known func�on for tumor progression. With 
his method of culturing combined with micro-
array analysis we here iden�fy a cluster of 
genes responsive to progressive cell clustering 
that can be coupled to invasive growth via 
ALCAM func�onality. 
Confirma�on of altered L1CAM expression at 
protein level 
 To verify if our approach revealed a 
gene response that could contribute to 
tumor progression we examined the protein 
expression of a known tumor progression 
marker picked up by our micro-array analysis. 
As a marker present in many tumor types, 
including melanoma, L1CAM/CD171 was 
selected (Thies et al., 2002;Talantov et al., 
2005;Meier et al.,2006). Western blot analysis 
(Figure 2A) demonstrated low basal L1CAM 
level in cells grown at low cell confluence with 
the highest expression in BLM/ΔN-ALCAM cells, 
limited expression in parental BLM cells and no 
expression in BLM/sALCAM cells. Increased cell 
density, and thus increased ALCAM-mediated 
cell adhesion induced upregula�on of L1CAM 
expression in BLM and BLM/ΔN-ALCAM cells. 
Interes�ngly, the highest increase in full length 
L1CAM expression was observed in BLM/ΔN-
ALCAM cells cultured at high cell density, 
whereas parental BLM cells at high density 
primarily displayed high expression of cleaved 
L1CAM. This suggests proteoly�c degrada�on 
of L1CAM as func�on cell density and ALCAM-
mediated cell clustering. The protein data is in 
Low vs high density, 
monolayer
Low vs high density, 
collagen
Func�on or 
rela�on to cancer
references
sA ∆N BLM sA ∆N BLM
interleukin 8 AF043337 1,3 7,2 6,3 8 16,8 15,5 Chemokine, 
melanoma 
related
(Varney et al., 
2006)
colony s�mula�ng factor 2 
(granulocyte-macrophage)
M11734 1,2 5,6 5,7 2,5 11,9 6,2
intercellular adhesion 
molecule 1 (CD54)
NM_000201 1,7 4,9 6,6 4,2 10,6 21,2 “(Gho et al., 
1999;Swart, 
2002)”
B-factor, properdin NM_001710 1,3 10,3 5,5 1,5 9,4 10,8 complement (Hourcade, 
2008)
baculoviral IAP repeat-
containing 3
U37546 1,7 4,5 3,3 2,9 9 4,7
ephrin-A1 NM_004428 1,9 3,8 3,1 1,6 8,8 12 melanoma 
growht factor
(Easty et al., 
1999)
Transcribed locus R34841 1,3 6,1 6,1 2,1 8,7 9,6 unknown
hypothe�cal protein 
MGC5618
BF575213 1,6 6,9 6,5 2 8,4 9,8 unknown
Table 3: Gene expression profiles of genes responsive to ALCAM status and Cell density.
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Low vs high density, 
monolayer
low vs high density,
collagen
func�on or 
rela�on to cancer
references
sA ∆N BLM sA ∆N BLM
cyclin G2 L49506 1,5 3,4 4 3,7 8,3 9,5 cyclin
collec�n sub-family member 
12
NM_030781 2,5 19 27,4 1,3 7,3 10,6
intercellular adhesion 
molecule 1 (CD54)
AI608725 1,7 3,6 5,6 3,1 7,1 13,6 “(Gho et al., 
1999;Swart, 
2002)”
complement component 1, s 
subcomponent
BC007010 1,2 6,9 3,9 1,5 7 5 complement (Sim and 
Tsi�soglou, 
2004)
killer cell lec�n-like receptor 
subfamily C, member 1 
NM_002260 2,3 11,3 8,6 1,7 6,9 4,3
interferon-induced protein 
with tetratricopep�de 
repeats 2
AA131041 1,1 5,8 5,6 1,5 6,9 5,1
CD82 an�gen AI870617 2 5,8 11,1 2,8 6,7 18,1 tetraspanin, 
metastasis 
suppressor
(Tonoli and 
Barre�, 2005)
chemokine (C-X-C mo�f) 
ligand 1 
NM_001511 -1,4 4,8 4,3 1,4 6,5 4 chemokine  
melanoma
(Dhawan and 
Richmond, 
2002)
complement component 1, s 
subcomponent
M18767 1,3 9,8 8,2 1,3 6,5 6,8 complement (Sim et al., 
2004)
chemokine (C-X-C mo�f) 
ligand 2
M57731 -1,2 4,3 3,9 1,6 6,4 4,2 chemokine
interferon-induced protein 
with tetratricopep�de 
repeats 3
AI075407 1,1 3,6 4,7 1,6 6,2 7,7
Cyclin G2 L49506 1,9 3,7 5,7 3 6 9,1 cyclin
interferon-induced protein 
with tetratricopep�de 
repeats 1
NM_001548 1,4 4,4 5,7 1,7 6 7,8
complement component 1, r 
subcomponent
AL573058 1,3 6,3 8,9 1,5 5,5 10,7 complement (Sim et al., 
2004)
hypothe�cal protein FLJ20035 NM_017631 2,8 6,4 10,1 3 5,3 12,9 unknown
colony s�mula�ng factor 1 
(macrophage)
M37435 1,7 4,2 4,5 1,7 5,2 5,4
interleukin-1 receptor-
associated kinase 2
AI246590 1,3 3,7 3,5 3,1 5,1 6,8 intracellular 
kinases
(Ringwood 
and Li, 2008)
v-rel re�culoendotheliosis 
viral oncogene homolog B
NM_006509 1,4 3,1 3,1 2,7 4,9 7,1
hypothe�cal protein 
MGC13024
AW517464 2,5 4,5 6,5 2,6 4,7 6,6 unknown
FLJ20298 protein AW172431 2,9 4,9 5,2 2,7 4,3 4,9 unknown
chemokine (C-C mo�f) 
ligand 5
M21121 1,2 5,6 5,4 -1 4,3 14,3 chemokine, 
melanoma 
related
(Payne and 
Cornelius, 
2002)
L1 cell adhesion molecule AI653981 1,1 3,3 3,2 1,3 4,2 6
nuclear factor of kappa light 
polypep�de 
AB037925 1,3 3,1 4 1,7 4,2 5,3
gene enhancer in B-cells 
inhibitor, zeta
Family with sequence 
similarity 20, member C
AK026140 2,7 3,6 9 1,8 4,1 8,3
B-cell CLL/lymphoma 3 NM_005178 2 4,4 4,2 1,8 4,1 6,5 marker 
lymphoma, n�b 
related
(Ohno et al., 
2005)
fibroblast ac�va�on protein, 
alpha
U76833 2,9 3,9 4 1,8 4,1 3,9 serine protease, 
cancer related
(Kelly, 2005)
grancalcin, EF-hand calcium 
binding protein
NM_012198 1,8 4,9 5,3 3 4 9,1 neutrophils 
adhesion
(Xu et al., 
2006)
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Low vs high density, 
monolayer
Low vs high density, 
collagen
Func�on or 
rela�on to cance
references
sA ∆N BLM sA ∆N BLM
kelch-like 24 (Drosophila) AL120021 2,6 5,6 6,3 2,2 4 7,7 unknown
interleukin 1, alpha M15329 2,6 5,1 4,7 2,3 3,9 6,6 cytokine, involved 
in MMP-1 
synthesis
(Loffek et al., 
2005)
interferon-induced protein 
44-like
NM_006820 2,5 5,6 16,9 1,6 3,9 20,8
2’,5’-oligoadenylate 
synthetase 1, 40/46kDa
NM_002534 1,6 4,9 8,3 1,6 3,9 11,4 interferon 
induced enzyme
(Sarkar et al., 
1999)
latent transforming 
growth factor beta 
binding protein 3
NM_
021070
2,5 4,1 4,2 2,6 3,8 5 component 
of the ECM, 
modulator 
of TGF-? 
availability
(Todorovic et 
al., 2005)
superoxide dismutase 2, 
mitochondrial
X15132 -1 3,2 3,7 1,1 3,7 5,7 dismuta�on 
of superoxide 
anions
(Zelko et al., 
2002)
interferon-s�mulated 
transcrip�on factor 3, 
gamma 48kDa
NM_
006084
1,9 3,4 5,6 1,9 3,7 8,4 suppressing 
MMP-9 gene 
expression.
(Zhao et al., 
2007)
ATP-binding casse�e, 
sub-family A (ABC1), 
member 1
AF285167 1,7 3,2 4,5 2,3 3,6 7,7
transporter 1, ATP-binding 
casse�e, sub-family B 
(MDR/TAP)
NM_
000593
1,5 3,2 4,6 1,9 3,5 9,1
dihydropyrimidinase-like 3 NM_
001387
2,3 3,5 4,5 2,8 3,5 3,6 neurite 
outgrowth
(Kowara et 
al., 2007)
GABA(A) receptor-
associated protein like 1
AF087847 2,6 3,8 3,5 2,4 3,5 3,6
superoxide dismutase 2, 
mitochondrial
W46388 1,1 3,1 3,6 1,6 3,4 6,6 dismuta�on 
of superoxide 
anions
(Zelko et al., 
2002)
D site of albumin 
promoter (albumin D-box) 
binding protein
U79283 2,9 3,2 3,8 2,5 3,4 3,7
related RAS viral (r-ras) 
oncogene homolog
NM_
006270
2,1 3,2 3,5 2,6 3,3 4,6
CCAAT/enhancer binding 
protein (C/EBP), delta
NM_
005195
2,4 4 4,9 1,3 3,2 5 growth arrest (Zhang et 
al., 2008)
integrin, alpha 11 AF109681 1,5 5 4,1 1,2 3,2 3,2 breast cancer (So�riou et 
al., 2001)
prostaglandin F receptor 
(FP)
NM_
000959
2 3,3 4,1 2,5 3,2 4,6
guanylate binding protein 
2, interferon-inducible
NM_
004120
2,8 4,2 3,6 1,7 3,1 8,3
complement component 3 NM_
000064
1,2 4,3 7,6 1,5 3,1 5,7 complement (Sim et al., 
2004)
ATP-binding casse�e, 
sub-family A (ABC1), 
member 1
NM_
005502
1,5 3 3,1 2,1 3,1 5,9
GABA(A) receptor-
associated protein like 1
AF180519 2,7 3,3 3,8 2,3 3 3,9
type 1 tumor necrosis 
factor receptor shedding 
aminopep�dase regulator
BE551138 1,5 3,1 4 2,1 3 4,5
To test if the ALCAM and cell clustering gene response remains in a more in vivo like situa�on the panel of cells was cultured 
in 3D collagen la�ces. The cluster of genes coupled to an invasive phenotype (146 genes, figure 1) show that for the 57 
genes the gene response is maintained when these cells are cultured at high cell density in collagen type 1 (difference more 
than 3x). As BLM/∆-ALCAM have the most invasive phenotype, the list is sorted from top to bo�om beginning with the gene 
that is most responsive in BLM/∆-ALCAM cells cultured in collagen. 
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line with the mRNA expression levels found 
in the micro-array analysis and shows that 
L1CAM expression is highly upregulated by cell 
clustering. These data confirm our previous 
observa�on that ALCAM func�onality 
regulates L1CAM protein expression (van 
Kilsdonk et al., 2008d). Furthermore, it 
demonstrates that L1CAM expression is 
increased with increasing cell density and not 
subjected to degrada�on in case of impaired 
ALCAM-mediated cell adhesion.
Confirma�on of altered C1r and C1s expression 
at protein levels 
 Besides know tumor markers like L1CAM, 
the gene response upon cell clustering 
reveals genes without any link to melanoma 
progression or to tumor progression in 
general. These genes might be interes�ng 
novel candidates that could play a role in 
tumor progression. 
The iden�fica�on of both of the classical 
complement cascade ini�ators C1r and C1s 
in the micro-array and qPCR analysis is an 
interes�ng observa�on. C1r and C1s protein 
expression levels were determined using 
Western blot analyses on cell culture medium 
precipitates to further study their response to 
ALCAM status and progressive cell clustering. 
Figure 2B shows that the secre�on of both C1r 
and C1s is hardly detected in medium from 
BLM, BLM/ΔN-ALCAM and BLM/sALCAM cells 
grown at low cell density. However, increasing 
the cell density significantly enhanced the 
expression of C1s in all three cell lines. 
Strikingly, the expression was highly increased 
Figure 2: Expression of L1CAM, C1r and C1s in melanoma cells, effects of ALCAM status and cell density. 
A. BLM, BLM/sALCAM and BLM/N-ALCAM cells were cultured as monolayers at high and low density, cell lysates were 
subjected to western-blot analysis using a monoclonal an�body against L1CAM (L1-11A). BLM and BLM/∆N-ALCAM cells 
are posi�ve for L1CAM in contrast to BLM/sALCAM cells. L1CAM expression increases when the cell density increases in 
BLM and BLM/N-ALCAM cells, BLM/sALCAM have no L1CAM expression regardless of cell density. Both full-length and 
plasmin cleaved L1 are detected. -Ac�n servers as a loading control. 
B. To test if C1s and C1r are secreted and differen�ally expressed in the cell-lines western blot analysis was performed, a�er 
precipita�on, of condi�oned media. BLM, BLM/sALCAM and BLM/∆N-ALCAM cells were cultured as monolayers at low 
(L) and high cell density (H). All cell-lines are nega�ve for C1r and C1s expression at low cell density. With increasing cell 
density expression of C1r and C1s is drama�cally increased in BLM and BLM/∆N-ALCAM cells. BLM/sALCAM cells hardly 
respond to cell density changes. 
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Figure 3: C1s expression in primary melanoma. 
C1s expression varies within and between melanomas and comprises i) gradual increase within a melanoma (A-D) where a 
more intense expression is observed in the most invasive component (C versus D) , ii) moderate expression (E,F) and iii) low 
expression (G,H). Original magnifica�ons 1.25x (A,B), 5x (E,G), 20x (C,D), 40x (F,H). A,E,G: Haematoxylin & Eosin. Asterisks 
in E indicates melanophages. 
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in BLM and ΔN-ALCAM while the increase 
in sALCAM cells was only limited. Similar 
responses to ALCAM status and cell density 
changes are seen for C1r (figure 2B), although 
the expression levels are low compared to 
C1s. Increasing cell density increased the 
C4 consump�on by all cell lines, however, 
C4 consump�on was less in the medium of 
sALCAM expressing cells. This is consistent 
with the lower amount of C1r and C1s protein 
present in the BLM/sALCAM condi�oned 
medium (supplemental data figure 2). These 
protein data confirm the strong responses to 
increased cell density and ALCAM status as 
observed in the micro-array analysis. 
To further demonstrate C1s expression 
in melanoma, an immunohistochemical 
staining was performed on formalin-fixed 
and paraffin-embedded �ssue. Seven of 
the 10 melanomas analyzed did display C1s 
expression. Representa�ve images of C1s-
posi�ve melanomas are shown in figure 3 and 
reveal a gradual increase in cytoplasmic C1s 
staining intensity (Figure 3A-D), with highest 
intensi�es in the most invasive component 
(Figure 3D). Moderate (Figure 3F) and low 
(Figure 3H) cytoplasmic C1s expression could 
be observed. This small sample set confirmed 
that C1s is expressed in primary cutaneous 
melanomas. 
C1r and C1s density effects in different tumors 
 The increased expression of C1r and C1s 
in BLM cells upon cell clustering could be 
a BLM ar�fact. To show that the response 
to increased density is more universal we 
determined the mRNA expression level of C1r 
and C1s in several different tumor cell lines 
using qPCR. In figure 4 black bars represent 
C1r and C1s expression at low cell density, 
Figure 4: Expression of C1r and C1s in a panel of tumor cell lines. 
Quan�ta�ve PCR analysis of C1r and C1s mRNA levels in HT1080, PC3, Wm164 and CaCo-2 cells. Cells were cultured as 
monolayers at low (L) and high (H) cell density. Messenger RNA levels of cells cultured at low density (black bars) were 
compared to messenger levels of cells at high density (white bars). For each gene and each cell line expression levels at 
low density were set as 100%. Increased culture density significantly increased the expression of C1r and C1s in all cell 
lines, except C1r expression in CaCo-2 cells is unaffected by density changes. Experiment performed in triplo, significant 
difference (P ≤ 0.05, Student’s t - test). 
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whereas white bars represent expression at 
high cell density. In the HT1080 fibrosarcoma 
cell line a massive increase in expression of 
both proteins is observed when cell density is 
increased. Actually, in all cell lines tested the 
increase in expression is observed although 
at different levels. Except for the expression 
of C1r in CaCO-2 cells which does not increase 
upon cell density changes. These data show 
that the cell clustering gene response is a 
more general phenomenon and that C1r and 
C1s might play a role in several solid tumors. 
Discussion
 A remarkable pro-invasive change in 
melanoma growth phenotype is observed by 
the introduc�on of ΔN/ALCAM expression (van 
Kempen et al., 2004) whereas overexpression 
of sALCAM decreased invasion and metastasis 
rate (van Kilsdonk et al., 2008). Here, these 
changes in invasive behavior have been 
instrumental to inden�fy a cluster of genes 
responsive to ALCAM func�onality and 
invasion. Limited cell-cell contacts between 
BLM cells are not able to increase expression of 
these genes but when sufficient cell clustering 
is achieved expression is subsequently 
increased. ALCAM-ALCAM interac�ons seem 
to orchestrate the expression of genes that 
are upregulated by tumor cell clustering and 
addi�onally contribute to tumor progression. 
Specifically, we observed ALCAM dependent 
upregula�on of L1CAM consistent with 
invasive phenotypes. In addi�on, two 
proteases of the classical complement route, 
C1r and C1s, which have not been related 
to tumor progression previously, were 
upregulated in invasive melanoma cells upon 
cell clustering and ALCAM status. For C1s we 
confirmed expression in primary melanomas. 
From this we conclude that there is a cell 
density responsive gene cluster that is par�ally 
controlled by ALCAM status both in 2D and 3D 
cell cultures. 
Our data indicate that ALCAM func�ons as a 
signaling molecule that can affect the invasive 
behavior of melanoma cells. Previously, we 
have already shown that ALCAM status controls 
MMP-14-mediated ac�va�on of MMP-2 
(Lunter et al., 2005;van Kilsdonk et al., 2008). 
MMP-2 is a pro-invasive proteinase that plays 
a significant role in the progression of human 
melanomas (Hofmann et al., 2000;Hofmann et 
al., 2005). In line with this we here show that 
ALCAM controls the expression of another 
important tumor marker, L1CAM (figure 2A). 
Several reports have iden�fied L1CAM as a 
melanoma progression marker (Thies et al., 
2002;Primiano et al., 2003;Talantov et al., 
2005;Meier et al., 2006) and overexpression or 
suppression of L1CAM enhanced or diminished 
melanoma invasiveness, respec�vely (Meier et 
al., 2006). In our experiments, the expression 
of L1CAM directly correlates with the invasive 
phenotypes of the BLM/ALCAM cell lines. 
L1CAM is highly expressed in the super-invasive 
BLM/ΔN-ALCAM cells, endogenous levels are 
detected in parental invasive BLM cells while 
expression of L1CAM is hardly detected in the 
poorly invasive cell-line BLM/sALCAM (figure 
2A). The exact molecular mechanism that can 
explain the different effects of ΔN-ALCAM and 
sALCAM on L1CAM expression is subject of our 
further studies. 
Unexpectedly, the expression array and 
immunohistochemical data pointed towards a 
role for ALCAM in modula�ng the expression 
of C1r and C1s. The expression pa�ern of 
these complement factors in the variant BLM 
cell lines is comparable to that of L1CAM. 
It suggests that MMP-2 ac�va�on, L1CAM, 
C1r and C1s are linked to ALCAM status and 
directly correlate with invasive poten�al. 
However, how C1r and C1s contribute to 
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melanoma invasion is unclear. Most of the 
genes responsive to ALCAM func�onality 
like chemokines, chemokine receptors, 
complement component 3, C1r and C1s belong 
to the innate immune response (table 3). From 
this it is temp�ng to speculate about a role of 
ALCAM in the regula�on of a tumor related 
innate immune response. To our knowledge, 
the expression of complement components 
C1r and C1s in rela�on to melanoma or 
tumor progression in general has never been 
examined. The strong upregula�on and 
ac�vity of both proteins and correla�on with 
ALCAM expression in several tumor cell lines 
of different pathological origin (Degen et al., 
1998) hints to a more general contribu�on 
of C1r and C1s in tumor progression (Figure 2 
supplemental data at the end of this chapter). 
To confirm the possible correla�ons between 
ALCAM and C1r/s expression in melanoma and 
how this contributes to melanoma invasion, 
further studies are needed. 
Because cell division occurs at a higher 
rate than cell death in tumors, these highly 
prolifera�ve cancer cells o�en form an 
expanding tumor mass. As sustained tumor 
cell prolifera�on will increase homotypic 
cell-cell clustering these clusters could favor 
signaling responses promo�ng the invasive 
growth and migra�on. The comparison of 
low confluent cultures to superconfluent 
cultures used here may partly mimic some of 
the physiological signals induced by the rapid 
expansion of tumor �ssue. High cell density has 
been shown to alter several cellular processes. 
Previously we already showed the importance 
of melanoma cell clustering for the ac�va�on 
of MMP-2 in collagen matrices (Lunter et al., 
2005). Addi�onally, high cell density selec�vely 
enhances αvβ6 expression in a protein kinase 
C (PKC)–dependent manner in colon cancer 
lines (Niu et al., 2001), but we did not observe 
this in melanoma cells using our assay. The 
present set of experiments iden�fies a set of 
genes induced by increased melanoma cell 
clustering. The large set of genes iden�fied 
using only 2-dimensional culture methods was 
brought back to a smaller set of genes using 3-
dimensional collagen cultures. The molecular 
mechanism underlying the gene responses 
upon changes in culture density remain to be 
elucidated. One a�rac�ve possibility is that 
the homotypic cell-cell clustering effects rely 
on increased number of interac�ons between 
cell adhesion molecules. Manipula�ng the 
ALCAM func�onality indeed altered the cell-
clustering gene responses in favor of invasion. 
If ALCAM solely func�ons as an adhesion 
molecule then impairment of the ALCAM 
adhesive func�on, in any way, should allow 
migra�on because of the relieved adhesion. 
Overexpression of sALCAM and ΔN/ALCAM in 
BLM cells was suggested to interfere with the 
adhesive func�on of na�ve ALCAM. Although 
both approaches indeed interfere with ALCAM 
func�oning, they induce different invasive 
phenotypes (van Kempen et al., 2004;van 
Kilsdonk et al., 2008). The contribu�on of 
ALCAM to the different responses upon 
sALCAM and ΔN/ALCAM overexpression 
may now be defined. Downstream effects of 
ALCAM func�onality seem to be generated in 
two ways; 1, receptor-ligand interac�ons of 
ALCAM between two opposing cells (trans-
clustering) 2. Mul�meriza�on of ALCAM on 
the surface of one cell (cis-clustering). 
The divergent effects in the C1r/s and L1CAM 
profile between sALCAM and ΔN/ALCAM 
expression suggest an inverse rela�on 
between the extent of ALCAM cis-clustering 
and transcrip�on levels of these target genes. 
Full reduc�on on protein level can only be 
achieved a�er sALCAM expression, while the 
presence of only intact ALCAM may generate 
crosstalk to increase the response amplitude. 
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This interpreta�on is consistent with aberrant, 
cons�tu�vely elevated cis-clustering upon 
overexpression of ΔN-ALCAM and the absence 
of cis-clustering in sALCAM cells (van Kilsdonk 
et al., 2008). In contrast, func�onal regula�on 
of MMP-2 ac�va�on requires increasing 
trans-clustering of ALCAM at the cell surface 
which are absent in both sALCAM and ΔN-
ALCAM expressing cells. The iden�fica�on 
of the dual response profiles is in agreement 
with a complex sensor role in progressive cell 
confluence, which registers the extent of cell 
clustering (i.e. cell density) and controls the 
subsequent responses. 
Thus ALCAM may play a prominent sensor 
role in tumor development, but an exclusive 
contribu�on cannot be claimed in tuning of 
growth and cell confluence. The existence of 
addi�onal, parallel control factors is supported 
by the detec�on of an ALCAM-independent, 
cell-confluence-responsive set of genes (figure 
1, 41 genes) in the large microarray analyses. 
Therefore, it is temp�ng to speculate that 
more cell-cell adhesion molecules, alone or 
in coopera�ve assemblies, may fulfill similar 
sensor roles in different cellular contexts. 
Undeniably, the apparent connec�on between 
ALCAM and cell confluence defines a novel 
prototype of growth response, which s�ll 
needs to be linked to the grossly characterized 
cell signaling networks. Returning to our 
working hypothesis of ALCAM func�on in 
melanoma progression, we have provided 
experimental support that induc�on of 
ALCAM in con�nuous prolifera�ng ver�cal 
growth phase melanoma cells increased cell 
clustering and causes transcrip�onal and post-
transla�onal responses. These observa�ons 
support the assump�on that ALCAM and cell 
confluence coordinate the process of invasive 
melanoma growth.
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were present at high confluency. RNA was 
isolated using the RNeasy kit (Qiagen) from six 
independent 3D cultures each containing 1x106 
cells per sample for each cell line, reflec�ng 
high cell density (Lunter et al., 2005). For each 
cell line 3 individual samples were prepared (in 
total 18 collagen gels). 
Total RNA (100 ng) was used as star�ng 
material for cDNA prepara�on. Two-cycle 
amplifica�on protocol was followed. 
Genera�on of bio�nylated cRNA and 
subsequent hybridiza�on to U133Plus 2.0 
oligonucleo�de arrays (Affymetrix, Santa 
Clara, CA), washing and staining were 
performed according to Affymetrix Expression 
Analysis Technical Manual for two-cycle 
amplifica�on (Lockhart et al., 1996). The 
arrays were then scanned using a laser scanner 
GeneChip®Scanner (Affymetrix) and analyzed 
by using Affymetrix GeneChip Opera�ng 
So�ware (GCOS version 1.4) according to the 
manufacturer’s instruc�on. 
High level analysis of oligonucleo�de array 
 Array normaliza�on, expression value 
calcula�on, clustering and principal component 
analysis (PCA) were performed using DNA-Chip 
Analyzer (dChip) version 1.3 (Li and Wong, 
2001) (www.dchip.org). The Invariant Set 
Normaliza�on method and the model-based 
method were used for compu�ng expression 
values (Li et al., 2001). These values were 
expressed as mean and standard errors (SE). 
Criteria of >2 fold and p<0.05 were applied 
for comparison unless otherwise stated. 
Func�onal cluster analysis was performed 
by dChip, incorpora�ng gene ontology (GO) 
terms (h�p://www.geneontology. org) as well 
as pathways collec�on from GenMAPP (h�p:
// www.genmapp.org) and Kyoto Encyclopedia 
of Genes and Genomes (KEGG: h�p:// 
www.genome.ad.jp/kegg) (Zhong et al., 2003). 
For func�onal clusters and gene proximity 
Materials and Methods
Cell culturing 
 Adherent melanoma (BLM, WM164), 
fibrosarcoma (HT1080), colon carcinoma 
(CaCo-2) and prostate carcinoma (PC3) cells 
were maintained as monolayers in Dulbecco`s 
modified essen�al medium (DMEM) 
(Invitrogen) supplemented with 10 % fetal 
calf serum (FCS), 4mM L-glutamine and 2 mM 
pyruvate. BLM cells with amino-terminally 
truncated ALCAM (BLM/ΔN-ALCAM) and 
BLM cells with soluble N-terminal ALCAM 
fragments (BLM-sALCAM) were cultured as 
described previously (Degen et al., 1998;van 
Kempen et al., 2001;van Kilsdonk et al., 
2008). Three dimensional collagen cultures 
are prepared as shown previously (Lunter et 
al., 2005). All cells were grown un�l desired 
density was reached or split before confluency 
was reached. Frequent tes�ng showed that 
cells were free of mycoplasma contamina�on. 
cDNA prepara�on and GeneChip array 
hybridiza�on 
 cDNA micro-array analysis was performed 
using the HuGeneFL array (Affymetrix, Santa 
Clara, CA). For the first micro-array experiment 
RNA was isolated from five independent, 
clonal BLM/ΔN-ALCAM lines and compared 
with RNA from two independent BLM clones 
transfected with the empty expression vector. 
RNA isola�on, hybridiza�on, and array analysis 
were performed as described previously (de 
Wit et al., 2002). For the second large scale 
micro-array experiment RNA was isolated 
from three independent BLM, BLM/N-ALCAM 
and BLM-sALCAM monolayer cell cultures 
grown at low cell confluency (< 1x105 cells / 
cm2) and compared with RNA from high cell 
confluency cultures (>2.5x105 cells/cm2). The 
number of cell-cell contacts was limited at 
low confluency, while many mul�layers of cells 
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expression was performed using dChip. The 
t-sta�s�c was computed as (mean1 – mean2) / 
√(SE(mean1)2+ SE(mean2)2)), and its p-value is 
computed based on the t-distribu�on, and the 
degree of freedom is set according to Welch 
modified two-sample t-test (Li et al., 2001). 
The sta�s�cal significance of GO term, protein 
domain and pathway frequency was calculated 
as probability of observing at least κ probe 
sets annotated with a par�cular classifica�on 
within a list of selected probe sets (cluster) of 
size n where f was the total number of genes 
within a func�onal category, and g was the 
total number of probe sets on the chip set 
(Tavazoie et al., 1999). Sample classifica�on 
was performed by dChip based on Linear 
discrimina�ng analysis (LDA) and Principal 
component analysis (PCA) (Raychaudhuri et 
al., 2000). Correla�on coefficient analysis 
was performed based on Pearson’s linear 
regression model. P<0.05 was considered 
sta�s�cally significant. 
Reverse transcrip�on, PCR and quan�ta�ve 
Real-Time PCR 
 RNA was isolated using the RNeasy kit 
(Qiagen) according to instruc�ons. To remove 
genomic DNA, the RNA samples were treated 
with 1U DNase (Invitrogen) per 5 µl RNA for 
15 min at room temperature. The reac�on 
was stopped by adding 1 µl 25 mM EDTA and 
incubated at 65°C for 10 minutes. Reverse 
transcriptase (RT) Superscript III (Invitrogen) 
was used to transcribe the RNA into cDNA (5 
min at 25°C, 60 min at 37°C and 10 min at 94°C). 
The reac�on mixture contained 2 µl 0.1M DTT, 
0.6 µl 12.5 mM dNTPs, 0.4 µl oligo-dT, 0.5 µl 
RNAsin (40U/µl) and 0.5 µl RT diluted in 5x 
reac�on buffer. cDNA was diluted 1/50 and 
stored at -20°C. Primer sequences are given in 
table 4. All primers were synthesized by Isogen 
gene 5’®3’ 
GAPDH forward atc�c��gcgtcgccag
reverse �ccccatggtgtctgagc
Wnt-5a forward tggaaggactcatgaccaca
reverse gaggcagggatgatg�ctg
Gas-1 forward cggagc�gac�c�ggac
reverse cgtcctgaacactgcagctA
FAP forward acgtcggaggtcaatca�c
reverse gagccaccaga�gg��g
KIAA 0316 forward gcaaca�agtgcaggcaga 
reverse gagccaccaga�gg��g
hASNAi forward ggaccagatggaggacctg
reverse gagggccgagaaggtg�
TFPI-2 forward gctgtcga�ctgctgc�t
reverse ctccgcg�a�tcctg�g
ENA-78 forward gaagtggtagcctccctgaa
reverse �g�tccaccgtccaaaat
C1-r forward ctgctgacc�ccacacaga
reverse tcaaggtccacagc�ggtag
C1-s forward gaag�gtggagggacgtgt
reverse aatgccacagtccacagg�
DNA pol-a forward ctctacgagggtgtgccact
reverse tgtggtgtatggtccacagg
TIMP-2 forward gtagtgatcagggccaaagc
reverse caggccc�tgaacatc�t
MMP-2 forward ggca�caggagctctatgg
reverse gagcgatgccatcaaataca
SCCA forward tcctgggtggaaagtcaaac
reverse cccactgccc�tgaaatag
Htra-1 forward acagctggaatctcc�tgc
reverse �ggtgatggc��cc�t
MT1-MMP forward atcatggcaccc��acca
reverse cctgactcacccccataaag
table 4: primer sequecnes 
effects p<0.001 was considered sta�s�cally 
significant. Genome informa�on was obtained 
from NetAffx (h�p://www.affymetrix.com/ 
analysis/index.affx) and was based on UCSC 
Genome Bioinforma�cs. 
Sta�s�cs 
 Sta�s�cal analysis for array-based gene 
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Lifesciences (Maarssen, the Netherlands). 
cDNA levels were determined using SYBR 
green fluorescence with the ABI-Prism 7000 
(Applied Biosystems, Nieuwerkerk a/d IJssel, 
the Netherlands). Expression levels of three 
individual experiments were evaluated as 
the number of cycle difference from GAPDH. 
Significant changes from control samples were 
determined using Student’s T-test. P ≤ 0.05 
was considered significant. 
Western blo�ng 
 Cell extracts were prepared by using lysis 
buffer (50 mM Tris-HCl, pH 7.4, 1% NP40, 140 
mM NaCl, 1 mM MgCl2, and 1 mM CaCl
2
) 
containing 1 mM phenylmethylsulfonyl 
fluoride and proteinase inhibitor cocktail. 
Protein concentra�ons were determined 
using the BCA protein determina�on kit 
(Pierce, Rockford, IL), 15 g protein was loaded. 
Serum free media were precipitated using 2-
propanon at -70°C for 20 minutes followed by 
90 minutes at -20°C; precipitates were taken 
up in reducing sample buffer. A�er 5 minutes’ 
boiling media precipitates or cell lysates (20 
µg protein) were separated by SDS-PAGE, and 
transferred to PVDF Membrane (Millipore). 
Monoclonal an�body L1-11A (gi� of Dr. 
P. Altevogt) was used for the detec�on of 
L1CAM. Rabbit an� C1R an�body for Western 
blot detec�on of C1R was kindly provided by 
Dr Gerand Arlaud, Grenoble, France. 
If indicated blots were stripped using strip-
buffer (2% SDS, 62.5 mM Tris pH 6.8 and 100 
mM beta-mercaptoethanol) and re-probed 
for β-ac�n (Sigma). Bound primary an�bodies 
were visualized by appropriate HRP coupled 
secondary an�bodies and enhanced chemi-
luminescence using the ECL Plus Western 
blo�ng Detec�on System (Amersham 
Biosciences, Roosendaal, the Netherlands). 
Human �ssues 
 Formaldehyde-fixed and paraffin-
embedded primary cutaneous melanomas 
from adult pa�ents (n=10) with known follow-
up were obtained from the pathology archives 
of the Radboud University Nijmegen Medical 
Centre. Tissues were obtained according to 
local ethical guidelines and approved by the 
local regulatory commi�ee. 
Immunohistochemistry 
 Paraffin-embedded (4 µm) �ssue sec�ons 
were de-waxed and rehydrated through 
graded alcohols. Following an�gen retrieval 
with pronase (0.1% in PBS, 15 minutes at 
37°C), �ssues were preincubated with 20% 
normal horse serum for 20 minutes and 
subsequently incubated with a monoclonal 
an�body towards C1s (clone M81, 50g/
ml, Hycult Biotechnologies, Uden, The 
Netherlands) overnight at 4°C (Matsumoto 
and Nagaki, 1986). Liver �ssue was used as a 
posi�ve an�body control, a non-relevant IgG 
was taken along as a nega�ve control. Binding 
was visualized using Fast Red as a chromogen 
via the standard ABC-method (Alkaline 
Phosphatase, Vector Laboratories). Tissues 
were briefly counterstained with Haematoxylin 
and mounted with Imsol moun�ng medium 
(Klinipath BV, Duiven, The Netherlands). 
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Supplemental figure 1: Venn diagram overview of 
the microarray results, effects of ALCAM status and 
cell density.
Monolayer cultures of BLM, BLM/sALCAM and BLM/
DN-ALCAM cells grown at low and high cell density are 
compared using micro-array analysis. For each cell line 
all genes with an decreased expression (< 3x) upon cell 
density are depicted.  
Supplemental figure 2: C4 
consump�on assay
BLM, BLM/sALCAM and BLM/
∆N-ALCAM cells were cultured 
as monolayers at low (L) and 
high cell density (H) medium 
was taken and subjected to C4 
consump�on elisa assay. Black 
bars represent C4 consump�on 
at low cell density, white bars at 
high cell density. Dashed bars are 
the medium control (med) and 
the posi�ve C1r and C1s control 
(C1r/s). 
Supplementary Data
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Genes downregulated in BLM/
sALCAM cells at low cell density
Accession # Fold 
change
SPANX family, member B1 /// SPANX 
family, member B2
NM_013453 -53,9
RAB4A, member RAS oncogene family BC002438 -34,4
collagen, type I, alpha 1 BE221212 -29,9
nes�n AW028075 -29,6
angiotensin II receptor, type 1 NM_000685 -29,1
prostaglandin-endoperoxide synthase 2 NM_000963 -28,2
collagen, type I, alpha 1 K01228 -25,6
prostaglandin-endoperoxide synthase 2 AY151286 -23,2
collagen, type I, alpha 1 AI743621 -21,3
glutathione S-transferase M3 (brain) AL527430 -21
perios�n, osteoblast specific factor AY140646 -20,9
transgelin NM_003186 -20,1
perios�n, osteoblast specific factor D13665 -18,2
ASAP NM_024826 -17,8
solute carrier family 38, member 5 BG325630 -16,3
nes�n NM_024609 -14,9
insulin-like growth factor binding protein 3 M31159 -14,7
protease, serine, 7 (enterokinase) NM_002772 -14,1
insulin-like growth factor binding protein 5 AW007532 -12,8
HSCARG protein AI080701 -11,2
paternally expressed 10 AL582836 -11,1
ASAP AI887898 -10,2
perios�n, osteoblast specific factor AY140646 -10,1
G0/G1switch 2 NM_015714 -9,8
HSCARG protein BC002927 -9,8
insulin-like growth factor binding protein 3 BF340228 -9,6
armadillo repeat containing, X-linked 2 NM_014782 -8,7
elas�n microfibril interfacer 2 AF270513 -7,9
RAB4A, member RAS oncogene family NM_004578 -7,5
similar to RIKEN 4933428I03 AI804932 -7,5
endothelin 1 J05008 -7,1
myosin, heavy polypep�de 10, non-muscle AK026977 -7
hypothe�cal protein LOC169834 AI827906 -6,8
dermokine AA706316 -6,8
leucine rich repeat and fibronec�n type III 
domain containing 5
AI375083 -5,8
epithelial membrane protein 2 NM_001424 -5,8
nucleosome assembly protein 1-like 3 NM_004538 -5,7
leucine rich repeat containing 2 NM_024512 -5,5
epithelial membrane protein 2 AI089325 -5,4
CDNA FLJ39613 fis, clone SKNSH2009357 AK096932 -5,1
phospholipase A2, group IVA (cytosolic, 
calcium-dependent)
M68874 -5
endothelin 1 NM_001955 -4,9
membrane protein, palmitoylated 2 NM_005374 -4,9
brain-specific angiogenesis inhibitor 3 NM_001704 -4,8
potassium voltage-gated channel, 
subfamily G, member 1
AI332979 -4,7
AF4/FMR2 family, member 3 AW085505 -4,7
transforming growth factor, beta-induced, 
68kDa
NM_000358 -4,7
carbonic anhydrase XII BF752277 -4,7
odz, odd Oz/ten-m homolog 2 (Drosophila) AB032953 -4,6
carbonic anhydrase XII AL050025 -4,5
carbonic anhydrase XII NM_001218 -4,5
sphingolipid G-protein-coupled receptor, 1 NM_001400 -4,4
chorionic gonadotropin, beta polypep�de NM_000737 -4,2
cystathionine-beta-synthase BC007257 -4,1
Hypothe�cal protein DJ328E19.C1.1 AI569997 -4
Inhibin, beta A (ac�vin A, ac�vin AB alpha 
polypep�de)
AI343467 -4
tyrosine hydroxylase NM_000360 -3,9
chromosome 6 open reading frame 105 AA470369 -3,9
solute carrier family 2 (facilitated glucose 
transporter), member 3
AI631159 -3,8
thyrotropin-releasing hormone degrading 
enzyme
NM_013381 -3,7
matrix metallopep�dase 1 (inters��al 
collagenase)
NM_002421 -3,7
insulin-like growth factor binding protein 5 AW157548 -3,6
inhibin, beta A (ac�vin A, ac�vin AB alpha 
polypep�de)
M13436 -3,6
epithelial membrane protein 2 AV686514 -3,5
transglutaminase 2 AL031651 -3,5
LAIR hlog AI498747 -3,5
dapper, antagonist of beta-catenin, 
homolog 1 (Xenopus laevis)
NM_016651 -3,4
solute carrier family 2 (facilitated glucose 
transporter), member 3
BE550486 -3,4
transgelin BC010946 -3,4
androgen-induced 1 AF151861 -3,3
solute carrier family 2 (facilitated glucose 
transporter), member 3 
AA778684 -3,3
fa�y acid binding protein 5 (psoriasis-
associated)
NM_001444 -3,3
paternally expressed 10 BE858180 -3,1
H1 histone family, member 0 BC000145 -3,1
CDNA FLJ44429 fis, clone UTERU2015653 AI088063 -3,1
adhesion molecule with Ig-like domain 2 AC004010 -3,1
Hypothe�cal protein DJ328E19.C1.1 AA404260 -3
procollagen C-endopep�dase enhancer NM_002593 -3
serpin pep�dase inhibitor, clade E NM_000602 -3
Supplemental table 1: Gene expression profiles of genes responsive to ALCAM status.
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Genes upregulated in BLM/sALCAM 
cells at low cell density
Accession # Fold 
change
interleukin 7 NM_000880 3
extracellular matrix protein 2, female 
organ and adipocyte specific
NM_001393 3
�ssue factor pathway inhibitor J03225 3,1
crea�ne kinase, brain NM_001823 3,1
�ssue factor pathway inhibitor AF021834 3,3
Sep�n 10 AA418028 3,3
tumor necrosis factor receptor superfamily, 
member 11b 
BF433902 3,4
aldehyde dehydrogenase 6 family, member 
A1
AI640855 3,4
G protein-coupled receptor 160 BC000181 3,4
aldehyde dehydrogenase 6 family, member 
A1
NM_005589 3,5
Aldehyde dehydrogenase 6 family, member 
A1
AF130089 3,6
laminin, alpha 4 BC004241 3,7
caspase 1, apoptosis-related cysteine 
pep�dase 
NM_052889 3,7
complexin 1 BC002471 3,7
Tissue factor pathway inhibitor BF511231 3,7
neuronal pentraxin I NM_002522 3,7
family with sequence similarity 84, 
member B
AL039862 3,8
aldo-keto reductase family 1, member C2 M33376 3,8
brevican BC005081 4
G kinase anchoring protein 1 AK026487 4,2
KIAA1622 AB046842 4,2
Paired box gene 8 BF056746 4,2
Aldehyde dehydrogenase 6 family, member 
A1
AW612403 4,2
protein S (alpha) NM_000313 4,3
caspase 1, apoptosis-related cysteine 
pep�dase 
U13700 4,7
interferon induced with helicase C 
domain 1
NM_022168 4,7
carboxypep�dase A3 (mast cell) NM_001870 4,8
laminin, alpha 5 BC003355 4,8
caspase 1, apoptosis-related cysteine 
pep�dase 
U13699 5
aldo-keto reductase family 1, member C3 AB018580 7,3
laminin, alpha 4 NM_002290 8,8
annexin A10 AF196478 10,2
zinc finger protein 236 AK000847 42,1
Genes downregulated in BLM/∆N-
ALCAM cells at low cell density
Accession # Fold 
change
SPANX family, member B1 /// SPANX 
family, member B2
NM_013453 -85,9
collagen, type I, alpha 1 BE221212 -83
fa�y acid binding protein 5 (psoriasis-
associated)
NM_001444 -80,5
collagen, type I, alpha 1 K01228 -58,4
prostaglandin-endoperoxide synthase 2 NM_000963 -31,7
angiotensin II receptor, type 1 NM_000685 -27,4
collagen, type I, alpha 1 AI743621 -22
nes�n AW028075 -21,8
transgelin NM_003186 -21,6
prostaglandin-endoperoxide synthase 2 AY151286 -21,1
perios�n, osteoblast specific factor AY140646 -20,9
glutathione S-transferase M3 (brain) AL527430 -19,2
perios�n, osteoblast specific factor D13665 -16,2
ABI gene family, member 3 (NESH) binding 
protein
AB056106 -15,2
solute carrier family 38, member 5 BG325630 -14,5
paternally expressed 10 AL582836 -12,2
follista�n BF438173 -12,2
nes�n NM_024609 -12,2
neurotrimin AW085558 -11,9
insulin-like growth factor binding protein 5 AW007532 -10,6
H1 histone family, member 0 BC000145 -9,4
perios�n, osteoblast specific factor AY140646 -9,3
neurotrimin AW117456 -8,5
meiosis-specific nuclear structural 1 NM_018365 -8,4
elas�n microfibril interfacer 2 AF270513 -7,7
insulin-like growth factor binding protein 3 M31159 -7,7
insulin-like growth factor binding protein 3 BF340228 -7,6
endothelin 1 J05008 -6,9
membrane protein, palmitoylated 2 NM_005374 -6,7
Inhibin, beta A (ac�vin A, ac�vin AB alpha 
polypep�de)
AI343467 -6,6
leucine rich repeat and fibronec�n type III 
domain containing 5
AI375083 -6,4
OCIA domain containing 2 BG291649 -6,4
endothelial differen�a�on NM_001400 -6,4
leucine rich repeat containing 17 NM_005824 -6,3
myosin, heavy polypep�de 10, non-muscle AK026977 -6,2
odz, odd Oz/ten-m homolog 2 (Drosophila) AB032953 -6
dapper, antagonist of beta-catenin, 
homolog 1 (Xenopus laevis)
NM_016651 -5,9
similar to RIKEN 4933428I03 AI804932 -5,8
inhibin, beta A (ac�vin A, ac�vin AB alpha 
polypep�de)
M13436 -5,8
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melanocor�n 1 receptor BG034972 -5,4
CDNA FLJ39613 fis, clone SKNSH2009357 AK096932 -5,3
endothelin 1 NM_001955 -5
AF4/FMR2 family, member 3 AW085505 -4,9
bradykinin receptor B1 NM_000710 -4,8
heat shock 70kDa protein 2 U56725 -4,7
LAIR hlog AI498747 -4,6
transglutaminase 2 AL031651 -4,5
carbonic anhydrase XII BF752277 -4,4
CDNA FLJ12815 fis, clone NT2RP2002546 BG109855 -4,4
CDNA FLJ12815 fis, clone NT2RP2002546 BF940761 -4,3
hyaluronan synthase 2 NM_005328 -4,2
carbonic anhydrase XII AL050025 -4,2
tyrosine hydroxylase NM_000360 -4,1
follista�n NM_013409 -4,1
brain-specific angiogenesis inhibitor 3 NM_001704 -4
thymosin-like 8 NM_021992 -4
carbonic anhydrase XII NM_001218 -3,9
fibronec�n 1 BC005858 -3,9
fibronec�n 1 X02761 -3,9
transgelin BC010946 -3,8
fibronec�n 1 AF130095 -3,8
fibronec�n 1 AK026737 -3,7
CDNA FLJ31085 fis, clone IMR321000037 AV703555 -3,7
insulin-like growth factor binding protein 5 AW157548 -3,6
chorionic gonadotropin, beta polypep�de NM_000737 -3,6
matrix metallopep�dase 1 (inters��al 
collagenase)
NM_002421 -3,5
Hypothe�cal protein DJ328E19.C1.1 AI569997 -3,5
Hyaluronan synthase 2 AI374739 -3,4
BAI1-associated protein 2-like 2 AA532851 -3,3
glyoxalase domain containing 1 AI653050 -3,3
potassium voltage-gated channel, 
subfamily G, member 1
AI332979 -3,2
oxytocin receptor NM_000916 -3,1
HSCARG protein BC002927 -3,1
FLJ25476 protein W72455 -3,1
leucine rich repeat containing 2 NM_024512 -3,1
collagen, type VI, alpha 2 AY029208 -3,1
paternally expressed 10 BE858180 -3,1
Transcribed locus BF446723 -3
carbonic anhydrase XII BC001012 -3
thyrotropin-releasing hormone degrading 
enzyme
NM_013381 -3
Genes upregulated in BLM/∆N-
ALCAM cells at low cell density
Accesion # Fold 
change
G kinase anchoring protein 1 BF434321 3
protease, serine, 3 (mesotrypsin) AW007273 3
protease, serine, 2 (trypsin 2) NM_002770 3
DKFZP434L187 protein AA889613 3,1
protease, serine, 3 (mesotrypsin) NM_002771 3,1
solute carrier family 39 (zinc transporter), 
member 8
NM_022154 3,1
caspase 1, apoptosis-related cysteine 
pep�dase
NM_052889 3,1
complexin 1 BC002471 3,2
“Hypothe�cal gene supported by 
AK055666; BC039324”
AA459699 3,2
Paired box gene 8 BF056746 3,2
trophoblast glycoprotein NM_006670 3,3
aldo-keto reductase family 1, member C2 M33376 3,3
sestrin 2 AL136551 3,3
gb:BE877420 /DB_XREF=gi:10326196 
/UG_TITLE=ESTs
BE877420 3,4
Homo sapiens, clone IMAGE:5019307, 
mRNA
CA448125 3,4
calmegin NM_004362 3,4
laminin, alpha 4 BC004241 3,5
transmembrane protein 71 AI342543 3,5
ac�va�ng transcrip�on factor 3 NM_001674 3,5
solute carrier family 39 (zinc transporter), 
member 8
AB040120 3,6
protein S (alpha) NM_000313 3,6
interleukin 1 receptor accessory protein-
like 1
NM_014271 3,6
transmembrane protein 40 AI087937 3,6
annexin A10 AF196478 3,7
Ribosomal protein L5 AL137958 3,7
Sushi, nidogen and EGF-like domains 1 AW273830 3,7
caspase 1, apoptosis-related cysteine 
pep�dase 
U13699 3,7
caspase 1, apoptosis-related cysteine 
pep�dase
U13700 4
early growth response 1 NM_001964 4,1
egf-like module containing, mucin-like NM_001974 4,1
heat shock 22kDa protein 8 AF133207 4,1
interferon induced with helicase C 
domain 1
NM_022168 4,4
chromosome 20 open reading frame 100 AA211909 4,5
protein kinase (cAMP-dependent, cataly�c) 
inhibitor beta
AF225513 4,5
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family with sequence similarity 69, 
member A
AK027146 4,6
tenascin C (hexabrachion) NM_002160 4,6
G kinase anchoring protein 1 AK026487 4,8
phosphoprotein associated with 
glycosphingolipid microdomains 1
AK000680 4,9
Kell blood group precursor (McLeod 
phenotype)
NM_021083 5,2
proline rich 6 AA722878 5,2
CDNA FLJ11325 fis, clone PLACE1010383 BG435715 5,3
aldo-keto reductase family 1, member C3 AB018580 5,4
laminin, alpha 5 BC003355 5,5
proline rich 6 AA722878 5,7
nephroblastoma overexpressed gene BF440025 5,9
Similar to esterase/N-deacetylase (EC 
3.5.1.-)
BC014344 7,3
heat shock 70kDa protein 6 (HSP70B’) NM_002155 8
laminin, alpha 4 NM_002290 8,2
Hypothe�cal protein MGC10946 BE326710 8,5
SAM domain, SH3 domain and nuclear 
localisa�on signals, 1
NM_022136 12,9
fibroblast growth factor 13 NM_004114 14
Supplemental table 1: Gene expression profiles of genes 
responsive to ALCAM status. 
Mean fold change (<3x or >3x) in the expression of genes 
comparing BLM cells with BLM/ΔN-ALCAM cells and 
BLM cells with BLM/sALCAM cells. All cells are grown as 
monolayers at low cell density. 
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Melanoma progression is a mul�-step progression from a common melanocy�c nevus via the radial growth phase, the invasive ver�cal growth phase finally leading to metasta�c spread into distant organs. Migra�on and invasion of tumor cells requires 
secre�on of proteases to facilitate remodelling of the extracellular matrix including basement 
membranes. Here we used the de-epidermized dermis (DED) as a model for melanoma growth 
and invasion. Using this model we show that the dermal-epidermal basement membrane 
prevents invasion of metasta�c melanoma BLM and MV3 cells in the absence of co-cultured 
kera�nocytes. The presence of co-cultured kera�nocytes promotes invasion of the DED by 
BLM and MV3 cells. In the DED model matrix metalloproteinase-9, a protease ac�vated early 
in melanoma development, is secreted by the kera�nocytes and subequently ac�vated by 
an unknown soluble factor secreted by the melanoma cells. The dynamic interplay between 
kera�nocytes and melanoma cells is further shown by the altered growth pa�ern of melanoma 
cells and the finding that a reconstructed epidermis induces invasion. Overall, our findings show 
that the invasive behaviour of melanoma cells is determined by the melanoma cells themselves, 
but that the interplay between surrounding kera�nocytes and the melanoma cells plays an 
important role in melanoma invasion. 
Introduc�on 
 Kera�nocytes and melanocytes are the 
most common cells within the epidermis of 
normal skin. Exposure to sunlight s�mulates 
melanocytes to produce melanin and limit UV-
light induced DNA damage in epidermal cells. 
Growth control of these melanocytes in turn is 
strictly regulated by the kera�nocytes. During 
melanoma tumorigenesis the melanocytes 
escape from the growth control exerted by the 
kera�nocytes leading to benign melanocy�c 
lesions (Haass and Herlyn, 2005). From these 
hyperplas�c melanocy�c lesions melanoma 
can develop via the radial growth phase (RGP) 
to the ver�cal growth phase (VGP). Whereas 
RGP melanomas have only limited invasive 
poten�al, VGP melanoma cells infiltrate the 
dermis and eventually the subcutaneous fat, 
which can culminate in metastasis at distant 
sites (Miller and Mihm, Jr., 2006). 
 Several proteases are expressed during 
melanoma progression. Proteases facilitate 
ectodomain shedding, the proteoly�c cleavage 
of cell surface receptors, membrane bound 
growth factors and adhesion molecules from 
the cell surface (Arribas and Borroto, 2002). 
These modifica�ons on the tumor cell surface 
allow tumor cell prolifera�on and cell migra�on. 
Another important role for these proteases 
lies in the remodelling and degrada�on of the 
extracellular matrix (ECM) including basement 
membrane (BM) structures. Specifically the 
family of matrix metalloproteinases (MMPs) 
has been associated with tumor progression 
and metastasis of many different tumors 
including melanoma (Lynch and Matrisian, 
2002;Egeblad and Werb, 2002;Hofmann et 
al., 2005;Tousseyn et al., 2006;Arribas et al., 
2006). 
 Since melanoma development and 
metastasis is a complex mul�-stage process, 
in vitro melanoma models may improve the 
understanding of melanoma progression. 
Several in vitro models have been developed 
to study the migra�on and invasion of 
melanoma cells through extracellular matrix 
(ECM) components like fibronec�n, collagen 
and matrigel (Dewhurst et al., 1997;Murata 
et al., 1997;Se�or et al., 2005). Spheroids 
86 Chapter 5 87Melanoma Invasion in Reconstructed Skin
of melanoma cells, implanted in a collagen-
based matrix, are used as a simple model for 
melanoma behaviour. In this assay the invasive 
growth pa�ern of the cells used correlated 
with their melanoma staging (Smalley et al., 
2006). Disadvantage of these methods is the 
lack of a func�onal basement membrane (BM) 
and the absence of tumor stroma and normal 
cells. Human skin equivalents using contracted 
collagen gels seeded with normal skin cells 
(dermal fibroblasts and kera�nocytes (KCs) 
reflect the in vivo situa�on in more detail 
since they develop a BM (Meier et al., 2000). 
In this experimental set-up the BM is not yet 
developed when the tumor cells are added 
which make it possible for tumor cells to invade 
the collagen layer prior to BM establishment. 
Use of a pre-exis�ng BM is most likely the 
best op�on to study BM penetra�on of 
melanoma cells in vitro. The reconstructed 
human skin model based on de-epidermized 
a-cellular dermis (DED) retains their na�ve 
ECM and BM. Addi�onally, the possibility to 
integrate normal skin and stromal cells makes 
the DED an a�rac�ve model to evaluate the 
contribu�on the ECM and normal skin cells 
Results 
Growth behaviour of melanoma cells on 
acellular DED 
 When metasta�c melanoma cells (BLM) 
and non-metasta�c melanoma cells (530) 
are cultured air-exposed on the BM side of 
a DED the tumor cells rapidly proliferated 
and formed a thick sheet of tumor cells on 
Figure 1. Histology of 
melanoma cells cultured 
on human DED 
metasta�c BLM (A) and 
non-metasta�c 530 (B) 
melanoma cells cultured on 
the basement membrane 
side of human DED show no 
invasion through the BM 
into the dermis. BLM (C) 
and 530 (D) cells cultures 
on the dermal side of 
human DED migrate into 
the dermis. All sec�ons 
have been stained with 
H&E; 10x magnifica�on. 
have on melanoma development (Eves et al., 
2000;Dekker et al., 2000;Eves et al., 2003). 
 In this study, we used a basic model for 
tumor growth and invasion of melanoma cells 
using DED skin equivalents. With this model we 
study and define the minimal requirements for 
melanoma invasion. This is achieved by using 
na�ve ECM and BM structures in the absence of 
stromal fibroblasts. Since proteases and �ssue 
architecture are supposed to be important 
for melanoma invasion we inves�gated the 
contribu�on of these factors to melanoma 
growth and invasion. Using the model we 
found that �ssue architecture indeed is a 
factor required for invasive growth. 
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(KCs) could influence melanoma invasion we 
cultured our panel of melanoma cells on DEDs 
in the presence of KCs. 
In the presence of a reconstructed epidermis, 
formed by co-cultured kera�noctyes, the 
chronology of tumor morphogenesis is as 
follows: melanoma cells form expansive nests 
of tumor cells in between basal KCs and the 
BM (figure 2D and 3). Subsequently, metasta�c 
cells (BLM and MV3) penetrate through the 
BM into the dermis, non-metasta�c cells 
(IF6-l and 530) do not (figure 3). The data 
above demonstrates that the differences in 
tumor morphogenesis of non-metasta�c and 
metasta�c melanoma cells can be mimicked in 
vitro and that kera�nocytes contribute to the 
invasion of melanoma cells. 
Proteoly�c ac�vity in DED condi�oned 
medium 
The BM is an apparent barrier for melanoma 
invasion and the tumor cells need the 
presence of co-cultured KCs to penetrate 
through the BM. Proteoly�c ac�vity is linked 
to extracellular matrix remodelling and 
is believed to be a prerequisite for tumor 
Figure 2. Histological 
staining of BM structures in 
human DEDs 
Histology of kera�noctytes 
cultured on DEDs stained for 
BM components collagen IV 
(A), heparan sulphate (B) 
and laminin 5 (C). Laminin 5 
staining of Melanoma cells 
co-cultured with KCs shows 
penetra�on of the melanoma 
cells through the BM into the 
dermis addi�onally, nests 
of non-invasive cells are 
located on-top of the BM 
(D). Invaded tumor cells are 
indicated by arrowheads. 
Magnifica�on 10x for A-C 
and 20x for D. 
top of the BM (figure 1 A and B). The non-
metasta�c 530 cells show no invasion into 
the dermis. Suprisingly, the highly mestata�c 
BLM cells also fail to invade into the dermis. 
To show that the cells are migratory, both cell 
lines were cultured on the dermal side of the 
DED. In the absence of a BM, BLM (Fig 1C) and 
530 cells (Fig. 1D) migrated into the dermal 
compartment, in which the metasta�c BLM 
invaded deeper into the dermis. Similar results 
were shown for the metasta�c (MV3) and 
non-metasta�c (1F6-L) melanoma cell lines 
(not shown). The presence of BM structures 
was confirmed by heparan sulphate, laminin 
and collagen IV staining (figure 2) 
These results show that both tumor cell lines are 
capable of invading the dermal compartment, 
although with different efficiencies, but that 
the BM is a func�onal barrier for melanoma 
invasion when encountered in this model. 
Growth behaviour of melanoma cells on 
acellular DED with a recons�tuted epidermis 
Tumors are not just composed of tumor cells, 
non-tumor cells are known to influence tumor 
progression as well. To test if kera�nocytes 
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progression. To test if degrada�on of the 
BM by proteases of the family of matrix 
metalloproteinases is a likely explana�on for 
dermal invasion, we inves�gated the DED 
culture medium for proteoly�c ac�vity. A 
sample of the condi�oned culture medium 
was taken each day of air-exposed culturing 
and subjected to gela�n zymography. 
Expression of MMP-9 gradually increased 
during culturing of kera�nocytes on DEDs but 
it remained in its in-ac�ve pro-form. In the 
same medium small amounts of pro-MMP-2 
are detected (figure 4A). 
For BLM cells it is known that MMP-2 gets 
ac�vated when cultured at high cell density 
in collagen la�ces (Lunter et al., 2005). DED 
cultures of only BLM cells show a steady 
expression of pro-MMP-2 during the air-
exposed culture phase and a gradual increase 
in ac�ve MMP-2 as a result of accumulated 
cell growth (figure 4B). Li�le amounts of pro-
MMP-9 are secreted by BLM cells. 
Individual cultures of BLM and kera�nocytes 
showed no ac�va�on of MMP-9. Co-culturing 
BLM cells and kera�nocytes on the same DED 
Figure 3. Invasive poten�al 
of melanoma cells in the 
presence of kera�nocytes. 
Single cell invasion of 
metasta�c BLM (A) and MV3 
(C) cells into the dermis is 
observed when co-cultured 
with kera�nocytes. Non-
metasta�c cells 530 (B) and 
1F6-L (D) show no invasion 
in to the dermis in the 
presence of kera�nocytes. All 
sec�ons stained with H&E, 
magnifica�on 10x 
increases pro-MMP-9 levels and ini�ated 
MMP-9 ac�va�on (fig 4C). This indicates 
that, via an unknown mechanism, MMP-9 is 
ac�vated when BLM cells are co-cultured with 
kera�nocytes.
BLM derived soluble factors and proteoly�c 
ac�vity 
In order to define which soluble factors 
are involved in the ac�va�on of MMP-9 we 
performed medium exchange experiments. 
Secreted soluble factors from BLM or 
kera�nocytes seeded on air-exposed DEDs 
were collected in the culture medium for 
24 hours. To test if these condi�oned media 
contain ac�vators of MMP-9, they were 
subsequently transferred to a recipient DED 
culture. The recipient DED was cultured 
further with this condi�oned medium for 24 
hours, a�er which the medium was replace by 
fresh condi�oned medium daily for 14 days. 
As seen in figure 4D, medium condi�oned by 
kera�nocytes and given to a BLM DED has no 
effect on MMP-9 ac�va�on. Figure 4E shows 
that when medium condi�oned by a BLM DED 
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was given to a kera�nocyte DED ac�va�on 
of MMP-9 was induced. In both cases the 
donor DEDs had no ac�ve MMP-9 (not shown) 
confirming the absence of ac�ve MMP-9 in the 
individual cultures of BLM and kera�nocytes 
(figure 4A and 4B). This indicates that BLM 
cells secrete an unknown soluble factor that 
induces MMP-9 ac�va�on. 
Soluble factors and invasion 
The fact that the presence of kera�nocytes 
induces BM penetra�on of BLM cells in 
combina�on with the presence of ac�ve 
MMP-9 in these cultures suggested the 
involvement of MMP-9 in basement 
membrane penetra�on. To inves�gate this 
we transferred the condi�oned medium of an 
invasive donor BLM/KC construct (figure 5A) to 
a recipient construct containing only BLM cells 
(figure 5B). As seen in figure 5 the addi�on 
of “pro-invasive” condi�oned medium does 
not induce invasion of BLM cells. From this 
Figure 4. Gela�n zymography of medium condi�oned by human DED cultures. 
A. Zymography of media condi�oned by KCs during the 14 days of air-exposed culturing. Samples were taken every 24h of 
incuba�on. The expression of pro-MMP-9 gradually increases in �me and small amounts of pro-MMP-2 are detected in all 
samples while being nega�ve for the ac�ve forms of MMP-2 and MMP-9. B. In the same experimental set-up condi�oned 
BLM medium shows a gradual increase in pro-MMP-2 expression and to a lesser extent pro MMP-9 expression. As a 
consequence of cell crowding MMP-2 gets ac�vated in �me. C. In contrast to A and B condi�oned medium of a co-culture 
of KCs and BLM cells contains both the ac�ve and pro-forms of MMP-2 and MMP-9. D. Zymography of media condi�oned 
by BLM cells for 24 hours a�er it has first been pre-condi�oned for 24 hours by a donor kera�nocyte DED. The pro-form 
of both MMP-2 and MMP-9 are detected and for MMP-2 also the ac�ve pro-form is detected. E. Medium that is first 
pre-condi�oned by a BLM donor DED for 24 hours and subsequently transferred to a KC DED where it is condi�oned for 
an addi�onal 24 hours is posi�ve for the pro and ac�ve forms of MMP-2 and MMP-9. 
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we concluded that ac�ve MMP-9 alone is not 
sufficient for the ini�a�on of BM penetra�on 
and that any addi�onal soluble factors are not 
sufficient to induce BLM invasion. It appears 
that for BLM invasion physical interac�ons 
with the kera�nocytes are necessary. 
Presence of undifferen�ated kera�nocytes 
does not induce melanoma invasion 
The sugges�on that BLM invasion is 
dependent on contact with kera�nocytes 
raises the ques�on if the reconstructed 
epidermis needs to be intact. To assess 
whether the reconstructed epidermis is 
necessary for BLM invasion the DED cultures 
were kept submerged for 14 days to prevent 
the kera�nocyte differen�a�on. 
Submerged BLM DED cultures show growth 
without invasion. This is similar to air-exposed 
cultures of BLM cells alone (compare figure 6A 
with 1A). Without air-exposure kera�nocytes 
remain in a prolifera�ve monolayer without 
forming an epidermis (figure 6B). 
Submerged co-cultures of BLM cells with 
kera�nocytes remain non-invasive, but 
instead of hyper-prolifera�on of the tumor 
cells on top of the BM, the BLM cells grow 
in coordinated round shaped nests on top of 
the BM (fig. 6C). This shows that the physical 
interac�ons between KCs and tumor cells 
induce a coordinated growth phenotype. 
However, the lack of invasion indicates that 
instead of solely the presence of KCs, the 
epidermal architecture formed by terminally 
differen�ated KCs is required for BLM 
invasion. 
DED “sandwich” and tumor growth 
To inves�gate the possible contribu�on of 
a mechanical pressure generated by the 
expansion of the tumor cells on melanoma 
cell invasion we designed “sandwich” DED 
cultures. In these sandwich cultures BLM 
cells are cultured between two DEDs. In this 
way tumor cells are sandwiched between 
either two dermal sides or one BM and one 
dermal side. When tumor cells are grown on 
top of a BM DED and covered by a DED facing 
dermal side down, the tumor cells migrate 
up-ward into the dermal compartment (figure 
7). No penetra�on downwards through the 
BM is observed in these cultures. Changing 
the whole sandwich culture orienta�on 
does not change the migra�on direc�on, 
Figure 5. Invasive proper�es of a condi�oned medium 
donor and recipient human DED 
(A) Histology of an invasive BLM and KC co-culture DED 
of which condi�oned medium was taken every 24 hours of 
air-exposed culturing. This medium is transfered every 24 
hours to a recipient DED containing only BLM cells. A�er 14 
days of culturing this recipient BLM DED shows no invasion 
(B). H&E staining, magnifica�on 10X 
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Discussion 
 Our goal was to establish a minimal model 
for melanoma morphogenesis and invasion. 
Using the DED model we are able to determine 
the effects non-tumor cells and tumor-ECM 
interac�ons have on invasion. Addi�onally, 
proteoly�c ac�vity can be followed during 
culturing. 
The in vitro invasion of melanoma cells 
using the DED model resembles the first 
step of in vivo metasta�c behaviour. Both 
non-metasta�c melanoma cell-lines used 
are incapable of dermal invasion, whereas 
metasta�c cell-lines breached the BM and 
invaded the dermis readily when co-cultured 
with kera�nocytes. Dermal invasion of 
metasta�c cell-lines depended on the integrity 
of a reconstructed epidermis for dermal 
invasion, confirming the previous finding for 
melanoma cell line HBL which only invaded the 
dermis in the presence of fibroblasts and KCs 
(Eves et al., 2000;Eves et al., 2003). It appears 
that soluble molecules and protease are less 
important factors for invasion than epidermal 
integrity. Not all metasta�c melanoma cell 
lines require the presence of adjacent skin 
cells for BM penetra�on; C8161 and A375-
Figure 6. Undifferen�ated kera�nocytes induce an altered 
growth pa�ern of BLM cells. 
BLM cells grown on a DED and kept submerged rapidly 
proliferate on top of the BM but show no invasion through 
the BM into the dermis (A). Under submerged condi�ons 
KCs are unable to differen�ate and form small sheets of 
cells when not intact with the BM (B). Nest like shapes 
containing tumor cells are formed on top of the BM when 
BLM and KCs are cultured under submerged condi�ons (C). 
H&E staining, magnifica�on 10X
i.e., melanoma cells always migrate, either 
up-ward or down-ward, into the dermal 
compartment irrespec�ve of any chemota�c 
factors from the medium. When tumor cells 
are cultured between two dermal side DEDs 
the tumor cells migrate in both direc�ons i.e. 
into both DEDs (figure 7B). Thus, by changing 
the BM orienta�ons we can direct tumor cells 
to migrate into the direc�on of apparent least 
resistance. 
A selec�on of colour figures is given at the end 
of this chapter
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SM cells were invasive without co-cultured 
normal skin cells in a similar model (Eves et 
al., 2003). In this study the skin cells were not 
necessary for invasion but they did influence 
the invasive behaviour. Skin cells increased 
the invasion of C8161 cells while reducing the 
invasion of A375-SM cells (Eves et al., 2003). 
From this and our results it seems that the 
invasive proper�es lie within the melanoma 
cells themselves but that it can be influenced 
by surrounding normal epithelial and stromal 
skin cells. 
The contribu�on of stromal cells to melanoma 
progression has been recognized for a 
long �me. Stromal cells secrete growth 
factors and proteases necessary for tumor 
growth and invasion (Ruiter et al., 2002). 
The communica�on between tumor cells 
and kera�nocytes appears to be of less 
importance since melanoma cells escape from 
growth control by surrounding cells (Haass et 
al., 2005). However, our results clearly show 
that the ac�va�on of KC-derived MMP-9 was 
dictated by a, yet unknown, soluble factor 
released by the BLM cells (figure 4). Autocrine 
MMP-9 ac�va�on by the BLM cells does not 
contribute to the ac�ve MMP-9 pool since 
BLM cells cannot ac�vate MMP-9, thereby 
confirming the crosstalk between KC and BLM 
cells. It remains unclear if the KCs directly 
ac�vate MMP-9 under influence of the BLM 
condi�oned medium or that an unknown 
factor in the BLM derived medium itself 
ac�vates MMP-9 molecules. The mechanism 
for proteoly�c conversion of pro-MMP-9 
to ac�ve MMP-9 is not clearly understood. 
In human skin tumor necrosis factor (TNF-
) is most likely the factor that controls the 
proteoly�c ac�va�on of MMP-9 (Han et al., 
2002). TNF-down-regulates the expression 
of �ssue inhibitor of metalloproteinases-1 
(TIMP-1) and as a consequence increases 
Figure 7. Histology of sandwich DED experiments 
When BLM cells are cultures on the BM side of a DED and covered with the dermal side of an opposing DED they migrate 
into the dermis of the covering DED. No invasion through the BM into the lower DED occurs (A,B). Culturing BLM cells 
between the dermal sides of two opposing DEDs results in migra�on into both DEDs (C, D). In A and C (H&E staining), 
arrows indicate the direc�on of migra�on. BMs are indicated by arrowheads in B and D (heparan sulphate staining), 
addi�onally the arrowheads show the DED orienta�on from dermis to BM. 
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the ac�va�on of MMP-9 (Han et al., 2002). 
It is possible that melanoma cell derived 
chemokines influence MMP-9 ac�va�on. 
In primary melanoma, expression of MMP-
9 is restricted to horizontal growth phase 
melanomas (van den Oord et al., 1997), and 
suggested a role in breaching the BM. However, 
MMP-9 ac�va�on alone is not sufficient to 
induce BM penetra�on in our model, since 
medium containing ac�ve MMP-9 does not 
render BLM cells invasive (figure 4). Therefore, 
the role of MMP9 at this stage of disease 
remains unclear. The transi�on from horizontal 
to ver�cal growth requires the induc�on 
of an angiogenic response (van Kempen et 
al., 2008). MMP-9 is able to promote tumor 
angiogenesis be releasing matrix-sequestered 
vascular endothelial growth factor (Bergers 
et al., 2000). As such, the effect of MMP9 in 
early stages of tumor biology may not be pro-
invasive, but pro-angiogenic. MMP-9 deficient 
mice display suppression of metasta�c 
spread of melanoma cells, indica�ng that 
MMP-9 is important for tumor metastasis 
(Itoh et al., 1999). However, macrophage-
derived MMP-9 prepares distal lung �ssue for 
eventual metasta�c coloniza�on in a vascular 
endothelial growth factor receptor-1 (VEGFR-
1) dependent manner in an experimental 
metastasis mouse model (Hiratsuka et al., 
2002). Therefore, MMP9 ac�vity in early and 
late stage tumors most likely does not reflect 
the invasive capacity of melanoma cells. 
Regarding MMP-2 ac�va�on, we already 
showed that BLM cells, depending on the 
status of the adhesion molecule ALCAM, 
were metasta�c in nude mice in the absence 
of ac�ve MMP-2 (Lunter et al., 2005). MMP-2 
ac�va�on might be important for other tumor 
biology processes since in MMP-2 knockout 
mice, a reduc�on of experimental lung 
metastasis from melanoma cells is observed 
(Itoh et al., 1998). 
Besides secreted proteases, soluble paracrine 
growth factors coming from the KCs could 
contribute to dermal invasion. However, 
addi�on of condi�oned medium coming 
from invasive constructs did not lead to 
invasion. Thus, medium taken from invasive 
cultures lacks a factor that ini�ates BM 
penetra�on. Addi�onal pro-invasive signals 
could be necessary. These pro-invasive 
signals may come from melanoma contacts 
with KCs. However, co-culturing BLM and 
undifferen�ated KCs showed no invasion 
at all. We do see that in these cultures the 
overall tumor growth pa�ern is drama�cally 
changed. Instead of forming mul�ple layers 
of tumor cells on top of the BM, the tumor 
cells showed nest forma�on in the presence 
of undifferen�ated KCs. So it is not exclusively 
the interac�on with KCs that induces invasion. 
The KC-driven tumor nest forma�on shows 
again the importance of the interplay between 
tumor cells and kera�noctyes for melanoma 
invasion. Whereas normal skin homeostasis 
is maintained by homotypic E-cadherin 
interac�ons between the KCs and melanocytes 
(Tang et al., 1994), the effects shown above 
are not the result of E-cadherin interac�ons 
since BLM cells lack E-cadherin expression as 
do most of the metasta�c melanoma cell lines 
(Hsu et al., 1996). 
From our experiments it appears that the 
presence of terminally differen�ated KCs in 
the recons�tu�ng epidermis determines the 
invasion. One possibility is that the mul�ple 
layers of terminally differen�ated KCs form 
an impermeable layer for the tumor cells, but 
this does not necessarily mean that tumor cells 
start to invade. 
A mechanis�c answer could be that the 
high prolifera�on rate of the tumor cells 
leads to cell crowding, in combina�on with 
an impermeable epidermis this generates a 
mechanical pressure that forces the tumor 
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cells to penetrate through the BM. 
To mimic these pressure phenomena melanoma 
cells were grown between two DEDs. Tumor 
cells are capable of migra�ng away from the 
medium when a dermal side is on top of a BM 
indica�ng that the experimental migra�on 
signals are not one-direc�onal gravita�onal 
or chemotac�c s�muli (figure 7). In addi�on, 
when tumor cells are grown between two 
dermal sides the tumor cells equally invaded 
the lower and the top DED (figure 8). Under 
these culture condi�ons we can direct the 
tumor cells into the dermis but not through 
the BM. Tumor cells are known to have a high 
prolifera�ve capacity and ECM remodelling 
capaci�es to facilitate tumor growth. These 
ECM remodelling effects are not apparent in 
the culture set-up using two DEDs in which 
no BM degrada�on occurs. One explana�on 
might be that tumor cells can modulate 
the ECM but not the basement membrane 
for which they need other cells i.e. MMP-9 
ac�va�on by kera�nocytes. Overall our results 
suggest that for experimental invasion tumor 
cells rely on cross talk with kera�nocytes. This 
cross talk facilitates ac�va�on of proteases 
and BM penetra�on. 
In this study we used DEDs without fibroblasts 
to define the minimal requirements for 
melanoma invasion. Fibroblasts may alter the 
growth and invasive abili�es of the tumor cells 
by secre�on of growth factors and proteases 
which we cannot exclude from present data 
(Ruiter et al., 2002). Our work now can be 
extended with the use of fibroblasts to 
further study the effects fibroblasts have on 
melanoma development. Addi�onally, the use 
of specific protease inhibitors could iden�fy 
the proteases that facilitate melanoma 
invasion. Besides tumor, non-tumor cells and 
stromal cells, infiltra�ng immune cells are 
known to secrete proteases and therefore 
could influence to tumor progression 
(Coussens et al., 2000;Coussens and Werb, 
2001). The contribu�on of these cells could 
also be determined in this DED set-up. 
 Our and data from others show that the 
reconstruc�ng skin model used here is a 
good model for melanoma invasion. This 
could lead to be�er understanding of the 
melanoma metasta�c cascade which in 
turn will be beneficial for the treatment or 
preven�on of metastasis in vivo. Submerged 
“sandwich” growth and invasion models may 
be applicable for other solid tumors as well. 
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Materials and Methods
Cell culturing 
 Adherent melanoma cells (BLM) were 
maintained as monolayers in Dulbecco`s 
modified essen�al medium (DMEM) 
(Invitrogen) supplemented with 10 % fetal 
calf serum (FCS), 4 mM L-glutamine and 2 mM 
pyruvate. BLM cells with amino-terminally 
truncated ALCAM (BLM/ΔN-ALCAM) and 
BLM/sALCAM cells were cultured as described 
previously (Degen et al., 1998;van Kempen et 
al., 2004;van Kilsdonk et al., 2008). All cells 
were grown un�l desired density was reached 
or split before confluency was reached. 
Frequent tes�ng showed that cells were free 
of mycoplasma contamina�on. 
Gela�n zymography 
 Condi�oned media were mixed with 2x 
non-reducing sample buffer [150 mmol/L 
Tris-HCl (pH 7.0), 4% SDS, 22% glycerol] 
and incubated for 10 minutes at 65C. Five 
microliters of media/sample buffer mixture 
were separated on a 10% polyacrylamide 
gel containing 1 mg/mL gela�ne Bloom 300 
(Merck). A�er electrophoresis, the gel was 
washed and incubated for 1 hour in 50 mmol/L 
Tris-HCl (pH 7.4) containing 2% Triton X-100 to 
renature the gela�nases. A�er washing twice 
in 50 mmol/L Tris-HCl (pH 7.4), the gel was 
incubated for 18 hours in 50 mmol/L Tris-HCl 
(pH 7.4), 5 mmol/L CaCl
2
, 1% Triton X-100, 
0.02% NaN
3
, and subsequently stained by 
Coomassie brilliant blue R-250. 
Genera�on of human skin equivalents using 
de-epidermized dermis 
 DEDs were prepared as described before 
(van Kilsdonk et al., 2008). During the 
medium-exchange experiments medium from 
the donor culture was condi�oned for 24 
hours before being transferred to the recipient 
culture where it remains for another 24 hours. 
Zymography samples were taken a�er each 
24 hour of incuba�on. Immediately a�er the 
removal of the condi�oned medium from the 
donor culture, fresh medium is added and again 
condi�oned for 24 hours. This new condi�oned 
medium is transferred to the recipient culture 
a�er the old condi�oned medium is taken 
off. This con�nuous medium-exchange was 
sustained for 14 days of air-exposed culturing. 
Condi�oned media were taken every day 
and subjected to gela�n zymography. A�er 
harves�ng, the skin equivalents were formalin 
fixed and embedded in paraffin. 
Immunohistochemistry 
 Sec�ons (6 µm) were deparaffinised 
in ethanol and rehydrated for 
immunohistochemical analysis using an�-
heparan sulphate proteoglycan an�body (Ab) 
JM-403 (1:1000) (van den Born et al., 1995) 
and calcyclin (1: 500) (Weterman et al., 1993). 
A�er incuba�on with primary an�bodies, 
sec�ons were stained with avidin-bio�n-
peroxidase complex system (Vectastain elite 
ABC kit; Vector Laboratories Inc, Burlingame, 
USA). To visualize Ab binding AEC staining 
(Calbiochem) was performed. Counterstaining 
was performed with Mayer’s haematoxylin 
(Sigma). Finally, sec�ons were washed in 
tap water, dried and mounted in glycerol 
gela�n (Sigma). In addi�on, we performed 
a hematoxylin-eosin (HE) staining on serial 
sec�ons. 
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Figure 1. Histology of melanoma cells cultured on human DED
Figure 2. Histological staining of BM structures in human DEDs
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Figure 7. Histology of sandwich DED experiments 
Figure 3. Invasive poten�al of melanoma cells in the presence of kera�nocytes. 
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Nucleoporin 88 kDa (Nup88) is a tumor marker, overexpressed in various types of cancer. In Drosophila Nup88 (mbo) was reported to selec�vely mediate the nucleocytoplasmic transport of NF-κB, an ubiquitous transcrip�on factor involved in immune responses, 
apoptosis, and cancer. We addressed the func�on of Nup88 in mammalian cells. Selec�ve 
deple�on of Nup88 by small interfering RNA (siRNA) inhibited NF-κB-dependent reporter gene 
ac�va�on and the nuclear transloca�on of NF-κB without affec�ng the upstream ac�va�on 
pathway in NIH3T3 cells. In contrast, nuclear transloca�on of glucocor�coid receptor was 
not reduced by the deple�on of Nup88. In metasta�c melanoma cells overexpressing Nup88, 
cons�tu�ve ac�va�on of NF-κB was found both in nucleus and cytoplasm. Nup88 deple�on in 
these cells reduced TNF-induced nuclear accumula�on of NF-κB subunits. We conclude that 
Nup88 regulates the ac�vity of NF-κB at the level of nucleocytoplasmic transport. Overexpression 
of Nup88 in tumor cells may, thus be involved in the cons�tu�ve NF-κB ac�va�on. 
Introduc�on
 Nucleoporin 88 kDa (Nup88) is a 
component of the nuclear pore complex (NPC) 
that mediates nucleocytoplasmic trafficking 
of macromolecules [1]. Nup88 is reported 
to be located at the cytoplasmic face of 
NPC in �ght associa�on with CAN/Nup214, 
another nucleoporin and a proto-oncogene 
implicated in leukemia [2–4]. It is a puta�ve 
tumor marker highly expressed in cancer 
and embryonic �ssues, and is postulated to 
play a role in oncogenesis and development 
[5,6]. Furthermore its expression levels 
highly correlate with the rate of metastasis 
and mortality of colon cancer [7] and with 
aggressiveness of breast cancer [8]. However, 
the func�onal consequences of Nup88 
overexpression in cancer remain unknown to 
date. 
A study carried out in Drosophila reported that 
members only (mbo), an ortholog of Nup88 
(26% homology to human Nup88), selec�vely 
regulated the nuclear transloca�on or export 
of dorsal, a member of the Rel protein family, 
which comprises NF-κB [9–11]. NF-κB is a 
ubiquitous transcrip�on factor media�ng the 
induc�on of a wide range of genes involved 
in immune response, inflamma�on, and 
apoptosis [12,13]. Cons�tu�ve ac�va�on of 
NF-κB is found in cancer, and its role in cancer 
is supported by a large body of evidence 
[14,15]. NF-κB, a dimer composed of subunits 
of the Rel family of proteins, is retained in the 
cytoplasm by its inhibitory partner, inhibitor 
of NF-κB (IκB). The paradigm of canonical 
NF-κB ac�va�on involves several cri�cal 
steps and its signaling pathway is triggered 
by ac�va�on of IκB kinase (IKK) complex, 
subsequent phosphoryla�on and degrada�on 
of IκB allowing the release of an ac�ve dimer 
of NF-κB [12]. Li�le is known, however, about 
any par�cular regula�on at the nuclear 
membrane. We postulated that mammalian 
Nup88 would exert a similar func�on as its 
Drosophila ortholog in regula�ng the nuclear 
localiza�on of NF-κB, and that overexpression 
of Nup88 in cancer could affect NF-κB ac�vity. 
In order to underscore a link between Nup88 
and NF-κB signaling, we have depleted Nup88 
by short interfering (si)RNA [16] and evaluated 
the func�onal consequences on NF-κB ac�vity 
by reporter gene assay, immunofluorescence 
and electrophore�c mobility shi� assay 
(EMSA).
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Results
 
Nup88 gene knock-down by siRNA reduces NF-
jB-dependent gene ac�va�on.
To assess the func�onal rela�onship between 
Nup88 and NFκB, we applied siRNA, using 
NIH3T3 cells stably transfected with a 
luciferase reporter gene under control of 
NF-κB (NF-κB-luc/ 3T3) as an assay system. 
We used siRNA targe�ng NF-κBp65 as a 
posi�ve control because of the non-redundant 
func�on of this subunit [19]. TNF s�mula�on 
induced NF-κB-dependent ac�va�on of the 
luciferase gene (Fig. 1A). Similar results were 
obtained with IL-1 or LPS as s�muli (results 
not shown). When the cells were transfected 
with an�-NF-κBp65 siRNA 24 h before TNF 
s�mula�on, luciferase ac�vity was reduced by 
94% (Fig. 1A). An�-Nup88 siRNA suppressed 
reporter gene ac�vity with nearly equal 
efficacy (85%). Both siRNA targe�ng NF-κBp65 
and Nup88 inhibited basal levels of luciferase 
ac�vity as well (Fig. 1A). Two control siRNAs 
targe�ng human ac�vated leukocyte cell 
adhesion molecule (hALCAM) and hNF-κBp65 
with one mismatch [16] exerted no effect. 
Therefore, we concluded that Nup88 was 
indispensable for NF-κB-dependent gene 
ac�va�on s�mulated with TNF. 
The efficacy of mRNA deple�on by the siRNA 
duplexes used above was assessed by Q-RT-
PCR analysis. The results showed selec�ve 
suppression of Nup88 mRNA levels by an�-
Nup88 siRNA varying between 65% and 90%, 
while other siRNA species had no effect (Fig. 
1B). Similarly, gene knock-down of NF-κBp65 
was highly sequence specific as only siRNA 
against mouse (m) NFκBp65 significantly 
downregulated the target mRNA and an�hNF-
κBp65 siRNA had no effect (Fig. 1C). The 
silencing efficiency varied between 60% and 
70%. 
Nup88 gene knock-down by siRNA selec�vely 
prevents nuclear accumula�on of NF-κB 
without inhibi�ng its ac�va�on.
We then examined the cellular localiza�on 
of NF-κB a�er Nup88 gene knock-down 
Figure 1. Effect of Nup88 deple�on on NF-κB dependent reporter gene expression 
NF-κB-luc/3T3 cells were transfected with siRNAs targe�ng hALCAM, hNF-κBp65, mNF-κBp65, and mNup88. A. The 
luciferase ac�vity was measured 6h later with or without TNF s�mula�on (10 ng/ml). This experiment is a representa�ve 
of four independent experiments. *P<0.02, **P<0.002, ***P<0.0001. Gene knockdown of B. Nup88 and C. NF-κB p65. The 
levels of mRNA were determined by Q-RT-PCR and expressed as percentage compared to mock transfec�on. *P<0.02
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in 3T3 cells by immunofluorescence (IF). 
Without s�mulus NF-κB was predominantly 
cytoplasmic in all condi�ons (Fig. 2A: a, c, 
and e), but the total level was reduced in the 
cells transfected with an�-NF-κBp65 siRNA 
(Fig. 2Ac). This reduc�on in protein levels 
was in agreement with mRNA levels (60–70% 
reduc�on) (Fig. 1C). Upon TNF s�mula�on 
NF-κB translocated into the nucleus in mock-
transfected cells and in cells transfected with 
an�-NF-κBp65 siRNA (Fig. 2Ab and d). The 
nuclear transloca�on induced by TNF at this 
dose was observed in virtually all cells. In 
contrast, NF-κB mainly stayed in the cytoplasm 
of cells treated with an�-Nup88 siRNA (Fig. 
2Af). These results suggested that Nup88 
mediated the nuclear transloca�on of NF-κB. 
Cells treated with an�-Nup88 siRNA grew 
normally (data not shown), precluding any 
gross defect in the general nucleocytoplasmic 
transport of macromolecules. To assess 
general nuclear transport, we examined 
ligand-induced nuclear transloca�on of the 
glucocor�coid receptor (GR). In the absence 
of ligand dexamethasone (DEX) GR localiza�on 
was predominantly cytoplasmic as expected 
(Fig. 2Ba and c). Treatment with DEX induced 
ligand-dependent nuclear transloca�on of GR 
in both mock- and Nup88 siRNA-transfected
cells (Fig. 2Bb and d). Thus we concluded that 
NF-κB suppression a�er Nup88 deple�on 
was not due to an unspecific blockade of all 
nucleocytoplasmic transport. 
We then examined whether the observed 
effects a�er Nup88 deple�on were due to a 
blockade of the upstream NF-κB ac�va�on. 
Figure 2. Selec�ve effect of 
Nup88 deple�on on NF-κB 
nuclear transloca�on
NF-κB-luc/3T3 cells were 
transfected with siRNAs 
targe�ng NF-kBp65 and/or 
Nup88 and analyzed by 
confocal microscopy. A. 
The cells were s�mulated 
with TNF (50 ng/ml) for 1h, 
and NF-κB was detected 
by an�-NF-κBp65 and an�-
mouse IgG-FITC B. The cells 
were s�mulated with DEX 
(100μg/ml) for 1/2h, and GR 
was visualized by an�-GR 
and an�-mouse IgG-TXRD. 
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NF-κB-luc/3T3 cells were transfected with 
an�-Nup88 siRNA and subcellular frac�ons 
were analyzed by EMSA. Without TNF 
s�mulus, low cons�tu�ve levels of ac�vated 
NF-κB were found in the nucleus (Fig. 3A, 
lanes 1–4). Upon TNF s�mula�on high levels 
of ac�vated NF-κB appeared in the nucleus 
in mock-transfected cells (Fig. 3A, lane 7). In 
contrast, the majority of ac�vated NF-κB was 
Figure 3. NF-κB ac�va�on in 3T3 cells and BLM cells
A. NIH3T3 cells were transfected with siRNA targe�ng mNup88 (siRNA), cytoplasmic (Cp) and nuclear (Nc) frac�on of the 
cells were isolated 1h a�er the TNF s�mula�on (50 ng/ml), and analyzed by EMSA. B. Cell extracts containing ac�vated 
NF-κB signal a�er TNF s�mula�on (lane 6 and 7 of A) were analyzed with supershi� assay using an�bodies against NF-
κB p65 and/or NF-κB p50. C. BLM cells from different culture and passages were visualized by an�-Nup88 and alexa 647. 
Expression at a. the nuclear membrane  b. par�ally at the nuclear membrane and nucleoplasmic c. nucleoplasmic  D. BLM 
cells with or without TNF s�mula�on (50 ng/ml) were analyzed with EMSA 1h a�er the s�mula�on. E. Supershi� assay of 
the nuclear  frac�on of TNF-s�mulated cell (lane 4 of D).
cytoplasmic in cells transfected with Nup88 
siRNA (Fig. 3A, lanes 6 and 8, respec�vely). 
These results indicated that NF-κB ac�va�on 
did occur in cells treated with Nup88 siRNA but 
the ac�vated NF-κB remained cytoplasmic. 
Analysis of NF-κB by supershi� assay using 
an�bodies against individual subunits 
iden�fied both p65/p50 heterodimer and p50 
homodimers (Fig. 3B). The low cons�tu�ve 
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level of NF-κB appears to be p50 homodimer 
(Fig. 3A, lane 3), TNF s�mula�on ac�vated 
both homo- and heterodimer of NF-κB (Fig. 
3B, lanes 4–6), and Nup88 gene knock-down 
resulted in cytoplasmic accumula�on of both 
ac�ve complexes (Fig. 3B, lanes 1–3).
Cons�tu�vely ac�ve NF-κB in malignant 
melanoma cells.
We then addressed the consequences of Nup88 
overexpression and nuclear transloca�on of 
NF-κB in tumor cells. Through screening we 
selected a metasta�c melanoma cell line BLM 
which expressed very high levels of Nup88. BLM 
cells showed characteris�c overexpression of 
Nup88 on the nuclear membrane extending 
to the cytoplasm as reported in other tumor 
cells (Fig. 3Ca). However, BLM cell popula�ons 
appeared heterogeneous in regard to Nup88 
distribu�on, showing some�mes nuclear and 
intermediate localiza�on (Fig. 3Cc and b, 
respec�vely). Notably, this heterogeneity of 
cell popula�ons varied within cell cultures, 
with passage number and cell density. A 
recent report described an altered subcellular 
localiza�on of Nup88 depending on its rela�ve 
abundance to Nup214 and could explain our 
observa�on [11]. We then analyzed the NF-κB 
ac�va�on in these cells. Strong cons�tu�ve 
ac�va�on of NF-κB complexes was detected 
in the nucleus (and to a lesser extent in 
cytoplasm) with further enhancement a�er 
TNF s�mula�on (Fig. 4D). These complexes 
were iden�fied as p65/p50 heterodimers and 
p50 homodimers by supershi� assay (Fig. 4E). 
Both NF-κB dimers were thus cons�tu�vely 
ac�ve and displayed a dual cytoplasmic and 
nuclear distribu�on in BLM in associa�on 
with high levels of Nup88 overexpression. 
The cons�tu�ve nuclear localiza�on of NF-κB 
was in agreement with an earlier report on 
malignant melanoma [20], while the nuclear 
localiza�on in 3T3 cells required ac�va�ng 
s�muli (Fig. 3A). These results suggested that 
Nup88 overexpression in malignant cells could 
contribute to cons�tu�ve ac�va�on of NF-κB 
both in cytoplasm and in nucleus. We have 
examined another melanoma cell line 530 
(Supplementary Fig. 4), but these cells were 
difficult to transfect and therefore excluded 
from further study.
Nup88 gene knock-down in malignant 
melanoma cells inhibits nuclear accumula�on 
of NF-κB. 
We then assessed the rela�onship between 
Nup88 deple�on and localiza�on of NF-κB 
subunits in BLM cells by  immunofluorescence. 
A�er transfec�on with siRNA targe�ng 
Nup88, cells were s�mulated with TNF and 
microscopically analyzed using an�bodies 
against NF-κBp65 and Nup88 combined 
with appropriate secondary an�bodies (Fig. 
4: NF-κBp65: green, Nup88: blue). Without 
s�mulus, NF-κBp65 predominantly localized 
in cytoplasm. Upon TNF s�mula�on NF-κBp65 
translocated into the nucleus (Fig. 4Ab). A�er 
an�-Nup88 siRNA treatment hardly any Nup88 
protein was detectable anymore (Fig. 4Bc and 
d) and NF-κBp65 remained cytoplasmic upon 
TNF s�mula�on (Fig. 4Bb). These findings 
were in line with the observa�ons in mouse 
3T3 cells, and supported the indispensable 
role of Nup88 in regula�ng the subcellular 
localiza�on of NF-κB subunits. Similar to NF-
κBp65 the nuclear transloca�on of NF-κBp50 
subunit was induced by TNF and dependent on 
Nup88 In addi�on the subcellular distribu�on 
of NF-κBp50 seemed also modulated by the 
abundance of NF-κBp65 (Supplementary Fig. 
4). We conclude that Nup88 regulate the 
nucleocytoplasmic trafficking of both subunit 
of NF-κB in malignant cells.
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Discussion
 Led by a Drosophila study that iden�fied an 
unexpected selec�ve role of mbo (an ortholog 
of Nup88) in regula�ng nucelocytoplasmic 
transport of dorsal [9,10], we set out to 
inves�gate the possible link between 
Nup88 and NF-κB ac�va�on. NF-κB is a 
pivotal transcrip�on factor governing innate 
and adap�ve immunity as well as cancer 
progression [12]. The canonical ac�va�on of 
NF-κB involves a cascade of events, leading 
to the release of NFκB from an inac�ve 
cytoplasmic complex and subsequent 
transloca�on to the nucleus [12]. While the 
cytoplasmic signaling is well characterized, 
the regula�ons at the nuclear membrane 
have a�racted less a�en�on. Our results 
provide the first evidence that the mammalian 
Nup88 may play a role in the transport of NF-
κB similar to the observa�ons in Drosophila 
[9,10]. The EMSA assays reveal that the 
nucleocytoplasmic transport as a main target 
of regula�on by Nup88. 
Figure 4. Effect of Nup88 deple�on in BLM cells overexpressing Nup88
BLM melanoma cells were transfected with or without siRNA, s�mulated with TNF and analyzed by confocal microscopy 
at 1h a�er the s�mula�on. A. mock, B. siRNA deple�on of hNup88. NF-κBp65 and Nup88 were detected by an�-NF-κBp65 
and an�-rabbit IgG-FITC (green) and an�-Nup88 labeled with Alexa 647 (blue). The last column shows the overlay of all 
fluorescent channels.
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Nucleocytoplasmic transport of proteins 
involves transport receptors that recognize 
nuclear import (NLS) or export signals (NES) on 
the cargo proteins. The complex is transported 
through NPC via sequen�al interac�ons with 
nucleoporins in a Ran GTPase-dependent 
manner [1], and dis�nct nucleoporins 
determine substrate specificity. Nup153 
is involved in import of proteins mediated 
by impor�n-α/impor�n-β complexes [21], 
whereas Nup358/RanBP2 and Nup214 play 
a role in export of proteins dependent on 
CRM1 export complexes [22,23]. Recent 
report iden�fied narrower specificity of 
Nup214 than all CRM1-depen-dent export 
[3,23]. All these reports point to certain 
level of subset specificity, most likely arising 
from the composi�on of cargo complex. Our 
data suggest a role for mammalian Nup88 
in media�ng nucleocytoplasmic transport 
of NF-κB similar to the report in Drosophila 
[9,10]. Total nuclear NF-κB reflects its 
dynamic shu�ling: The nuclear import of 
NF-κB depends on impor�n-α/impor�n-β 
determined by a classical (c)NLS [24], and 
its export is CRM1- dependent [25]. The 
deple�on of Nup88 by siRNA did not affect 
ligand-induced nuclear accumula�on of GR, 
which harbors the bipar�te NLS that also binds 
to impor�n-α/impor�n-β transporter [26]. On 
the other hand, nuclear export of GR is CRM1-
independent [27]. Therefore, these data 
suggest either certain selec�vity in the role of 
Nup88 in impor�n-α/impor�n-β-dependent 
nuclear import,  or support more in favor of 
export as the main target of ac�on as reported 
in Drosophila [10,11].We were not able to 
demonstrate a direct physical associa�on 
between Nup88 and subcomponents of NF-
κB by co-immunoprecipita�on (unpublished 
data). This may be due to indirect associa�ons 
involving other components, but the iden�ty 
of other components remains elusive. Nup88 
was never shown to directly bind to transport 
complex, whereas Nup214 does bind directly 
to CRM1[3], and it is highly likely that Nup88 
associates with the transport cargo via 
Nup214. Recent study revealed mul�meric 
protein complex containing Nup88, Nup153 
and impor�n-α at specific condi�on [28]. It 
also remains to be elucidated which subclass 
of proteins besides NF-κB depends on Nup88 
for nucleocytoplasmic transport. Nup214-
Nup88 subcomplex is reported to mediate 
the nuclear export of CRM1-dependent 
NFAT in human cells [3], whereas Drosophila 
studies demonstrated more inhibitory role of 
these subcomplex in nuclear export of NF-κB 
[9,10]. The  discrepancy was thought to be 
due to different species, but our results rather 
support the role of Nup88 demonstrated 
in the Drosophila study. However, the 
interdependency between Nup214 and Nup88 
[3,22] and varying subcellular localiza�on 
[10,28] makes it difficult to dis�nguish the role 
of each component. 
We demonstrated the indispensable role 
of Nup88 in media�ng the gene ac�va�on 
induced by NF-κB in normal (NIH3T3) and 
metasta�c tumor cells (BLM). Coordinated 
degrada�on and synthesis of IκB isoforms 
regulate the ac�vity of NF-κB both in 
cytoplasm and in nucleus [29]. Overexpressed 
Nup88 may serve as a protec�ve shu�le and 
preserve a cytoplasmic pool of ac�ve NF-
κB for con�nuous supply into the nucleus, 
resul�ng in perpetual NF-κB ac�vity as 
observed here in BLM cells. EMSA assays 
detected cons�tu�vely ac�vated NF-κB in both 
nucleus and cytoplasm of BLM cells, which 
express high levels of Nup88. While chronic 
NF-κB ac�va�on in tumor cells is frequently 
accompanied by cons�tu�ve ac�va�on of IKK 
[30], preserva�on of ac�vated NF-κB would 
provide another mechanism favoring sustained 
NF-κB ac�va�on. Nup88 overexpression could 
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Materials and methods
Cell culturing. 
 NIH3T3 and BLM cells were maintained in 
Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% FCS. TNFα and 
dexametasone (DEX) were purchased from 
R&D systems (Minneapolis, MN) and Sigma 
(St. Louis,  MO), respec�vely. 
siRNA. 
 Sense and an�-sense ssRNA corresponding 
to the target sequences (Table 1A) were 
purchased as HPLC purified oligonucleo�des 
(RNA-TEC, Leuven, Belgium) and annealed to 
generate dsRNA. The cells were transfected 
with dsRNA (100 nM) using oligofectamine 
(Invitrogen, Carlsbad, CA). 
RNA isola�on and quan�ta�ve (Q)-RT-PCR. 
 Cells were seeded at the density of 6x 
105 cells/well, and transfected with siRNA 
24h later. RNA was isolated 24h a�er the 
transfec�on using RNeasy kit (Qiagen) and 
reverse-transcribed by standard methods. 
Q-PCR was performed by the ABI/Prism 7000 
using SYBR Green Master mix (Both Applied 
Biosystems Foster City, CA). Primer sequences 
used for the analysis are enlisted in Table 1B.
Luciferase reporter gene assay. 
 NIH3T3 cells were transfected with a 
plasmid construct carrying five consensus 
NF-jB binding sites followed by a luciferase 
reporter gene, and a stable clone with the 
highest responses to TNFα and IL-1 was 
selected (NF-jB-luc/ 3T3). NF-κB-luc/3T3 cells 
were seeded in a crystal 96-well micro�ter 
plate (Porvair) at the density of 3x104 cells/
well 24 h before transfec�on. At 24 h a�er 
transfec�on the cells were s�mulated with 
TNFα (10 ng/ml). A�er 6h s�mula�on cells 
were harvested and the lysate was analyzed 
effect perpetual NF-κB ac�vity and ul�mately 
fuel aberrant cell growth. Therefore, our 
findings suggest that Nup88 is not only a 
marker for malignant cells, but also a poten�al 
therapeu�c target. Its prominent effects on 
NF-κB warrant further research. 
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for luciferase ac�vity using the Bright-Glo 
luciferase assay system (Promega, Madison, 
WI) and luminomeric detec�on according 
to the manufacturer’s instruc�on (Polarstar 
Galaxy, BMG LabTechnologies, Offenburg, 
Germany).
Electrophore�c mobility shi� assay (EMSA). 
 Cells were grown in six-well plate, 
frac�onated into cytoplasmic and nuclear 
frac�on 1h a�er TNF s�mula�on and were 
subjected to EMSA as previously described 
[17,18]. We have used the following probe 
represen�ng the NF-κB binding site of IL-6 
promoter: 5‘-AGCTATGTGGGATTTTCCCAT
GAGC-3‘ (underlined: single κB mo�f). Ten 
micrograms of lysate was loaded on each lane. 
The supershi� experiments were performed 
with an�-p65 and an�p50 an�bodies (Santa 
Cruz Biotechnology). 
Immunofluorescence (IF).
 NF-κB-luc/3T3 cells (4x104 cells/ well) or 
BLM cells (2x104 cells/well) were seeded in 
an eight-well Lab-TekII chamber slide (Porvair, 
Shepperton, UK) 24h before the transfec�on. 
Twenty-four hours a�er the transfec�on, the 
cells were s�mulated with TNF (50 ng/ml) for 
1 h or with DEX (100 lM) for 1/2 h, washed 
with PBS and fixed with methanol at -20 °C. 
We used rabbit an�-NF-κBp65 an�body, 
rabbit an�-GR an�body, goat an�-NF-κBp50 
an�body (Santa Cruz Biotechnology) and 
an�-Nup88 monoclonal an�body [6]. FITC 
or TXRD conjugated secondary an�bodies 
(SouthernBiotech,Birmingham, AL) were used. 
Nup88 an�body was labeled with Alexa 647 
using a labeling kit (Molecular Probes). The 
cells were analyzed by confocal fluorescence 
microscopy using the Leica TCS NT (Leica 
GmbH, Germany).
Sta�s�cal analysis. 
Data are represented as means ± SD. Level of 
significance for comparisons between two-
independent  samples were determined using 
Student’s t-test. 
Table 1
sequences used
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Adhesion molecules endow tumor cells with the necessary cell-cell contacts and cell-matrix interac�ons. As such, adhesion molecules are involved in cell signalling, prolifera�on and tumor growth. Rearrangements in the adhesion repertoire allow tumor cells to migrate, 
invade and form metastasis. Besides these membrane bound adhesion molecules several 
soluble adhesion molecules are detected in tumor cell-lines supernatant and pa�ent body fluids. 
Truncated soluble adhesion molecules can be generated by several conven�onal mechanisms, 
including alterna�ve splicing of mRNA transcripts, chromosomal transloca�on, and extracellular 
proteoly�c ectodomain shedding. Vesicle (ectosomes and exosomes) secre�on is an alterna�ve 
mechanism media�ng the release of full-length adhesion molecules. Soluble adhesion molecules 
func�on as modulators of cell adhesion, induce proteoly�c ac�vity and facilitate cell-signalling. 
Addi�onally, adhesion molecules present on secreted vesicles might be involved in the vesicle-
target cell interac�on. 
Based on currently available data, released soluble adhesion molecules contribute to cancer 
progression and therefore should not be regarded as unrelated and non-func�onal side products 
of tumor progression. 
1. Introduc�on 
 One of the hallmarks of cancer is the 
ability of cancer cells to dissociate from 
the primary tumor and form metastasis 
at distant sites. For successful metastasis 
tumor cells have to invade locally and 
they have to follow the sequen�al steps of 
intravasa�on, intravascular transporta�on, 
stasis, adhesion, extravasa�on and finally the 
cells have to keep on prolifera�ng (Hanahan 
and Weinberg, 2000;Bidard et al., 2008). 
During these migratory processes tumor cells 
reorganize their cytoskeleton and modulate 
the surrounding extracellular matrix (ECM), 
in addi�on, tumor cells con�nuously change 
their cell surface adhesion repertoire. Changes 
in adhesion profile allow tumor cells to detach 
from and a�ach to specific cells, basement 
laminas and other ECM components, adap�ng 
them to the changing micro-environment 
encountered during migra�on and metastasis. 
 These changes in adhesion not only 
allow migra�on directly, they also modify 
intercellular communica�on of tumor cells 
with stromal cells and alter signalling from and 
to the ECM. 
Several cell adhesion molecules mediate 
tumor cell adhesion to adjacent tumor cells 
and tumor stroma cells. These include, 
among others, members of the cadherin 
and immunoglobulin (Ig) super families 
(Bogenrieder and Herlyn, 2003;Haass et al., 
2005), while integrins facilitate adhesion to 
the ECM. The general idea is that altered 
adhesion is important for the pathogenesis of 
tumor progression and metastasis.  
The changing adhesion repertoire on tumor 
cells can be regulated at various levels, e.g 
transcrip�on and transla�on, the spa�al 
distribu�on along the plasma membrane, 
endocytosis and degrada�on, and forma�on 
of higher order adhesion complexes. Besides 
these processes, several adhesion molecules 
are also present in soluble forms outside of the 
cell, sugges�ng addi�onal release mechanisms 
regula�ng the presence of adhesion molecules 
on the cell surface and in the extracellular 
space. 
While our knowledge of adhesion molecules 
grows, we have learned that, in addi�on to the 
conven�onal view of full-length membrane 
spanning molecules media�ng adhesion, 
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adhesion molecules may have soluble secreted 
full-length and/or shorter forms with the same 
or different func�ons. 
This review will focus on the origin, release 
and implica�ons of soluble adhesion 
molecules found in several cancers. Given 
the diversity of mechanisms that result in the 
forma�on and/or release of soluble adhesion 
molecules we will, therefore, discuss the three 
most important mechanisms separately: (I) 
Ectodomain shedding, (II) alterna�ve splicing 
and (III) vesicle release. Furthermore we 
highlight the genera�on and consequences of 
selected soluble adhesion molecules in more 
detail. 
2. Mechanisms of adhesion molecule 
release 
2.1 Ectodomain shedding 
 Ectodomain shedding is the proteoly�c 
cleavage of cell surface receptors, membrane 
bound growth factors and adhesion molecules 
from the cell surface (Arribas and Borroto, 
2002). 
The best known func�on of ectodomain 
shedding is the release of membrane bound 
growth factors such as epidermal growth 
factor (EGF), transforming growth factor (TGF-
α)and tumor necrosis factor (TNF-α) thereby 
facilita�ng paracrine signalling (Blobel, 2005). 
Furthermore, transmembrane receptors for 
cytokines and growth factors can be released 
by ectodomain shedding (Heaney and Golde, 
1998;Levine, 2004). Shedding of receptors 
either inac�vates the receptor, or the released 
ectodomain sequesters soluble ligand (Blobel, 
2005). 
Generally, protein ectodomain shedding 
results in a soluble fragment and a fragment 
that remains on the cell-surface. That can 
occur cons�tu�vely or can be induced by 
several non-physiological s�muli such as 
phorbol esters (PMA) (Fitzgerald et al., 
2000;Gasbarri et al., 2003), pervanadate or 
cholesterol extrac�ng agents (Fitzgerald et 
al., 2000;Gutwein et al., 2003). Physiological 
ac�vators of ectodomain shedding are 
chemokines, cytokines and growth factors 
(Fitzgerald et al., 2000). Ectodomain shedding 
is usually catalyzed by proteases of the 
metalloproteinases (MMPs) and a disintegrin 
and metalloproteinases (ADAMs) families. 
2.1.1 Proteases involved in ectodomain 
shedding 
ADAMs 
 The family of ADAMs comprises 23 
zinc-dependent mul�domain proteases 
composed of a signal-pep�de, propep�de, 
metalloprotease, disintegrin-like, cysteine rich 
and epidermal growth factor like domains, a 
transmembrane region and a cytoplasmic tail 
(Stone et al., 1999), poten�ally giving them 
adhesive and proteoly�c func�ons (Primakoff 
and Myles, 2000). The prodomain ini�ally 
keeps the metalloprotease site inac�ve 
through a cysteine switch (Van Wart and 
Birkedal-Hansen, 1990;Becker et al., 1995). 
In order to get ac�vated the N-terminal 
prodomain needs to be cleaved from the rest 
of the protein by pro-protein convertases 
(PCs) in the trans Golgi-network (Lum et al., 
1998;Roghani et al., 1999;Howard et al., 
2000;Kang et al., 2002). In contrast to the 
predominantly membrane-bound ADAMS, 
the ADAM-related metalloproteinase family of 
ADAMTs (ADAMs with trombospondin mo�fs) 
are secreted proteases (Porter et al., 2005). 
Although ADAMTs are expressed in various 
cancers no clear evidence for ectodomain 
shedding is reported. 
ADAMs are involved in the proteolysis of the 
extracellular matrix, ac�va�on of enzymes, 
processing of cytokines, growth factors and 
receptors, modula�on of cell adhesion and 
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migra�on. As such, ADAMs play important 
roles in angiogenesis and axon guidance; 
they also may be involved in inflamma�on, 
Alzheimers disease, and asthma (Seals and 
Courtneidge, 2003;Reiss et al., 2006;Tousseyn 
et al., 2006;Roy et al., 2006). Upregula�on of 
ubiquitous ADAMs is a common phenomenon 
in a variety of human tumors (Arribas et al., 
2006). 
Matrix metalloproteinases 
 Over 20 zinc-dependent extracellular 
endopep�dases make up the family of matrix 
metalloproteinases (MMPs). In general 
MMPs contain a signal pep�de, a N-terminal 
propep�de, a cataly�c domain and a hinge 
region followed by the C-terminal hemopexin 
domain. The specific subset of MT-MMPs 
(membrane-type MMPs) contain an addi�onal 
transmembrane domain (MT1-,2-,3- and MT-
5-MMP) or a glycosylphospha�dyl-inositol 
(GPI) anchor (MT4- and MT-6-MMP) making 
them membrane bound while the remaining 
MMPs are secreted as soluble proteases. 
All MMPs are produced as latent zymogens 
and need to be ac�vated before they full-fill 
their proteoly�c ac�vity. MMP ac�va�on 
depends on the cysteine switch (Van Wart et 
al., 1990) and can occur both intracellularly 
and extracellularly by several proteases 
including MMPs themselves. 
The proteoly�c ac�vity of both groups 
of proteases (ADAMs and MMPs) can be 
inhibited by their endogenous inhibitors, �ssue 
inhibitors of MMPs (TIMPs). TIMPs appear to 
play both a repressive and progressive role 
in cancer progression. Despite their name, 
TIMPs not only inhibit protease ac�vity but 
are also involved in the ac�va�on of MMP-
2 and regulate cell prolifera�on, apoptosis 
and angiogenesis indica�ng that a delicate 
balance between proteases and inhibitors 
is more important than the presence or 
absence of individual components (Jiang et al., 
2002;Chirco et al., 2006). 
ADAMs and MMPs together have a broad 
range of substrates and therefore play a 
role in many physiological and pathological 
processes. MMP and ADAM expression has 
been associated with tumor progression and 
metastasis of many different tumors (Zhang 
et al., 1995;Lynch and Matrisian, 2002;Egeblad 
and Werb, 2002;Hofmann et al., 2005;Tousseyn 
et al., 2006;Arribas et al., 2006). Tumor-
related proteases were ini�ally considered 
to be responsible for the degrada�on and 
remodelling of the ECM, but the spectrum of 
substrates has moved to addi�onal substrates 
and ectodomain shedding. The first shedding 
protease or “sheddase” iden�fied was tumor 
necrosis factor-α (TNF-α) conver�ng enzyme 
(TACE / ADAM17) (Black et al., 1997). ADAM-17 
is involved in the cleavage of, among others, 
cytokine receptors belonging to the TNFR, 
TLR and the type I cytokine receptor families 
(reviewed in (Levine, 2004) and L-selec�n, and 
transforming growth factor-α (Peschon et al., 
1998). 
2.1.2 Modula�on of cell adhesion by 
ectodomain shedding 
 Several adhesion molecules emerge by 
ectodomain shedding and play an important 
role in altering (tumor)cell adhesion and 
migra�on. The standard form of CD44, 
CD44H, has been shown to be spontaneously 
cleaved by MT1-MMP releasing a soluble 70 
kDa fragment(Naor et al., 1997). An unknown 
serine protease releases a 90 kDa fragment 
(Kajita et al., 2001). Only its shedding by MT1-
MMP contributes to enhanced mo�lity. Besides 
MT1-MMP, ADAM-10 and -17 were found to 
cleave CD44 from tumor cells (Nakamura et al., 
2004;Murai et al., 2004;Nagano et al., 2004). 
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A model for cell migra�on was proposed in 
which the ac�va�on of PKC and Rac induced 
ADAM 17 mediated CD44 cleavage at the 
leading edge of migra�ng cells resul�ng in 
cell crawling. While at the rear end Ca2+ 
influx ac�vates ADAM-10 followed by CD44 
cleavage facilita�ng cell detachment from 
the matrix (Nagano and Saya, 2004;Nagano 
et al., 2004). The shed ectodomain of CD44 
itself is not involved in the migra�on but the 
impaired cell adhesion allows cells to detach 
from the ECM and subsequently move on to 
different sites (Kajita et al., 2001).Ectodomain 
cleavage of CD44 is detected in several human 
tumor �ssues (Okamoto et al., 2002). CD44 
is also present outside the cell in released 
cell fragments found at the trailing edge of 
migra�ng melanoma cells in 3 dimensional 
collagen la�ces (Mayer et al., 2004). 
MT1-MMP is involved in the processing of 
several pro-integrins to integrins. Pro-β3, 
pro-αV, pro-α3 and pro-α5 precursors are 
processed to mature integrin subunits by MT-
1MMP thereby altering adhesion of tumor 
cells and their migra�on on ECM components 
(Deryugina et al., 2000;Ratnikov et al., 
2002;Deryugina et al., 2002;Baciu et al., 2003). 
The 4 subunit is a substrate of MMP-7 and its 
cleavage interferes with β4 lamin interac�ons 
(von Bredow et al., 1997). In prostate cancer 
cells and prostate cancer �ssue specimens 
the α6-integrin is cleaved to the shorter α6p-
integrin by the urokinase-type plasminogen 
ac�vator (uPA) (Demetriou et al., 2004). 
Blocking this cleavage with uPA inhibitor PAI-1 
reduces cell invasion and migra�on on laminin 
(Pawar et al., 2007). It remains unknown if the 
shed 6 fragment contributes to the enhanced 
migratory phenotype. Similar to CD44, 
integrins are present in the cell fragments 
found at the trailing edge of migra�ng 
melanoma cells (Mayer et al., 2004). 
Surface �ssue transglutaminase (tTG), a co-
receptor for β1 integrins and ECM molecules 
is cleaved from cancer cells by MT1,2,3-MMP 
at three different sites thereby inac�va�ng its 
enzyma�c and coreceptor func�on (Belkin et 
al., 2001). As a consequence, adhesion and 
migra�on on fibronec�n is decreased but 
migra�on on collagen is increased. Strikingly, 
fibronec�n, an ECM ligand of tTG, inhibits the 
proteoly�c degrada�on of its own receptor 
sugges�ng that surrounding ECM components 
may reciprocally regulate proteolysis of their 
specific cell surface adhesion receptors (Belkin 
et al., 2001). Later it was found that MMP-2 is 
sufficient in cleaving tTG and works in concert 
with its ac�vator, MT1-MMP, in the regula�on 
of tTG func�onality (Belkin et al., 2004). To 
the best of our knowledge, involvement with 
tumor progression of the released domain of 
tTG has not yet been studied. 
From these data it appears that ectodomain 
shedding of adhesion molecules only 
abrogates adhesion or modifies adhesion 
molecules, leaving the released ectodomains 
without any func�on. However, there are 
examples in which the released ectodomain 
exerts the cell func�onal effects. 
Shedding of Nr-CAM, a member of the IgCAM 
family, has been shown to be a result of 
cleavage by an unknown metalloprotease 
in B16 melanoma cells and HEK 293 cells 
(Conacci-Sorrell et al., 2005). Overexpression 
of the Nr-CAM ectodomain or addi�on of 
a medium containing shed Nr-CAM both 
enhanced cell prolifera�on, mo�lity, and AKT 
ac�va�on of NIH3T3 cells. Tumorigenesis 
in mice is enhanced when the extracellular 
domain of Nr-CAM is retrovirally transduced. 
This suggests that the shed ectodomain of 
Nr-CAM promotes a tumorigenic phenotype 
(Conacci-Sorrell et al., 2005) A second example 
is the s�mula�ng effect of a E-cadherin 
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complete secreted soluble extracellular 
variant as seen for PECAM (Goldberger et 
al., 1994) and P-selec�n (Ishiwata et al., 
1994). On the other hand shorter forms of 
membrane bound molecules containing only 
the membrane distal structures are found as 
seen for ALCAM in endothelial cells (Ikeda and 
Quertermous, 2004). 
Several cancer related adhesion molecules 
are known to occur as soluble variants as 
a consequence of alterna�ve splicing. A 
secreted form of cadherin-11, lacking the 
transmembrane region and the cytoplasmic 
tail, promotes invasion of breast carcinoma 
cells via a yet unknown mechanism (Feltes et 
al., 2002). 
A soluble N-terminal fragment of P-cadherin 
(sP-cadherin, 50 kDa) lacking several exons 
is expressed in cutaneous melanoma. 
However, it is uncertain if it is generated 
through alterna�ve splicing or chromosomal 
transloca�on (Bauer et al., 2005). Knockdown 
of sP-cadherin using an�sense techniques 
resulted in a reduc�on of migra�on and 
invasion (Bauer and Bosserhoff, 2006). A 
model was proposed in which sP-cadherin 
inhibited homophilic interac�ons between 
full-length P-cadherin of neighbouring cells 
and as a result facilitates cell dissimina�on. 
In addi�on, soluble forms of CD44 (sCD44) 
are generated via alterna�ve splicing (Yu and 
Toole, 1996), and have been found in ascites 
of cervical and ovarian carcinoma pa�ents 
(Gadducci et al., 1997;Gadducci et al., 1998). 
Overexpression of sCD44 comprising only 
exons 1–5, 15 and 16 in colon cancer cells 
increased cell prolifera�on and resistance to 
apoptosis but decreased cellular adhesion to 
hyaluronan (HA) (Subramaniam et al., 2007) 
indica�ng that sCD44 could be involved in 
tumor progression. The antagonis�c effect 
sCD44 has on binding of cells to HA is also seen 
in melanoma cell lines (Ahrens et al., 2001). 
shedded fragment on migra�on and ivasion 
of E-cadherin posi�ve tumor cells. This will be 
discussed in more detail in sec�on 3.3. 
Above men�oned effects of ectodomain 
shedding are involved in tumor cell release 
from the primary tumor and migra�on on 
ECM components and between stromal cells. 
Shedding could also play a role in extravasa�on. 
Tumor cells may use mechanisms that 
resemble transendothelial migra�on (TEM) 
of leukocytes to sites of inflamma�on. 
Specifically the docking and locking events for 
leukocytes and cancer cells to endothelial cells 
occur with considerable similari�es (Miles 
et al., 2007). Several adhesion molecules 
are involved in leukocyte TEM including E-, 
P- and L-selec�n, ICAM-1, VCAM-1, PECAM 
and integrins (Garton et al., 2006;Miles et 
al., 2007). In order to roll on, adhere to and 
move over and in between endothelial cells 
mul�ple, sequen�al adhesive interac�ons are 
necessary. Ectodomain shedding is a rapid way 
to respond and adapt the adhesive repertoire 
necessary for TEM. Shedding of L-selec�n, 
ICAM-1 and VCAM-1 modulates adhesion 
between leukocytes and endothelial cells and 
thereby facilita�ng TEM (Garton et al., 2006). 
Although no clear evidence exists, several 
of these adhesion molecules have also been 
shown to be involved or at least be expressed 
in tumor cells, therefore it might be that 
ectodomain shedding is important for tumor 
cell extravasa�on. 
2.2 Alterna�ve splicing 
 Alterna�ve splicing of mRNA transcripts 
can result in secre�on of cell adhesion 
molecule variants or trunca�on of membrane 
bound molecules. Soluble adhesion molecules 
generated by alterna�ve splicing contain 
signal pep�des but lack the anchor of a 
transmembrane domain resul�ng in a nearly 
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2.3 Vesicle secre�on 
 Cells can release membrane vesicles into 
the extracellular micro-environment. These 
vesicles either originate from outward budding 
of the plasma-membrane (ectosomes) or 
upon fusion of microvesicular bodies (MVBs) 
with the plasma membrane thereby releasing 
their internal luminal vesicles which are called 
exosomes once they are released from the 
cell. As these vesicles originate directly or 
indirectly from the plasma membrane they 
contain several membrane bound proteins 
including adhesion molecules. In the further 
review text the term “vesicles” collec�vely 
refer to ectosomes and exosomes. 
2.3.1 Ectosomes 
 Membrane proteins can be released 
from the cell via ectosomes. Ectosomes are 
submicron (100nm-µ1m) membrane-derived 
vesicles released by various normal and 
malignant cells. Release of ectosomes involves 
the increase of cytosolic Ca2+ this could induce 
the collapse of plasma membrane asymmetry 
by s�mula�on of a lipid scramblase and the 
outward pump floppase and inhibi�on of 
the aminophospholipid translocase flippase. 
In addi�on, calcium dependent proteolysis 
facilitates cytoskeleton degrada�on and 
allows par�cle release (Hugel et al., 2005). 
Membranes of ectosomes consist of proteins 
and lipids similar to the plasma membrane of 
the cell they originated from, and enclose a 
cytoplasmic content. Due to the plas�city of 
the plasma membrane, the content of these 
ectosomes is regulated by controlled inclusion 
or exclusion of specific lipids and proteins 
(Hugel et al., 2005;Ratajczak et al., 2006b). This 
sor�ng mechanism explains the highly diverse 
phenotype and content of microvesicles, even 
when originated from the same cell. 
2.3.2 Exosomes 
 A specific subset of vesicles are the so 
called exosomes. In contrast to ectosomes, 
exosomes are of endosomal origin. Exosomes 
are membrane vesicles (30-100nm) released 
when mul�vesicular bodies, formed by 
inwards budding of endosomal membranes, 
fuse with the plasma membrane and release 
their intraluminal vesicles, which are then 
called exosomes. (A broader scope on 
exosome biogenesis is reviewed in (Thery et 
al., 2002;Keller et al., 2006;Li et al., 2006;van 
Niel et al., 2006). Exosomes release is 
observed in a wide variety of cells ranging from 
haematopoie�c (red blood cells, lymphocytes 
and dendri�c cells), epithelial and neuronal 
cells to tumor cells (Thery et al., 2002;Andre et 
al., 2002;van Niel et al., 2006). Furthermore, 
exosomes can be detected in biological fluids 
such as plasma (Caby et al., 2005), pleural 
effusions (Andre et al., 2002;Bard et al., 
2004), urine (Keller et al., 2007) and breast 
milk (Admyre et al., 2007). Tumor-derived 
exosomes that inhibit T-cell func�ons have 
been isolated from ovarian cancer pa�ents’ 
sera (Taylor and Gercel-Taylor, 2005). The 
commonly used method for vesicle isola�on 
is a series of sequen�al centrifuga�on steps 
to remove cells and debris, followed by a 
final ultracen�fuga�on step. However, this 
protocol does not discriminate between larger 
ectosomes and smaller exosomes. Further 
iden�fica�on of exosomes is based on their 
density in sucrose gradients (1.13-1.19 g/ml) 
and size determina�on (flowcytometry or 
electron-microscopy). 
2.3.3 Vesicle func�on: general 
 Vesicles are biologically ac�ve en��es 
involved in several cellular processes (Keller et 
al., 2006;Li et al., 2006;van Niel et al., 2006). 
The func�on of a vesicle is determined by 
protein content within and at the surface of 
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2.3.3.1 Protease transport (pla�orm for 
ectodomain shedding) 
 In contrast to the soluble adhesion 
molecules generated by alterna�ve splicing 
or ectodomain shedding, direct effects of 
soluble adhesion molecules originated from 
secreted vesicles on tumor cell migra�on have 
not been addressed. Yet, vesicle release may 
contribute to impaired adhesion by facilita�ng 
ectodomain shedding. 
Several papers show the presence MMP-
2 (Ginestra et al., 1998;Dolo et al., 
1999;Tarabole� et al., 2002), MMP-9 (Dolo 
et al., 1998;Ginestra et al., 1998;Dolo et al., 
1999;Tarabole� et al., 2002), MT1-MMP 
(Tarabole� et al., 2002) and urokinase-type 
plasminogen ac�vator (uPA) (Ginestra et al., 
1997) in or at vesicles themselves. Ascites 
derived-membrane vesicles contain MMP-2, 
MMP-9 and uPA (Graves et al., 2004;Runz 
et al., 2007). In addi�on to these proteases, 
ADAM 10 and ADAM 17 are also present in 
secreted exosomes (Stoeck et al., 2006). The 
presence of several proteases in combina�on 
with several transmembrane proteins raises 
the interes�ng possibility that secreted vesicles 
mediate proteoly�c shedding and therefore 
acts as a mechanism to bring proteases and 
substrates together in a coordinated fashion. 
For both L1CAM and CD44, ectodomain 
shedding in MVBs has been shown (Gutwein 
et al., 2003;Gutwein et al., 2005;Stoeck et 
al., 2006). In contrast to ADAM-17 mediated 
cell-surface ectodomain shedding of L1CAM 
and CD44, ADAM 10 mediates the shedding 
in endosomes that are subsequently released 
as exosomes. Once the exosomes are released 
further cleaving by ADAM-10 is also observed. 
Together these findings suggest a role for 
exosomes as a pla�orm for ectodomain 
shedding (Keller et al., 2006). Addi�onal 
adhesion molecules like the epithelial tumor 
marker EpCAM (Runz et al., 2007), MelCAM 
the vesicle and the cell type of origin. Tumor 
secreted vesicles may be important for the 
modula�on of and escape from the an�-tumor 
immune response (Valen� et al., 2007). For 
instance, tumor derived vesicles are known 
to induce apoptosis of lymphocytes (Andreola 
et al., 2002;Huber et al., 2005), modulate the 
differen�a�on of monocytes (Valen� et al., 
2007) and reduce cytotoxicity {340}. Besides 
immune surveillance, tumor released vesicles 
are involved in angiogenesis (Kim et al., 
2002;Hegmans et al., 2004;Tarabole� et al., 
2006) and ac�vate signal transduc�on {429}. 
Proteomic analysis on different kind of vesicles 
would increase the knowledge on the protein 
composi�on and thereby the understanding of 
their roles in vitro and in vivo. 
Proteomic analysis has already been 
performed on vesicles derived from dendri�c 
cells (DCs) (Thery et al., 1999;Thery et al., 
2001), B-cells (Wubbolts et al., 2003), intes�nal 
epithelial cells, mesothelioma cells (Hegmans 
et al., 2004) and on exosomes from cancerous 
pleural effusions (Bard et al., 2004).However, 
the cellular source of these exosomes was not 
specified. Proteomic analysis has also been 
perfomed on colorectal cancer cells derived 
microvesicles (Choi et al., 2007). Together 
these studies show that rela�vely specific 
subsets of proteins are commonly, but not 
for all cell types, targeted to exosomes. They 
include cytoskeletal components, proteins 
involved in intracellular membrane fusions 
and transport, signal transduc�on proteins, 
metabolic enzymes, heat shock proteins, and 
adhesion molecules (Thery et al., 2002;Bard et 
al., 2004). Also enrichment of specific proteins 
is observed, such as immunoglobulins, 
complement components (Bard et al., 2004), 
tumor an�gens and tumor-associated proteins 
such as Mart-1, Mel-CAM, Her2, TRP and 
GP100 (Mears et al., 2004). 
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(Mears et al., 2004), CD44 and several 
integrins (Dolo et al., 1998;Baj-Krzyworzeka 
et al., 2006) are present on tumor derived 
microvesicles, which makes them suscep�ble 
targets of ectodomain shedding. In addi�on, 
these molecules may have, yet unknown, 
specific func�ons on or within these vesicles. 
Strikingly, release of full-length TNFR1 by 
exosome-like vesicles can be blocked by the 
addi�on of TAPI-2, a broad spectrum inhibitor 
of zinc metalloproteinases, indica�ng that 
the exosome release of TNFR1 requires the 
cataly�c ac�vity of zinc metalloproteinases, 
but does not involve ectodomain shedding 
(Hawari et al., 2004). From this one could 
speculate that zinc metalloproteinases, like 
ADAM10 and 17, are also involved in the 
genera�on of exosomes (Keller et al., 2006). 
3. Selec�on of soluble adhesion 
molecules in more detail 
 During tumor development and 
progression several adhesion molecules are 
present as soluble variants (table 1, at the end 
of this chapter). For a selec�on of adhesion 
molecules the genera�on and func�on of their 
soluble variants is discussed in more detail 
below. 
3.1 Basigin/ emmprin 
 Extracellular matrix metalloproteinase 
inducer (EMMPRIN/CD147/basigin) is a 
plasma membrane glycoprotein belonging 
to the immunoglobulin superfamily. Its 
expression is detected on the surface of 
many tumor cells and correlates with a more 
aggressive phenotype. EMMPRIN mediates 
stromal interac�ons thereby s�mula�ng the 
produc�on of VEGF and several MMPs (MMP-
1,2,3 and 14) by fibroblasts and endothelial 
cells (Yan et al., 2005). 
EMMPRIN release from tumors cells can be 
mediated either by proteoly�c shedding 
(Taylor et al., 2002) or via microvesicles (Sidhu 
et al., 2004;Baj-Krzyworzeka et al., 2006). The 
proteoly�c shedding of EMMPRIN is inhibited 
by zinc chelators and by the broad spectrum 
MMP inhibitor GM6001 sugges�ng the 
involvement of MMPs (Tang et al., 2004;Haug 
et al., 2004). In agreement with this, Haug et 
al (2004) found EMMPRIN to be cleaved, in 
vitro, at the membrane-proximal region by 
MMP-1 and MMP-2. In addi�on to the release 
of full length EMMPRIN, a novel shorter 
form of EMMPRIN was iden�fied, a 22-kDa 
fragment found in culture medium of HT1080 
and A431 cells (Egawa et al., 2006). Shedding 
of this fragment was enhanced by phorbol 
12-myristate 12-acetate (PMA). Because this 
shedding was inhibited by TIMP-2, but not 
by TIMP-1, this process implies the ac�vity 
of MT-MMPs (Egawa et al., 2006). Together 
with expression and inhibi�on studies MT1-
MMP was found to be the major enzyme 
responsible for the shedding of the 22-kDa 
EMMPRIN fragment. The MT1-MMP cleavage 
site (Asn98-Ile99) is located in the linker region 
connec�ng the two Ig-like domains, therefore 
the cleaved fragment contains the N-terminal 
Ig domain necessary for MMP inducing ac�vity 
and homophilic interac�ons. As expected, the 
purified soluble 22 kDa fragment retained 
MMP inducing ac�vity (Egawa et al., 2006). 
 As a member of the immunoglobulin 
superfamily EMMPRIN has the characteris�c 
orienta�on with its N-terminus on the 
outside and it’s C-terminus on the inside of 
the cell. Taylor et al (Taylor et al., 2002) found 
that breast cancer cells released EMMPRIN 
containing both the C- and N-terminus, 
sugges�ng vescicle release. However, no 
associa�on with vesicles could be detected, 
leading to the specula�on that EMMPRIN 
is not a transmembrane glycoprotein at all. 
Sidhu et al (Sidhu et al., 2004) clarified this 
issue by showing that EMMPRIN is indeed 
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released via microvesicle shedding in a 
PKC, Ca2+ and MEK1/2-dependent signalling 
controlled manner. A�er secre�on these 
vesicles rapidly break down and release 
bioac�ve full-length EMMPRIN. Due to the 
short life-span of these vesicles the major 
source of soluble intact EMMPRIN, in �me, 
appears to be the supernatant, but it actually 
originated from secreted vesicles. The vesicle-
mediated release of EMMPRIN was confirmed 
in several tumor cell lines (Baj-Krzyworzeka et 
al., 2006). 
Recently, Millimaggi et al (Millimaggi et al., 
2007) showed that microvesicles derived 
from ovarian carcinoma cell lines s�mulated 
proangiogenic ac�vi�es of HUVECS in vitro in 
an EMMPRIN depended fashion. Addi�on of 
tumor-derived vesicles to HUVECS induces an 
transcrip�onal upregula�on of endothelial cell 
MMPs, which may contribute, al least partly, 
to the in vitro angiogenesis. In this study it 
remains unclear whether vesicle-associated or 
vesicle-released EMMPRIN induce angiogenic 
responses in target cells. 
EMMPRIN is a good example of a 
transmembrane adhesion receptor that can be 
released into the environment by ectodomain 
shedding and/or vesicle release. Regardless of 
the release mechanism of soluble EMMPRIN, 
the ectodomain s�ll acts as an MMP inducer. 
Shedding of EMMPRIN reduces the total 
amount of cell surface protein while increasing 
the soluble form (Egawa et al., 2006). Loss of 
membrane bound EMMPRIN is expected to 
decrease contact with the directly surrounding 
stroma cells (fibroblasts), while soluble 
EMMPRIN modulate angiogenesis (Sidhu et 
al., 2004;Egawa et al., 2006;Millimaggi et al., 
2007).
3.2 L1CAM 
 L1 cell adhesion molecule (L1CAM, CD171) 
is a 200-220 kDa type I membrane adhesion 
molecule belonging to the immunoglobulin 
superfamily. It consists of six aminoterminal 
Ig-like domains and five fibronec�n-type III 
repeats, followed by a transmembrane region 
and a highly conserved cytoplasmic tail. The 
extracellular Ig domains are involved in both 
homophylic and heterophylic binding (De 
Angelis et al., 1999;De Angelis et al., 2002). 
Specifically the RGD (Arg-Gly-Asp) site in Ig 
domain 6 mediates heterophylic interac�ons 
with several integrins. L1CAM has been 
implicated in a number of physiological 
processes necessary for proper nervous 
system development such as neuronal 
outgrowth, pathfinding and neuronal cell 
migra�on (Hortsch, 1996;Brummendorf et al., 
1998;Hortsch, 2000). 
Expression of L1CAM has also been detected 
in a variety of tumors including lung carcinoma 
(Katayama et al., 1997), renal carcinoma 
(Meli et al., 1999;Allory et al., 2005), glioma 
(Senner et al., 2002), melanoma (Thies et al., 
2002;Fogel et al., 2003b), ovarian carcinoma 
(Fogel et al., 2003a), and colon carcinoma 
(Gavert et al., 2005). 
Overexpression of L1 induces conversion 
from a non-invasive radial growth phase 
(RGP) to an invasive ver�cal growth phase 
(VGP) melanoma and suppression of L1CAM 
func�on significantly reduces melanoma cell 
migra�on and invasion on matrigel (Meier et 
al., 2006). Similar enhanced migratory effects 
are obtained when L1CAM is expressed in 
colon carcinoma cells, whereas knockdown of 
L1CAM reduces haptotac�c mo�lity (Gavert 
et al., 2005). In these colorectal carcinoma 
cells L1CAM has been iden�fied as a target 
of the β-catenin-TCF signalling pathway 
(Gavert et al., 2005). L1CAM can be released 
from the membrane, the most important 
release mechanism being ectodomain 
shedding (Beer et al., 1999;Gutwein et 
al., 2000;Mechtersheimer et al., 2001). In 
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vitro, L1CAM can be released from the cell-
membrane by metalloproteases such as ADAM-
10 (Gutwein et al., 2000;Mechtersheimer 
et al., 2001;Gutwein et al., 2003), ADAM-17 
(Maretzky et al., 2005b;Stoeck et al., 2006) 
and serine proteases like plasmin (Nayeem et 
al., 1999). 
In addi�on to ectodomain shedding at the 
cell surface, L1CAM is released from ovarian 
carcinoma cells in exosomes. Cleaving of 
L1CAM by ADAM-10 can occur already in 
the endosomes or a�er libera�on of the 
exomes (Gutwein et al., 2003;Gutwein et 
al., 2005;Stoeck et al., 2006). We recently 
iden�fied L1CAM in exosomes derived from 
melanoma and fibrosarcoma cells in vitro 
(unpublished data). 
The shed ectodomain of L1CAM retains its 
ability to support integrin-mediated cell 
adhesion and migra�on of melanoma cells 
(Beer et al., 1999) through autocrine/paracrine 
binding to αvβ5 integrins (Mechtersheimer et 
al., 2001) and triggers signal-regulated kinase 
(ERK) phosphoryla�on (Gutwein et al., 2005). 
An addi�onal role for soluble L1CAM lies in the 
protec�on against apoptosis, although soluble 
L1CAM only par�ally rescued carcinoma and 
neural cells from apoptosis (Stoeck et al., 
2007). Soluble L1CAM is detected in serum 
and ascites of pa�ents with uterine and 
ovarian carcinomas, sugges�ng that it may 
serve as a marker for predic�on of clinical 
outcome (Fogel et al., 2003a). 
3.3 Cadherins 
 Cadherins consist of a large family of widely 
expressed Ca2+-dependent transmembrane 
adhesion molecules that generally mediate 
homophilic cell-cell interac�ons. The best 
characterized cadherins are epithelial (E-
) cadherin and neural (N-) cadherin, both 
belonging to the sub-family of classical type-I 
cadherins. 
Classical cadherins are comprised of a 
large extracellular domain containing five 
calcium binding repeats, a single spanning 
transmembrane region and a cytoplasmic 
domain that binds to β, γ, catenin or 
plakoglobin which links to α-catenin and the 
ac�n cytoskeleton promo�ng stable cell-cell 
adhesion (Mareel et al., 1997;Angst et al., 
2001;Conacci-Sorrell et al., 2002). Several 
proteases are known to cleave E-cadherin in 
different �ssues or cell-lines. 
MMP-3 and MMP-7 release a soluble 80 kDa 
E-cadherin fragment (sE-cadherin) from the 
cell membrane of MDCK cells, MCF-7 cells 
(Noe et al., 2001), prostate carcinoma cells 
(Davies et al., 2001) and alveolar-like epithelial 
cells (McGuire et al., 2003). MMP-9 was shown 
to cleave E-Cadherin in ovarian carcinoma 
cells upon integrin aggrega�on (Symowicz 
et al., 2007). Besides these soluble MMPs, 
MT1-MMP has been shown to cleave both 
E- and N-cadherin in ischemic rat kidney cells 
(Covington et al., 2006) whereas MT5-MMP 
cleaves only N-cadherin in neurons (Monea 
et al., 2006). Both E-cadherin (Maretzky et 
al., 2005a) and N-cadherin (Reiss et al., 2005) 
can be cleaved by ADAM-10 in vitro and during 
embryonic development in vivo. Recently, 
human kallikrein 7 (hK7) was shown to cleave 
E-cadherin in pancrea�c carcinoma cells 
(Johnson et al., 2007) and kalikrein 6 (hK6) was 
shown to induce E-cadherin shedding in an 
MMP dependent manner (Klucky et al., 2007). 
Furthermore plasmin cleaves E-cadherin in oral 
squamous cell carcinoma cells (Hayashido et 
al., 2005). Although ADAM mediated cleavage 
is important for cell adhesion and migra�on, 
a correla�on between ADAM-10 cleavage of 
E- and N- cadherin and tumor progression or 
metastasis has not been determined. 
Shedding of E-cadherin impairs cell adhesion 
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and allows tumor cell-cell dissocia�on 
and thus conversion to a more migratory 
phenotype. In addi�on to this pro-invasion 
effect, the soluble cadherin released a�er 
shedding could retain its binding func�on 
or even gain addi�onal func�on(s). Noe et 
al showed that cleavage of E-cadherin by 
MMP-3 or -7 itself is not responsible for 
increased invasion since immuno-deple�on 
of the shed ectodomain from condi�oned 
medium did not affect tumor cell aggrega�on 
and invasion (Noe et al., 2001). Similar results 
were obtained with the plasmin and kalikrein 
7 cleaved E-cadherin ectodomains (Ryniers 
et al., 2002;Johnson et al., 2007) indica�ng 
that E-cadherin shedding s�mulates invasion 
in a paracrine manner. Shed E-cadherin 
ectodomains promote cell junc�on disrup�on 
and cell dissemina�on thereby altering the 
migratory phenotype (Symowicz et al., 2007). 
High concentra�ons of sE-cadherin may 
even act as a chemotac�c agent for prostate 
carcinoma cells (Chunthapong et al., 2004). In 
addi�on, the presence of soluble E-cadherin 
leads to increased expression of MMP-2, -9 
and MT1-MMP on both mRNA and protein 
level, thereby facilita�ng ECM degrada�on 
and favouring tumor invasion (Nawrocki-Raby 
et al., 2003). 
Although cleaved by several proteases, N-
cadherin shedding has not been reported 
in cancer. Soluble forms of N-cadherin are 
involved in migratory processes (Derycke et 
al., 2006b) and promote neurite outgrowth 
(Paradies and Grunwald, 1993) which requires 
the presence of the fibroblast growth factor 
(FGF) receptor (U�on et al., 2001). N-cadherin 
mediates cis-interac�ons with FGFR leading to 
increased FGFR stability and as a consequence 
sustained MAPK-ERK ac�va�on and MMP-9 
expression (Suyama et al., 2002). 
Soluble N-Cadherin is found in several 
human body fluids and is significantly higher 
in the serum of cancer pa�ents (Derycke 
et al., 2006a). Given the large number of 
proteases known to cleave cadherins and the 
iden�fica�on of soluble cadherins in pa�ent 
material, soluble cadherins may represent 
novel cancer biomarkers (De Wever et al., 
2007). 
4. Func�on of soluble adhesion 
molecules 
 Ectodomain shedding appears to be the 
simplest and fastest way to diminish cell-
cell adhesion and/or cell-matrix adhesion. 
Disrup�on of adhesion integrity by cleaving 
adhesion molecules facilitates tumor cell 
release from the primary tumor or adapts 
the tumor cell adhesion repertoire making it 
suitable for migra�on. 
This does not take into account the presence of 
the, intrinsic to ectodomain shedding, soluble 
cleaved ectodomain. Released ectodomains, 
independent of their origin (alterna�ve 
transcrip�on, ectodomain shedding or vesicle 
burst), may bind paracrine or autocrine back 
to the full-length membrane bound adhesion 
molecule thereby ac�ng as a nega�ve 
compe�tor that interferes with adhesion. In 
the case of ectodomain shedding, not only the 
cleavage of the full-length molecule hampers 
adhesion, the released ectodomain further 
prevents stable adhesion between remaining 
full-length molecules and synergis�cally 
promote migra�on and invasion.  (see figure 
1 for a model) 
The extracellular released ectodomains of 
adhesion molecules seem to func�on broader 
than impairing adhesion. Shed ectodomains 
are inducers of proteoly�c ac�vity as seen for 
EMMPRIN and E-cadherin (see above) or cell-
signaling (L1CAM, see above). Vesicles could 
thereby act as stable transport mechanisms 
for these signalling molecules to distant sites. 
128 Chapter 7 129Soluble Adhesion Molecules in Human Cancers
Another effect specific for ectodomain 
shedding is seen a�er CD44 ectodomain 
shedding whereby the remaining intracellular 
part is further processed and acts as a 
transcrip�onal ac�vator (Okamoto et al., 
2001). A similar scenario is seen for E-cadherin, 
addi�onal cleavage of E-cadherin leading to 
release of β-catenin from the membrane and 
thereby increasing the level of cytoplasmic β-
catenin (Itoh et al., 1999). 
Both ectodomain shedding and alterna�ve 
transcrip�on of adhesion molecules in general 
leads to a truncated soluble ectodomain, in 
contrast to the full-length adhesion molecules 
liberated from cells by vesicle release. 
Vesicle-bound adhesion molecules might serve 
as specific anchors for vesicle associa�on to 
target cells media�ng subsequent delivery 
of vesicle payload. Besides proteins, tumor 
derived microvesicles contain mRNA (Baj-
Figure 1. Schema�c overview of soluble adhesion molecule forma�on. 
In the primary tumor cells adhere to each other or to stroma cells via full-length func�onal cell-adhesion molecules (A) 
or to the ECM via integrins. As a result of alterna�ve splicing par�al adhesion molecules lacking the transmembrane 
binding domain are released by tumor cells (B). Shedding of adhesion molecules can occur at the cell membrane either 
induced by soluble proteases or membrane-bound proteases (C). If these soluble adhesion molecules retain their adhesive 
proper�es they can bind to (I) another soluble molecule, (II) the cell they originated from (autocrine) or (III) a neighbouring 
cell (paracrine). This nega�ve compe��on between membrane bound molecules and soluble molecules reduces the ne�o 
amount of possible single adhesion interac�ons, and as a consequence reduces the total amount of homotypic adhesion 
(A,B,C). Membrane vesicles take up adhesion molecules from the membrane during their forma�on (D). If these vesicles 
lyse out-side of the cell they release full-length adhesion molecules (E). These full-length adhesion molecules func�on in 
similar ways as truncated adhesion molecules. A combina�on of vesicle release and ectodomain shedding occurs for some 
adhesion molecules. The localized presence of proteases and adhesion molecules within or on these secreted vesicles 
contributes to vesicle-mediated ectodomain shedding (F). Adhesion molecules present on secreted vesicles might also be 
involved in the (selec�ve) vesicle docking to target cells, whereby vesicle payload (mRNA or protein) is delivered (G). 21 
Note that the model has been scaled for the adhesion molecules on the le� side, while it is scaled to the vesicles on the 
right side of the white bar. 
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Krzyworzeka et al., 2006). Although there is no 
direct evidence for mRNA transporta�on and 
up-take, it was shown that the microvesicles 
are engulfed by monocytes making it likely 
that they also take up the mRNAs. Another 
recent study shows that microvesicles derived 
from embryonic stem cells contain mRNA and 
in fact could horizontally transfer these mRNAs 
to target hematopoie�c progenitor cells where 
they are translated into the corresponding 
proteins (Ratajczak et al., 2006a). Not only 
microvesicles contain mRNAs, exosomes 
are also found to contain specifically packed 
mRNAs and microRNAs (Valadi et al., 2007). 
Transfer of these mRNA containing exosomes 
to recipient cells resulted in specific protein 
synthesis (Valadi et al., 2007). Importantly, 
vesicle uptake was cell-type specific (Valadi et 
al., 2007). It might be that the specific adhesion 
or receptor repertoire on the recipient cell 
and/or vesicle determines the a�achment of 
specific vesicles. 
Recently, it was shown that microvesicles 
derived from endothelial progenitor cells 
trigger/s�mulated angiogenesis in endothelial 
cells (Deregibus et al., 2007). RNase treatment 
of the vesicles almost completely abrogated 
the angiogenic response, while the vesicles 
were internalized by the recipient cells, 
poin�ng to an RNA dependent mechanism. 
Moreover, blocking of α4-integrin and 
CD29 (β1-integrin) but not ICAM-1 and 
CD44 molecules prevented internaliza�on 
and as a consequence abrogated the 
angiogenic response. These results show that 
internaliza�on, mediated by specific adhesion 
molecules, is required but that the mRNA is 
the main inducer of the angiogenic program 
(Deregibus et al., 2007). Integrins were already 
shown to be involved in solid adhesion of B-
cell-derived exosomes to ac�vated fibroblasts 
(Clayton et al., 2004). ICAM-1 is necessary for 
the immune ac�vity of exosomes secreted by 
LPS-treated dendri�c cells (DCs). ICAM-1 could 
either help with the capture of exosomes by 
the recipient an�gen presen�ng cells (APCs), 
or favor T-cell binding to the recipient APC 
bearing exosomes at its surface (Segura et 
al., 2005). This suggests a specific anchoring 
func�on of adhesion molecules necessary for 
vesicle docking on target sites. 
Mayer et al showed that migra�ng aggressive 
human melanoma cells shed off par�cles 
from their trailing edge into the remodelled 
extracellular matrix (Mayer et al., 2004). These 
par�cles seem to resemble both ectosomes 
and exosomes. Although the func�on of 
this par�cle release is unclear they might 
represent guiding beacons through the path 
of less resistance. In other words, the vesicles 
or cell membrane deposi�ons remain in trails 
of remodelled ECM and provide paracrine 
informa�on to passing cells (Peduzzi et al., 
1994;Mayer et al., 2004). Yet, this might 
only be the case for cells with mesenchymal 
characteris�cs, while cells with epithelial 
characteris�cs depend on fibroblast-led 
invasion (Smalley et al., 2006) 
The mechanism of path guiding beacons, 
mediated either by remaing vesicles or shed 
ectodomains, is in line with the hypothesis 
that substrate anchored soluble N-cadherin 
supports grip necessary for cancers cells to 
move along nerves (U�on et al., 2001;De 
Wever et al., 2007).
5. Concluding remarks 
 Apparently the effects of soluble adhesion 
molecules can be roughly divided in two 
groups based on their subcellular origin. 
First, modifica�ons or rearrangements 
of the cell-surface adhesion repertoire 
necessary for migratory processes can 
be achieved by ectodomain shedding or 
alterna�ve transcrip�on whereby the released 
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ectodomains are involved in the disrup�on 
of cell-cell interac�ons. Second, released 
ectodomains from vesicles appear to be 
involved in transfer of informa�on, either by 
direct signalling or by complete vesicle uptake 
followed by mRNA/miRNA or protein transfer. 
 Based on current available data, released 
soluble adhesion molecules in cancer should 
no longer be regarded as unrelated and non-
func�onal side products of tumor progression. 
Further inves�ga�on is required to determine 
the mechanisms that ini�ate, control and 
mediate shedding events and vesicle secre�on 
in more detail. Generally, iden�fica�on of 
novel proteoly�c substrates among membrane 
bound proteins (either receptors, cytokines 
and/or adhesion molecules) would increase 
our knowledge of the effects of ectodomain 
shedding, whereby proteomic screening seems 
most informa�ve. In addi�on, experiments 
will be required to determine the func�on 
of adhesion molecules in vesicle release and 
vesicle uptake by target cells. Specifically, 
since several soluble adhesion molecules 
are detected in tumor samples or cancer 
pa�ent material (table 1), the biological and 
clinical consequences that soluble adhesion 
molecules have in tumor development, 
tumor progression and metastasis need to 
be clarified. The fact that soluble adhesion 
molecules and vesicles specific for tumor 
progression are present in blood and other 
body fluids makes them a�rac�ve targets for 
micro-invasive screening and diagnos�cs. 
Table 1. (on the right page)
Overview of cancer-related adhesion molecules known to be proteoly�cally cleaved, to have soluble forms due to 
alterna�ve transcrip�on or to be released via vesicles. For each adhesion molecule the release mechanism(s) is/are given 
and the cancer type(s) involved. Adhesion molecules targeted by ectodomain shedding are given with the corresponding 
protease(s). If the specific protease is not yet determined, the responsible protease family based on protease inhibitor 
studies is given. Exosome or ectosomes refers to the origin of vesicle released adhesion molecules. Electron microscopy or 
sucrose gradient centrifuga�on determined the size and thus the origin of the vesicles, if the vesicle origin is unclear the 
general term vesicle is used. If a soluble form of an adhesion molecule is found in pa�ent material the corresponding source 
of pa�ent specimens is given. 
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General discussion
 Tumor cells have to dissociate from the 
primary tumor in order to metastasise. 
Successful metastasis is usually accompanied 
by the loss of homotypic tumor cell adhesion 
(Hanahan and Weinberg, 2000;Bidard et al., 
2008). The increased expression of ALCAM 
during melanoma progression paradoxically 
counteracts the release of melanoma cells 
from the primary tumor. Despite this, 
experimental and pathological data point 
to an important role for ALCAM in, among 
others, melanoma metastasis. 
We used the N-terminally truncated ALCAM 
molecule (ΔN-ALCAM) and the soluble N-
terminal part of ALCAM (sALCAM) to modulate 
ALCAM mediated cell adhesion and to assess 
the func�on of wild-type ALCAM in metasta�c 
cells. Over-expression of ΔN-ALCAM in 
metasta�c melanoma cells reduced cellular 
aggrega�on and increased cell migra�on. 
In nude mice, these cells displayed reduced 
subcutaneous tumor growth and accelerated 
lung metastasis (van Kempen et al., 2004). 
This study showed that a�enua�on of ALCAM 
interac�ons provides a gateway for metastasis 
and suggests that ALCAM mediated cell 
clustering introduces a rate limi�ng step for 
the transi�on between primary tumor growth 
and �ssue invasion (Swart et al., 2005). 
Addi�onal data underlining the rate limi�ng 
ac�on of ALCAM comes from the use of 
sALCAM expression in metasta�c melanoma 
cells. The secreted variant sALCAM, which is 
an�cipated to target only the ligand binding 
module, prevents the focal recruitment of 
ALCAM clusters and interrupts extended, 
intercellular ALCAM network forma�on. 
In contrast to ΔN-ALCAM overexpression, 
sALCAM expression decreased cell mobility 
and lung metastasis forma�on in nude mice 
(van Kilsdonk et al., 2008). Although the 
expression of sALCAM and ΔN-ALCAM show 
contradic�ve effects on migra�on and the rate 
of metastasis both approaches interfere with 
proteoly�c ac�va�on of MMP-2 (chapters 2 
and 3). 
The phenotypes induced by either sALCAM 
or ΔN-ALCAM, thus, display both overlapping 
and opposite cellular proper�es and cannot 
be accommodated by a plain role of ALCAM 
in cell-cell interac�ons. Closer inspec�on 
discloses that the pleiotropic effects are well 
compa�ble with a networking role of ALCAM 
that integrates complex, micro-environmental 
signalling and invasive growth dynamics 
(chapter 4).
ALCAM working model
 The hypothe�cal stepwise model of 
ALCAM func�onality proposed in chapter 1 
can now be updated with current available 
experimental data (figure 1). The model 
predicts that progression from step 1 via 
step 2 to step 3 is accompanied by altered 
expression of genes that are both responsive 
to ALCAM and increased cell-clustering. 
We have shown that increasing the cell 
density of cultured melanoma cells indeed 
results in the up-regula�on of a large cluster 
of genes including L1CAM, complement 
components and the ac�va�on of MMP-2 
which is dependent on ALCAM func�onality 
(chapter 4). Sustained oncogenic tumor 
growth allows the tumor to reach a cri�cal 
primary tumor mass, passing this threshold 
ini�ates invasive, metastasis competent, cells 
to leave the primary tumor (step 3). Because 
cis- and trans-clustering of wild type ALCAM 
together facilitate homophylic and homotypic 
adhesion both ALCAM interac�ons contribute 
to sustained primary tumor growth. If the 
increasing tumor mass ini�ates intracellular 
signalling cascades, it is temp�ng to speculate 
148 Chapter 8 149General discussion
that ALCAM clustering itself should generate 
these signals. Manipula�ng ALCAM clustering 
either by sALCAM expression or ΔN-ALCAM 
expression indeed alters cell signalling upon 
increased cell density (chapter 4). 
Introducing ΔN-ALCAM in the melanoma 
cells shows that impairing ALCAM mediated 
adhesion apparently generates a short cut 
from step 1 to step 4 thereby bypassing step 
2 and 3. In contrast, introduc�on of sALCAM 
apparently leaves the cells in a state between 
step 1 and 2. Cells expressing sALCAM 
apparently lack the signalling induced by 
ALCAM clustering that induces invasion. 
How can the different invasive and metasta�c 
behaviour of ΔN-ALCAM and sALCAM cells be 
explained? The overexpression of ΔN-ALCAM 
decreases the number of trans-interac�ons 
but it introduces more cis-clustering on the 
membrane. In sALCAM expressing cells the 
trans-interac�ons are decreased but also 
cis-clustering and ALCAM recruitment to 
sites of cell-cell contact is decreased (see 
chapter 3). Apparently the signal that leads 
to the ac�va�on of MMP-2 comes from the 
coordinated ALCAM network forma�on 
since both N and sALCAM cells lack MMP-2 
ac�va�on. In contrast to MMP-2 ac�va�on, 
expression of L1CAM and complement 
ac�va�on appears to be regulated by signals 
coming from ALCAM cis-clustering. Increased 
cis-clustering as in ΔN-ALCAM expressing 
cells leads to increased L1CAM expression 
and complement ac�va�on. In sALCAM 
expressing cells the lack of cis-clustering 
leads to decreased expression of L1CAM and 
to decreased complement expression and 
ac�vity (chapter 4). 
Overall this suggests that ALCAM func�ons as 
a cell-surface sensor that integrates complex, 
micro-environmental signalling and invasive 
growth dynamics and func�ons as a rate 
limi�ng step in melanoma progression. 
However, an exclusive contribu�on for ALCAM 
cannot be claimed. The existence of addi�onal, 
parallel control factors is supported by the 
detec�on of an ALCAM-independent, cell-
confluence-responsive set of 41 genes (figure1 
from chapter4) in the micro-array analyses. 
Therefore, it cannot be excluded that more 
cell surface molecules, alone or in coopera�ve 
assemblies, may fulfill similar sensor roles in 
different cellular contexts. 
We consider a model in which ALCAM 
recruits and connects molecular partner(s) 
to other ALCAM molecules and their own 
Figure 1 Working model for the role of ALCAM in melanoma progression.
See text for details
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interactors, thereby organizing the posi�on 
of cell-surface proteins in order to allow signal 
transduc�on, cell adhesion and/or mo�lity. 
For the family of tetraspanins it is know that 
they form small microdomains on the cell 
surface that incorporate other cell surface 
molecules like integrins, Ig superfamily 
proteins and cadherins (Hemler, 2005). Like 
tetraspanins ALCAM interacts with itself on 
the cell surface thereby making it possible 
that ALCAM builds up membrane domains in 
a similar way. Progressive ALCAM clustering 
could promote the sequestra�on or tethering 
of addi�onal components like MT1-MMP and 
L1CAM into these ALCAM network mediated 
membrane domains. Co-localiza�on of 
ALCAM and cadherins may be relevant to 
accomplish significant regulatory effects 
(Tomita et al., 2003). Also the interac�on of 
ALCAM with the cytoskeleton (Nelissen et 
al., 2000;Te et al., 2007) might lead to re-
localiza�on and recruitment of other proteins 
to these domains. The molecules present in 
these ALCAM mediated cell surface domains 
together might lead to the complex synergis�c 
signalling events that accompany melanoma 
tumor progression. In line with this is the 
observa�on that ALCAM expression in non-
malignant ALCAM nega�ve 530 melanoma 
cells increases cell clustering but does not alter 
the invasive capacity indica�ng that addi�onal 
factors are required for invasion (van Kempen 
et al., 2001). In this context, ALCAM would 
play the role of a cell surface coordinator 
that organizes complex, micro-environmental 
signalling and invasive growth dynamics. As a 
first step towards defining this model further, 
the iden�fica�on of ALCAM interac�ng 
molecules can be subject of future research. 
ALCAM and (tumor-) stem cell biology
 The classical view of melanoma progression 
described above is that of a step wise process 
from mature melanocyte via dysplas�c nevus, 
RGP and VGP to metasta�c melanoma. Yet, 
recent advances led to a melanoma stem cell 
model in which the melanoma stem cell, 
together with the tumor microenvironment, 
directly lead to the observed clinical outcomes 
without progressing through intermediate 
steps. 
Self-renewing melanoma stem cells sustain 
the stem-cell popula�on while giving rise to 
progenitor cells that may a�ain the capacity 
to self-renew. These progenitor can give 
rise to differen�a�ng clones of varying 
dominance that contribute to the overall 
tumor heterogeneity found in melanomas 
(Zabierowski and Herlyn, 2008). ALCAM is a 
commonly used cell surface marker to select 
for pluripotent stem cells from mesenchymal 
progenitor popula�ons (Swart et al., 2005). 
Furthermore ALCAM is a characteris�c feature 
of metasta�c human colorectal cancer stem 
cells (Dalerba et al., 2007). In addi�on to 
ALCAM two other stem cell markers (CD133 
and nes�n) were found to be increased during 
melanoma tumor progression (Klein et al., 
2007). Characteriza�on of ALCAM in melanoma 
tumor growth may also be instrumental to 
unravel common developmental func�ons. 
ALCAM is expressed in blastocysts and 
endometrial epithelial cells underscoring its 
role in developmental processes (Fujiwara et 
al., 2003). Based on these results it is temp�ng 
to speculate that progression to malignant 
melanoma involves ALCAM expression and 
that ALCAM may be involved in gene�c 
pathways that par�cipate in stem cell biology 
and normal �ssue development. However, 
recent research challenges the tumor stem 
cell hypothesis by showing that there is no rare 
small subset of cancer cells that con�nually 
regenerates a tumor (Quintana et al., 2008). 
In addi�on they show that no known tumor 
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stem cell markers, including ALCAM, could 
dis�nguish tumorigenic from non-tumorigenic 
cells in assays that detect much higher 
frequencies of tumorigenic cells. The ALCAM-
posi�ve stem cell phenotype might s�ll 
contribute to developmental processes, but 
in tumor progression the role for ALCAM can, 
for now, be best explained by our hypothe�cal 
step-wise model.
Soluble ALCAM forms 
 The transi�on from step 3 to 4 in the 
ALCAM model resembles the altera�ons 
in adhesion that facilitate migra�on and 
invasion. Proteoly�c cleavage of ALCAM 
might induce invasion and metastasis. MMP-
9 derived from kera�nocytes and ac�vated 
by melanoma cells could play a role in these 
processes (chapter 5). The ALCAM dele�on 
mutants are poten�ally generated products 
of proteolysis. In our experiments we show 
that by introducing these ALCAM variants 
in metasta�c cells ALCAM func�on and 
metastasis can be modulated. Since there is 
an almost perfect correla�on between MMP-2 
and ALCAM expression in human melanoma 
cell-lines (Degen et al., 1998;Hofmann et al., 
2000) in combina�on with the presence of 
both proteins at the invasive front of primary 
melanomas (van Kempen et al., 2000;Hofmann 
et al., 2000) suggests that proteoly�c cleavage 
of ALCAM in vivo is mediated by MMP-2. 
The rela�on between MMP-2 and ALCAM 
is further strengthened by our observa�on 
that ALCAM is necessary for the MT-1MMP 
mediated ac�va�on of MMP-2 (chapter 2). 
However, overexpression of ac�ve MMP-2 in 
ALCAM posi�ve BLM cells or culturing BLM 
cells in collagen did not show any trace of shed 
ALCAM in the culture medium nor on the cell 
surface (not shown) making it unlikely that 
ALCAM is a proteoly�c substrate of MMP-2. 
We clearly show that ALCAM is involved in 
the induc�on of proteolysis (chapter 2 and 
3) and although our data hint to proteolysis 
of ALCAM itself, we could not detect ALCAM 
cleavage. Despite that we did not detect 
MMP-2 mediated ALCAM cleavage, ALCAM is a 
substrate for proteoly�c cleavage. Recently it 
has been shown that ALCAM can be shed from 
the cell membrane by ADAM17 in vitro (Bech-
Serra et al., 2006). In vivo an almost full-length 
soluble form of ALCAM has been detected in 
ascites of ovarian carcinoma pa�ents (Rosso 
et al., 2007). In vitro analysis confirmed the 
involvement of ADAM17 in the release of this 
soluble ALCAM from the membrane. Inhibi�ng 
ADAM17 ac�vity decreased the mo�lity of 
ovarian carcinoma cells in vitro (Rosso et al., 
2007). These observa�ons are in line with our 
own results (this thesis and van Kempen et al., 
2004) and support the migra�on a�enua�ng 
effect of ALCAM expression. 
More in vivo data is coming from Hodgkin 
lymphoma pa�ent plasma in which soluble 
ALCAM was detected as well as in the culture 
supernatant of Hodgkin lymphoma cell lines 
(Ma et al., 2007). The release mechanism 
of ALCAM is not provided in this study. In 
contrast to this rela�vely large shed ALCAM 
forms, endothelial cells express a small 
ALCAM transcript as a result of alterna�ve 
transcrip�on (Ikeda and Quertermous, 2004). 
This small transcript results in a small soluble 
secreted N-terminal ALCAM fragment, using 
recombinant protein techniques the authors 
show that this sALCAM fragment hampers cell 
migra�on. 
Besides being cleaved or secreted as an 
alterna�ve transcribed protein, we recently 
isolated ALCAM from exosomes coming 
secreted by several human cancer cell-lines 
(unpublished data). Combining this with the 
fact that ALCAM is a target of proteolysis it 
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is plausible that these exosomes serve as a 
pla�orm for ALCAM cleavage as is the case for 
L1CAM (chapter 7). Alterna�vely, the released 
exosomes containing ALCAM might func�on in 
a similar way as single sALCAM fragments do. 
Besides the genuine ALCAM release from the 
plasma membrane as described above, other 
mechanisms exist that lower the amount of 
ALCAM molecules on the cell membrane. 
Clatherin-dependent internaliza�on of ALCAM 
upon single chain an�body binding (Piazza 
et al., 2005) has been observed. Strikingly, 
endocytosed ALCAM is rapidly recycled back 
to the cell membrane thereby making it a 
rapid manner to modify ALCAM-mediated 
cell adhesion. It is unclear if binding of soluble 
ALCAM fragments elicit similar temporarily 
ALCAM internaliza�on effects. All together 
these data point to a func�on of ALCAM in 
migratory processes for which the regula�on 
appears to be on the cell surface by modula�ng 
the presence or appearance of ALCAM.
Regula�on of de novo ALCAM 
expression 
 It appears that the func�onality of ALCAM 
is mostly regulated on the post-transcrip�onal 
level, by shedding, internaliza�on or release 
via membrane derived vesicles. However, 
regula�on of de novo ALCAM expression in the 
ver�cal growth phase of primary melanomas 
remains unclear. 
Several observa�ons in literature point to the 
importance of inflammatory cytokines for the 
regula�on of ALCAM expression. Blood brain 
Barrier (BBB) endothelial cells up regulate 
ALCAM expression during inflammatory 
processes along with ICAM-1, a direct target 
of NF-κB signaling (Cayrol et al., 2008). DM-
GRASP, the avian orthologue of ALCAM, is 
induced in v-rel-mediated tumor development 
and may be involved in the growth of v-rel 
tumor cells (Zhang et al., 1995). 
The correla�on between MMP-2 ac�va�on 
and ALCAM expression might be the result 
of a co-regulatory mechanism. Expression 
and ac�va�on of MMP-2 and MT1-MMP are 
known to be induced by NF-κB signaling (Kim 
and Koh, 2000;Han et al., 2001). 
The involvement of NF-κB in ALCAM 
expression regula�on is further strengthened 
by the presence of three NF-κB binding sites 
in the ALCAM gene promoter sequence (Van 
Kempen personal communica�on). In this 
regard the over expression of tumor marker 
Nup-88 (chapter 6) can be an important 
mechanism in regula�ng the expression of 
several pro-invasive proteins including ALCAM 
and MMPs. However, we found that in BLM 
cells specific knockdown of NF-κB or Nup-88 
using siRNAs did not decrease ALCAM and 
MMP-2 expression (data not shown), whereas 
levels of known NF-κB targets like interleukin-
8 and ICAM-1 did decrease. 
The cons�tu�ve ac�va�on of NF-κB induced 
by over expression of Nup-88, therefore, 
does not lead to increased ALCAM expression. 
Overall these data suggest that NF-κB is 
not involved in the regula�on of ALCAM 
expression. This is supported by the finding by 
van Kempen (personal communica�on), which 
shows that muta�ng the NF-κB binding sites in 
an ALCAM promoter construct did not result 
in reduced ac�vity of the reporter transfected 
in BLM cells. Overal this suggests that ALCAM 
expression is not regulated by NF-κB. 
Besides melanoma, ALCAM is expressed in 
many other malignancies although expression 
of ALCAM varies between different tumor 
types (chapter 1). Expression is increased 
in colon carcinomas, esophegeal cell 
carcinomas and bladder carcinomas, whereas 
its expression is decreased in prostate 
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Summary
 During melanoma progression the 
repertoire of adhesion molecules on tumor 
cells is changed. These rearrangements in 
the adhesion repertoire allow tumor cells 
to migrate, invade and form metastasis. 
Ac�vated leukocyte cell adhesion molecule 
(ALCAM) is an adhesion molecule expressed 
at the invasive front of primary melanomas 
and appears to play an important role in 
the progression and metastasis of human 
melanoma. The goal of the study described 
in this thesis was to characterize the func�on 
ALCAM has in melanoma tumor progression. 
 Chapter 1 gives an overview of our current 
knowledge of the expression and func�on 
of ALCAM. Although ALCAM expression 
was ini�ally iden�fied in leukocytes, more 
informa�on becomes available regarding its 
adhesive role tumor progression and other 
migratory processes. 
 In chapter 2 we show that progressive 
ALCAM mediated cell clustering controls 
the proteoly�c cascade for ac�va�on of 
gela�nase A/matrix metalloproteinase-2 
(MMP-2), which involves forma�on of an 
intermediate ternary complex of membrane 
type 1 MMP (MT1-MMP/MMP-14), �ssue 
inhibitor of metalloproteinase-2 (TIMP-2), and 
pro–MMP-2 at the cell surface. Trunca�on of 
ALCAM severely impaired MMP-2 ac�va�on in 
a nude mouse xenogra� model, in which we 
previously observed diminished primary tumor 
growth and enhanced melanoma metastasis. 
Compara�ve studies of two-dimensional 
monolayer and three-dimensional collagen-
gel cultures revealed that extensive cell-to-cell 
contacts, wildtype ALCAM, and cell-to-matrix 
interac�ons were all indispensable for efficient 
conversion of pro–MMP-2 to its ac�ve form 
in metasta�c melanoma cells. Truncated, 
dominant nega�ve ALCAM diminished MMP-
2 ac�va�on via reduced transcript levels and 
decreased processing of MT1-MMP. Failure of 
the proteoly�c cascade a�er selec�ve ALCAM 
deple�on by RNA interference was mainly due 
to incomplete MT1-MMP processing, which 
was otherwise promoted by extensive cell-to-
cell contacts. 
 Overexpression of a secreted N-terminal 
fragment, sALCAM, in metasta�c melanoma 
cells disturbed clustering of endogenous 
ALCAM and inhibited ac�va�on of matrix 
metalloproteinase (MMP)-2 (chapter 3). 
Exposure of HT1080 fibrosarcoma cells to 
sALCAM similarly inhibited MMP-2, sugges�ng 
a broader impact on ALCAM-posi�ve 
tumour cells. In contrast to the previously 
reported, invasion promo�ng effects of an 
N-terminally truncated, transmembrane 
variant (ΔN-ALCAM), sALCAM impaired the 
migratory capacity of transfected cells in vitro, 
reduced basement membrane penetra�on 
in recons�tuted human skin equivalents 
and diminished metasta�c capacity in nude 
mice. Remarkably, L1 neuronal cell adhesion 
molecule (L1CAM/CD171), another progression 
marker of several cancers including melanoma, 
was suppressed upon sALCAM overexpression 
but up-regulated by ΔN-ALCAM. 
To further elucidate the role of ALCM micro 
array experiments were performed under 
different culture condi�ons and with different 
ALCAM status (chapter 4). 
The par�ally overlapping and opposite effects 
induced by alterna�ve strategies targe�ng 
ALCAM func�ons, collec�vely, a�ribute an 
integra�ve role to ALCAM in orchestra�ng cell 
adhesion, growth, invasion and proteolysis 
in the tumour �ssue micro-environment and 
disclose a therapeu�c poten�al for sALCAM. 
 In Chapter 5 we used the De-epidermized 
dermis (DED) as a model for melanoma 
invasion. Using this model we show that, in 
the absence of co-cultured kera�nocytes, 
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the dermal-epidermal basement membrane 
prevents invasion of melanoma cells that gave 
rise to metastasis in nude mice. In the presence 
of co-cultured kera�nocytes however, these 
cells can breach the basement membrane. 
The dynamic interplay between kera�nocytes 
and melanoma cells is shown by the ac�va�on 
of MMP-9 by kera�nocytes when co-cultured 
with melanoma cells. 
 Expression of ALCAM and MMP-2 was 
suggested to be transcrip�onally regulated 
by NFκ-B, an ubiquitous transcrip�on factor 
involved in immune responses, apoptosis and 
cancer. We find that selec�ve deple�on of 
Nup88 inhibited NFκ-B-dependent reporter 
gene ac�va�on and the nuclear transloca�on 
of NFκ-B without affec�ng the upstream 
ac�va�on pathway in NIH-3T3 cells (chapter 
6). In melanoma cells overexpressing Nup88, 
cons�tu�ve ac�va�on of NFκ-B was found 
both in nucleus and cytoplasm. Nup88 
deple�on in these cells reduced TNF-induced 
nuclear accumula�on of NFκ-B subunits. We 
conclude that Nup88 regulates the ac�vity 
of NFκ-B at the level of nucleocytoplasmic 
transport in both normal and tumor cells. 
Overexpression of Nup88 in tumor cells may, 
thus be involved in the cons�tu�ve NFκ-B 
ac�va�on, and contribute to the cancerous 
growth. However, selec�ve knockdown of 
NFκ-B by small interfering RNA (siRNA) in 
metasta�c melanoma (BLM) cells did not 
reduce expression of ALCAM nor MMP-2 
expression (chapter 8). 
 Chapter 7 outlines the large group of 
adhesion molecules involved in tumor 
progression that could be present as soluble 
molecules outside the cell. The origin, 
func�ons and fates of these soluble molecules 
is reviewed. 
 The results presented in this thesis are 
discussed in chapter 8. 
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Samenva�ng
 Tijdens de ontwikkeling van het humane 
huidmelanoom is het repertoire van adhesie 
moleculen aan veranderingen onderhevig. 
Deze veranderingen in adhesie eigenschappen 
maken het mogelijk dat tumor cellen migreren, 
invaderen en metastases vormen. Ac�vated 
leukocyte cell adhesion molecule (ALCAM) 
is een adhesie molecuul dat tot expressie 
komt op het invasieve front van primaire 
melanomen en lijkt een rol te spelen in de 
voortgang en metastasering van het humane 
huidmelanoom. Het doel van de studie 
beschreven in dit proefschri� is om de func�e 
die ALCAM in het humane melanoom vervult 
in detail te bestuderen. 
 Hoofdstuk 1 gee� een overzicht van de 
recente kennis over de expressie en func�e 
van ALCAM. Ook al is ALCAM expressie als 
eerste ontdekt in leukocyten, er komt steeds 
meer informa�e beschikbaar over de adhesie 
rol in tumor ontwikkeling en andere migra�e 
processen. 
 In hoofdstuk 2 laten wij zien dat ALCAM 
gemedieerde cel clustering de ac�vering 
van gela�nase A/matrix metalloproteinase-2 
(MMP-2) controleert. Hierbij is de vorming van 
een �jdelijk complex van membrane type 1 
MMP (MT1-MMP/MMP-14), �ssue inhibitor of 
metalloproteinase-2 (TIMP-2), en pro–MMP-2 
op het cel oppervlak betrokken. Verwijdering 
van een klein stukje ALCAM (geknipt ALCAM, 
ΔN-ALCAM) vermindert de ac�vering van 
MMP-2 in een muis model voor het melanoom. 
In dit model is eerder al gevonden geknipt 
ALCAM leidt tot een verminderde primaire 
tumor groei en een verhoogde metastasering. 
Vergelijkingen tussen 2 dimensionale mono-
laag en 3 dimensionale collageen-gel kweken 
laten zien dat voldoende cel-cel contacten, 
wild-type ALCAM en cel-matrix interac�es 
nodig zijn voor een efficiënte ac�vering van 
pro-MMP-s in metastaserende melanoom 
cellen. Geknipt ALCAM voorkomt de ac�vering 
van MMP-s door het transcrip�e niveau en 
matura�e van MT1-MMP te verlagen. De 
verminderde ac�viteit van MMP-2 als gevolg 
van selec�eve verwijdering van ALCAM door 
RNA interferen�e komt voornamelijk door 
een niet complete matura�e van MT1-MMP, 
die normaal gesproken beter verloopt bij 
voldoende cel-cel contacten. 
 Gebruikmakend van een uitgescheiden 
N-terminaal ALCAM fragment, sALCAM, 
laten we zien dat over-expressie van sALCAM 
in metastaserende melanoom cellen de 
clustering van endogeen ALCAM verstoord 
en dat de ac�vering van MMP-2 geblokkeerd 
wordt (hoofdstuk 3). Blootstelling van HT1080 
fibrosarcoom cellen aan sALCAM laat op een 
gelijke manier een blokkering van MMP-2 
ac�vering zien. Dit suggereert dat sALCAM 
op meerder ALCAM posi�eve tumorcellen 
kan werken. In tegenstelling tot de eerder 
beschreven pro-invasieve effecten van geknipt 
ALCAM induceert expressie van sALCAM 
een verminderde migra�e capaciteit van 
getransfecteerde cellen in vitro, vermindert 
het penetra�e door basaal membranen 
in gereconstrueerde humane huid, en 
vermindert het de metastaserende capaciteit 
in muizen. Opvallend is dat de expressie 
van L1CAM, een ander adhesie molecuul 
betrokken bij verschillende tumoren inclusief 
het melanoom, onderdrukt is als sALCAM 
tot overexpressie komt maar verhoogt is als 
geknipt ALCAM tot expressie komt. Micro-
array experimenten onder verschillende 
kweek condi�es en met verschillende ALCAM 
varianten zijn gedaan om de rol van ALCAM 
verder te onderzoeken (hoofdstuk 4). De deels 
overlappende en tegengestelde effecten als 
gevolg van de verschillende manieren om de 
ALCAM func�e te verstoren laten samen zien 
dat ALCAM een coördinerende rol hee� bij cel 
160 Summary/Samenva�ng 161Summary/Samenva�ng
adhesie, groei, invasie en protease ac�viteit in 
de micro-omgeving van de tumor. 
 In hoofdstuk 5 is gebruik gemaakt van 
de-epidermized dermis (DED) als een model 
voor melanoominvasie. Met dit model laten 
we zien dat basaal membraan tussen de 
dermis en epidermis invasie van melanoom 
cellen die aanleiding geven tot metastasen 
in een muismodel blokkeert wanneer als er 
geen kera�nocyten meegekweekt zijn. In 
aanwezigheid van kera�nocyten kunnen deze 
cellen wel de basaalmembraan doorbreken. 
De dynamische wisselwerking tussen 
kera�nocyten en melanoom cellen is verder 
aangetoond door de ac�va�e van MMP-9 
door de kera�nocyten in aanwezigheid van 
melanoomcellen. 
 Van de expressie van ALCAM en MMP-2 is 
gesuggereerd dat deze geregeld wordt door 
NFκ-B, een veelvoorkomende transcrip�e 
factor die onder andere een rol speelt in 
immuunprocessen, apoptose and kanker. In 
melanoom cellen die kerngeassocieerd Nup88 
tot overexpresie brengen is een cons�tu�eve 
ac�viteit van NFκ-B gevonden, zowel in de 
kern als in het cytoplasma (hoofdstuk 6). 
We vonden dat uitschakeling van Nup88 de 
NFκ-B a�ankelijke reporter gen ac�vering 
verminderde en dat de verplaatsing van NFκ-
B naar de kern niet tot stand kwam in HIG-
3T3 cellen. Uitschakeling van Nup88 in deze 
cellen verminderd de TNF geïnduceerde kern 
ophoping van NFκ-B-subunits. Op basis van 
deze gegevens concluderen wij dat Nup88 
de ac�viteit van NFκ-B regelt door NFκ-B 
transport van en naar de kern te beïnvloeden 
zowel in normale als in tumor cellen. 
Overexpressie van nup88 in tumor cellen 
kan dus betrokken zijn bij de cons�tu�eve 
ac�viteit van NFκ-B en zodoende een bijdrage 
leveren aan tumor groei. Desondanks, 
selec�eve uitschakeling van NFκ-B door RNA 
interferen�e in metastaserende melanoom 
cellen leidt niet tot een vermindere expressive 
van ALCAM of MMP-2 (hoofdstuk 8). 
 Hoofdstuk 7 gee� een overzicht van 
de grote groep van adhesie moleculen die 
betrokken zijn bij tumor progressie en die 
een oplosbare vorm hebben buiten de cel. De 
herkomst, func�e en mogelijkheden van deze 
oplosbare moleculen is samengevat. 
 Alle resultaten besproken in dit 
proefschri� worden in het algemeen 
bediscussieerd in hoofdstuk 8. 
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